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1 ABSTRACT 
The biology of renal cell carcinoma (RCC) remains poorly understood. RCC, which 
accounts for up to 3% of all adult malignancies, is the most common neoplasm in 
the adult kidney and has been increasing in incidence. These tumors are classified 
into five main subtypes: clear cell, papillary, and chromophobe RCC, as well as 
collecting duct carcinoma and oncocytoma. Of these, clear cell and papillary are 
the two most frequently diagnosed subtypes and both arise from the proximal tube 
of the kidney. Despite sharing a common origin, they are histologically and 
genetically distinguishable and thus represent an optimal model system for 
studying tumor-specific and tumor-subtype specific expression patterns. The aim of 
this study was to identify potential marker genes for clear cell and papillary RCC, 
assess their specificity and relevance for the tumor-subtypes, and thus contribute 
to a better characterization of the tumor development and behavior of RCC. 
To address these questions, this study combined translational and transcriptional 
approaches to analyze the protein and gene expression of both tumor subtypes. 
The translational approach identified tumor-subtype specific protein expression 
patterns using SELDI-TOF technology (Surface Enhanced Laser Desorption Ionization 
– Time of Flight). In this way, the first specific protein pattern for papillary RCC 
was identified. The transcriptional approach also identified numerous genes having 
tumor-subtype specific regulations by using cDNA-microarrays. Genes with high 
potential to discriminate between normal and tumor tissue were further analyzed 
with independent methods. Most strikingly, the gene CD70 was identified as being 
specifically over-expressed in clear cell RCC, thus revealing a new, specific marker 
gene. Finally, the gene expression data was bioinformatically analyzed to elucidate 
the underlying biology of the gene regulations found. This revealed an 
accumulation of apoptosis-inducing genes that are equally regulated in both RCC 
subtypes. 
At a first glance, the induction of apoptosis seems to be antithetical to tumor 
survival. However, the induction of apoptosis in tumor-infiltrating lymphocytes, 
which are frequently observed in RCC, would provide a strategy to escape immune 
recognition. The group of apoptosis-inducing genes includes the gene CD70, which 
was then further studied regarding its function for the tumors in cell co-culture 
experiments. These experiments demonstrated the ability of CD70 to induce 
apoptosis in lymphocytes. Thus, CD70 over-expression in RCC could be responsible 
for lymphocyte apoptosis and lymphocyte dysfunction observed within the tumor 
environment. This would allow for an immune suppression and as such be a new, so 
far unknown mechanism for RCC to escape the human immune system. 
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2 INTRODUCTION 
2.1 EXPRESSION PROFILING AND MARKER GENE DISCOVERY 
In the past decade, transcriptional and translational expression profiling became 
common tools for the molecular dissection of cancer as the realization took hold 
that cancer development and behavior could not be reduced to single gene events. 
This transformation in the approach to cancer research was made possible by the 
development of genomic and proteomic techniques like microarrays and protein 
chips. Initially, investigations used techniques such as array-based genotyping 
(Figure 1), which allows for the simultaneous assessment of many molecular 
markers and remains a fast, cost-effective genotyping method (1). However, this 
focus on the DNA level did not necessarily reveal the inner workings of the cell. 
Recent advances, however, now make it possible to take a closer look into the 
actual environment within cells by focusing on the mRNA and protein level. 
Nevertheless, classical approaches for expression profiling and marker gene 
discovery comprise either transcriptional or translational expression profiling. In 
reality though, it is important to study profile expression patterns from multiple 
levels in order to have a better understanding of cancer biology. 
Currently, new RNA approaches applying microarray technology have been used in 
numerous studies to characterize various types of cancer (2-4). This approach uses 
the sequence resources created by the genome sequencing projects and other 
sequencing efforts to identify which genes are expressed in a particular cell type of 
an organism (Figure 1). One advantage of microarrays is the large number of genes 
that can be examined at the same time. However, the application of this technique 
in molecular studies is limited by the need for non-degraded, high quality RNAs, 
which are often only available in small amounts. In addition, the need for 
independent validation of the gene regulations found can be cost-intensive and 
time consuming (5). For this purpose, the majority of studies use quantitative PCR 
or immunohistochemistry to confirm the expression of the genes identified. 
Proteomic approaches have been applied recently to several types of cancer, 
driven by the thought that translational expression is even closer to the condition 
within the cells than transcriptional expression (6). In this context, SELDI-TOF 
(Surface Enhanced Laser Desorption Ionization – Time of Flight) technology has 
become a useful tool for a fast and effective profiling of the cancer proteome (7-
9). Even though this technique is less expensive than microarrays, it can also be 
time consuming due to the need for a subsequent identification of the protein 
peaks found (Figure 1). 
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Figure 1 Overview of classical and new approaches for biomarker discovery and identification 
(qPCR = quantitative PCR; IHC = immunohistochemistry). 
Although all approaches mentioned have been successfully applied for expression 
profiling and marker gene discovery in cancer (10;11), an improvement in the 
specificity and accuracy of profiling studies would be useful since no optimal 
marker gene for RCC exists and the biology of these tumors remains poorly 
understood (12-14). Previous studies are mostly focused on clear cell RCC and only 
a few took into account other RCC subtypes (15;16). Thus, this study combines the 
advantages of transcriptional and translational profiling by synthesizing a RNA 
approach and a protein approach to discover tumor-specific expression patterns for 
the two most common RCC subtypes, papillary and clear cell RCC. These two 
subtypes are an optimal model system to study the biology of RCC since they share 
a common cellular origin. 
Gene expression studies also often suffer from simply listing gene expression data 
without considering their potential function within the tumor environment. Thus, 
in this study, the transcriptional data was additionally analyzed using a functional 
profiling approach. This approach searches the expression data for genes belonging 
to a specific pathway or common mechanism and can thus point to a biological 
meaning of the regulations. Comprehending the underlying expression patterns 
could give insights into how RCC arise and subsequently develop into different 
subtypes. Such a study would not only yield more potential marker genes but give 
insights into the biology of RCC. 
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2.2 RENAL CELL CARCINOMA 
Renal cell carcinoma (RCC) comprises 3% of all human neoplasms and is increasing 
in incidence (17). RCC describes a family of epithelial tumors arising in the kidney 
that are rather homogeneous compared to other solid tumors like liver cancer, 
even though a variety of cell types are present. Furthermore, RCC is highly 
resistant to chemo-, radio-, and immunotherapy.  
The molecular basis of RCC is poorly understood, with only a few relevant genes 
having been identified so far (chapter 2.2.2). However, several pathways 
associated with RCC, in particular within clear cell RCC (chapter 2.2.2), have 
recently been elucidated (18). These pathways include the activation of the 
hypoxia response pathway by mutations of the Von Hippel-Lindau tumor suppressor 
gene and activation of the mammalian target of rapamycin (mTOR) signaling 
pathway (chapter 2.2.2; 19;20). Finally, little is known about the immune escape 
mechanisms of this cancer type which, despite frequent infiltration with immune 
cells, successfully manages to avoid immune recognition (chapter 2.2.3). 
2.2.1 PATHOLOGICAL CLASSIFICATION OF RENAL CELL CARCINOMA 
Renal cell carcinoma (RCC) can be classified based on histological appearance or 
solely on genetic information (Figure 2; 18). In addition to improvements in 
staging, appreciation for the histological diversity of RCC led to the modernization 
of renal tumor classification by the World Health Organization (WHO; 21). The four 
malignant types are clear cell, papillary, chromophobe, and collecting duct 
carcinoma (22;23). The clear cell variant is the most frequent type of renal cancer, 
accounting for approximately 70% of adult renal neoplasms, followed by the 
papillary variant accounting for approximately 15% (Table 1). Both clear cell and 
papillary RCC arise from the proximal tube. 
Table 1 World Health Organization (WHO) classification of renal cell carcinoma (RCC; *21). 
Benign Neoplasms Malignant Neoplasms (*relative frequency, %) 
• Renal Oncocytoma • Clear cell RCC (~70%) 
• Metanephric adenoma • Papillary RCC (~15%) 
• Papillary adenoma • Chromophobe RCC (~5%) 
 • Collecting duct carcinoma (~2%) 
 • RCC, unclassified (~8%) 
Several studies using classical cytogenetic analysis, comparative genomic 
hybridization or molecular genetic techniques showed that genetic alterations 
characterize the different RCC types as well as different steps of tumor 
development and progression (15;20;22-25). Clear cell RCC is characterized by 
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losses on chromosome 3p with mutations and hypermethylation of the Von Hippel-
Lindau gene (75 %; 18). In papillary RCC, gains of chromosomes 7 and 17 are 
frequent (18). In chromophobe RCC, combinations of losses of chromosomes 1, 2, 
10, and 13 frequently occur (Figure 2; 18). 
 
Figure 2 Current histological classification and cytogenetic correlations for renal cell carcinoma 
(RCC, alt. = alterations; in dark blue: cell of origin, in light blue: RCC subtype; 18). 
2.2.2 MARKER GENES AND PATHWAYS IN RENAL CELL CARCINOMA 
A few marker genes for renal cell carcinoma (RCC) have been identified with high-
throughput technologies (14;18;26). A closer look at those genes revealed their 
involvement in cancer associated pathways (Table 2). For example, Ki-67 is a 
nuclear antigen that is selectively expressed in proliferating RCC cells (27). In RCC, 
p53 mutations have been associated with cellular proliferation and a decrease in 
apoptosis (28). Gelsolin functions to sever actin during cell motility (29). Carbonic 
anhydrases (CAIX and CAXII) over-expression is a direct consequence of a Von 
Hippel-Lindau mutation which is found in 75% of sporadic clear cell RCC (ccRCC; 
30). PTEN regulates cellular migration, proliferation, and apoptosis. EpCAM is 
expressed on the cell surface of most carcinomas (31). It is also known that ccRCC 
and papillary RCC (pRCC) express high amounts of VEGF-A, an important regulator 
of tumor-induced angiogenesis in RCC. Specific blocking of VEGF-A seems to lead to 
inhibition of tumor growth (32;33). Unfortunately, the knowledge about possible 
functions of these genes or proteins is limited and not confirmed by further 
analysis. 
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Table 2 Potential molecular markers and their possible function in renal cell carcinoma (18). 
Function 
Hypoxia 
inducible Proliferation 
Immune 
regulatory 
Cell Cycle 
regulation 
Cell 
Adhesion Miscellaneous 
 
 
 
 
 
Marker 
genes 
 
CAIX 
 
CAXII 
 
CXCR-4 
 
HIF-1α 
 
VEGF 
 
IGF-I 
 
Ki-67 
 
PCNA 
 
Ag-NORs 
 
FasL 
 
IL2 
 
IFN-gamma 
 
p53 
 
bcl-2 
 
PTEN 
 
Cyclin A 
 
Akt 
 
S6 Kinase 
 
p27 
 
EpCAM 
 
EMA 
 
E-cadherin 
 
α-Catenin 
 
Cadherin-6  
 
Gelsolin 
Vimentin 
CA-125 
CD44 
Androgen 
receptors 
Caveolin-1 
VEGF-R 
Na+/K+ ATPase 
subunits 
DNA ploidy 
Some pathways enabled in RCC could be identified and the involvement of the 
potential marker genes was functionally elucidated. For example, the mammalian 
target of rapamycin (mTOR) pathway is up-regulated in RCC through the activation 
of downstream targets such as phosphorylated AKT (pAKT) and HIF (18). It has been 
speculated that not all RCC tumor types are equally amenable to treatment 
strategies targeting the mTOR pathway but the majority of patients have at least 
one component of the mTOR pathway affected (34). Another pathway, the hypoxia-
inducible pathway, plays an essential role in angiogenesis, glucose transport, 
glycolysis, pH control, epithelial proliferation, and apoptosis of common cancers. It 
is known that HIF-1α and related protein HIF-2α are controlled at the post-
translational level by hypoxia through the Von Hippel-Lindau (VHL) suppressor 
protein (35). VHL gene mutation or loss occurs frequently in ccRCC, suggesting a 
potential VHL-HIF tumorigenic pathway for ccRCC (36). It has been speculated that 
they are responsible for the ability of cancers to adapt to hypoxic environment and 
their resistance to radiation and chemotherapy (37;38).  
Among the genes that are under the control of HIF, carbonic anhydrase (CAIX) is 
particularly important for RCC (39). CAIX is thought to play a role in the regulation 
of intracellular and extracellular pH during periods of hypoxia in tumor cells, 
thereby allowing cancer cells to further proliferate and metastasize (40). Previous 
studies have shown that CAIX is induced constitutively in certain tumor types but is 
absent in most normal tissues, with the exception of epithelial cells of the gastric 
mucosa (41;42). Furthermore, previous immunohistochemical studies of malignant 
and benign renal tissues revealed that CAIX was highly expressed in RCC, suggesting 
that CAIX expression may be a useful diagnostic biomarker (43;44). 
The identification of these potential marker genes and enabled pathways is a 
crucial step towards a better understanding of the development and behavior of 
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RCC. However, knowledge about the mechanisms behind the ability of RCC to 
escape immune recognition is still very limited. 
2.2.3 IMMUNE ESCAPE MECHANISMS OF RENAL CELL CARCINOMA 
Renal cell carcinoma (RCC), like many other cancer types, has developed potent 
mechanisms to evade immune recognition (45). The immune system plays an 
important role detecting and eliminating pathogens that may do harm to the 
organism. Moreover, it serves as a watchdog against transformed cells that may 
lead to cancer (46). However, many tumors, including RCC, escape the immune 
system despite the presence of tumor-infiltrating lymphocytes (TILs).  
Lymphocytes are the key cells of the immune system for tumor surveillance and 
they are part of the adaptive immune response. These cells are able to recognize 
numerous tumor antigens (47;48). The expression of tumor antigens may be 
heterogeneous within a tumor, and a single patient can develop immune reactions 
to multiple antigens (49). However, in many cases the immune system is not 
activated and ignores the tumor (50). A closer look into the immune escape 
strategies has revealed multiple mechanisms at the cellular and molecular level  by 
which tumors become resistant to apoptosis or to counterattack the immune 
system (51). Cellular mechanisms include growing in immune privileged sites, the 
lack of adhesion molecules or establishing a physical barrier by stroma (52;53). At 
the molecular level it has been shown that tumors have impaired antigen 
presentation which can result in mutation or down-regulation of tumor antigens. In 
addition, the expression of immunosuppressive factors and molecules like cytokines 
or prostaglandins have been reported. Another very important strategy is the so 
called tolerance induction. Here, the tumors express molecules that directly 
influence the TILs and very often lead to their death. This strategy can explain the 
lack of T-cell response against tumor-associated antigens (54;55). 
It is likely that RCC is able to avoid immune recognition altogether (56). Even 
though, like for other solid tumors, TILs have been reported for RCC, most patients 
appear not to generate a significant antitumor response (57). Indeed, there is little 
evidence for local immune reactivity within RCC, as TILs express only minimal 
levels of IL-2 and IFN-gamma mRNAs (58;59). In contrast, there is evidence for an 
immune dysfunction of peripheral blood lymphocytes (60). Thus, the RCC 
microenvironment seems to have a deleterious effect on TILs (61). It has been 
hypothesized that a close interaction of lymphocytes with tumor-derived products 
may mediate the observed lymphocyte defect or even increased lymphocyte 
apoptosis within the tumor microenvironment (62). For RCC, only one mechanism 
for lymphocyte apoptosis has been identified so far and it is mediated by FasL 
(Figure 3; 62). In this mechanism, FasL binds to the receptor thus initiating the 
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activation of caspase 3 and 8 and leading to apoptosis. The same study also found 
that RCC-derived products such as gangliosides are likely to induce apoptosis in 
lymphocytes through inhibition of the activation of the transcription factor NF-кB 
even though the complete mechanism is not fully understood (62). 
 
Figure 3 Schematic representation of apoptosis mediated by Fas ligand (FasL). 1. FasL is a trimeric 
molecule. Fas is a monomer. 2. Binding of FasL causes trimerization of Fas which then binds death 
domain containing adapter proteins 3. The adaptor proteins recruit and activate caspase 8 which 
cleaves caspase 3 and enables the apoptosis cascade (63). 
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3 AIMS OF THIS STUDY 
The aim of this study is to provide a better understanding of the biology of renal 
cell carcinoma (RCC) by elucidating tumor development and tumor behavior. The 
tumor-specific expression patterns are to be analyzed in hopes that they might 
reveal the underlying biology of the regulations found and identify potential 
tumor-specific marker genes for clear cell and papillary RCC. Furthermore, the 
function of genes especially relevant for tumor development and tumor behavior 
shall be characterized in the course of this study. 
 
Postulates: 
1. Knowledge about the biology of RCC is still limited as is reflected by the fact 
that tumor development and behavior of these tumors are poorly 
understood. 
2. RCC divides into several subtypes, among them papillary and clear cell RCC 
which both derive from the proximal tube. But, even though sharing a 
common origin, these subtypes display a unique histological and genetical 
pattern and are thus an optimal model system for studying tumor-specific 
and tumor-subtype specific expression patterns. 
3. The processes which lead to cancer development are highly complex and 
they can not be fully explained by single gene events but by multiple 
changes in the expression patterns. These tumor-specific expression patterns 
can be detected on the translational as well as on the transcriptional level. 
4. The combination of a translational and a transcriptional approach could yield 
a better understanding of tumor-specific and tumor-subtype specific 
expression patterns and lead to the identification of potential new marker 
genes which could thus give insights into tumor development and behavior. 
Translational approach: 
5. The translational approach was designed to uncover changes in protein 
expression of the tumor subtypes. 
6. Clear cell and papillary RCC have discrete protein expression patterns that 
clearly separate the tumor subtypes. However, they also share protein 
regulations underlining their common origin. The differences in protein 
expression are of special interest since they can give insights into tumor 
behavior and tumor development. 
7. For the first time, these specific protein regulations were identified for 
papillary RCC. Three protein peaks (3339 Da, 25595 Da, and 45888 Da) were 
detected with a high potential to discriminate between papillary RCC and 
normal renal tissue. The two most prominent proteins peaks that distinguish 
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between papillary and clear cell RCC have a mass of 9233 Da and 5829 Da 
respectively. 
Transcriptional approach: 
8. The transcriptional approach was designed to uncover changes in gene 
expression of the tumor subtypes. 
9. Similar to the results from the translational approach, clear cell and 
papillary RCC were found to have tumor-subtype specific gene regulations 
but they also show similar gene expression. 
10. For clear cell RCC, four genes (FOSL2, CD70, TPA, and PGS2) with a high 
potential to discriminate between tumor tissue and normal renal tissue 
could be identified. Two of these genes (FOSL2 and CD70) were confirmed 
on the RNA level and the protein level by independent methods.  
11. The gene CD70 was identified as a tumor-specific marker gene for clear cell 
RCC. 
12. For papillary RCC, four genes (CD37, CALB1, MDU1, and CD68) with a high 
potential to discriminate between tumor tissue and normal renal tissue 
could be identified. Three of these genes (CALB1, MDU1, and CD68) were 
confirmed on the RNA-level with independent methods. An additional 
confirmation of these molecules at the protein-level could lead to new, 
specific marker genes for papillary RCC. 
13. The gene expression data derived from the transcriptional approach not only 
contains information about gene regulations but also about functional 
connections of the genes. Thus, a functional approach was carried out to 
bioinformatically search for genes that are involved in the same cellular 
processes. 
Functional approach: 
14. Several genes, which can induce apoptosis, are differentially regulated in 
both tumor-subtypes. Among them is the gene CD70.  
15. In general, the induction of apoptosis seems to be antithetical to tumor 
behavior. But the induction of apoptosis in tumor-infiltrating lymphocytes 
would provide an ideal mechanism to escape immune recognition. 
16. The gene CD70, but not its receptor CD27 which is needed for the induction 
of apoptosis, is expressed by the tumor cells. In contrast CD27 is strongly 
expressed by lymphocytes. 
17. The ability of CD70 to induce apoptosis in lymphocytes was shown by 
addition of either recombinant CD70 to a lymphocyte culture or CD70 
expression by RCC-cells in co-culture with lymphocytes. 
18. The involvement of CD70 and CD27 in the induction of apoptosis was proven 
by blocking experiments with anti-CD70 and anti-CD27 antibodies. 
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19. The induction of apoptosis in lymphocytes via the CD70/CD27 pathway is a 
new, so far unknown mechanism that RCC is potentially using to escape the 
immune recognition. 
20. The RCC subtypes, papillary and clear cell RCC, represent an ideal model 
system to study RCC biology since they enable the analysis of tumor-specific 
and tumor-subtype specific expression patterns. The synthesis of 
transcriptional and translational profiling represents a powerful tool for the 
molecular dissection of cancer. The combination of these approaches with a 
functional profiling also addresses functional connections between the 
regulations found and underlines the need for comprehensive approaches 
that reflect the complexity of tumor development and behavior. 
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4 MATERIALS AND METHODS 
In order to identify potential marker genes, expression profiling in clear cell and 
papillary renal cell carcinoma (ccRCC and pRCC) was performed on the genomic 
and proteomic level. For the protein expression profiling, a total of 40 RCC tissue 
samples (20 pRCC and 20 ccRCC) were analyzed via translational profiling (Part A of 
Figure 4 and chapter 4.3.1). To elucidate the gene expression patterns a total of 16 
RCC tissue samples (10 ccRCC and 6 pRCC) were subjected to a transcriptional 
expression analysis (Part B of Figure 4 and chapter 4.3.2). The genes found were 
analyzed via functional profiling (Part C of Figure 4 and chapter 4.3.3) and one 
specific gene, CD70, was examined more closely regarding its role within the tumor 
environment (Part D of Figure 4 and chapter 4.3.4). 
4.1 STRUCTURAL OVERVIEW OF EXPERIMENTS 
For the expression profiling, two different approaches were applied (Figure 4). 
First, the protein expression was examined via SELDI-TOF (Surface Enhanced Laser 
Desorption Ionization – Time of Flight) technology creating specific protein 
expression patterns for each tumor-subtype. Second, gene expression was analyzed 
via cDNA-microarrays resulting in lists of differentially expressed genes specific for 
both tumor-subtypes. 
 
Figure 4 Structural overview of experiments. (In blue bubbles: the profiling approaches used for 
target molecule identification, in light blue bubbles: the technical realization of the approaches, in 
light green bubbles: the confirmation methods for the gene expression data, in yellow bubble: the 
functional characterization of target molecule). 
For selected genes, a confirmation step was carried out using quantitative PCR 
(qPCR) as well as immunohistochemistry (IHC). Third, functional profiling was done 
in order to compare the gene expression datasets elucidating underlying patterns, 
like regulated genes that are involved in the same processes. Fourth, a functional 
analysis of one specific gene of interest was carried out using cell culture models 
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for apoptosis studies via an Apoptosis Assay (Figure 4). A description of the sample 
types used for these analyses is given in chapter 4.2, a detailed explanation about 
the methods used for the realization of the described approaches can be found in 
chapter 4.3. 
4.2 MATERIALS 
The experiments were carried out with two different sample types: for the 
profiling approaches tissue samples from clear cell renal cell carcinoma and 
papillary renal cell carcinoma (ccRCC and pRCC) were used. For the functional 
analysis RCC cell lines, a T-lymphocyte cell line, and native lymphocytes isolated 
from peripheral blood were used. 
4.2.1 TISSUE SAMPLES 
Samples from 30 patients with ccRCC and 26 patients with pRCC, containing non-
tumorous (“normal”) and tumor tissue were obtained from fresh nephrectomy 
specimens (Table 3). The samples were snap frozen in liquid nitrogen and stored at 
–80°C at the Department of Urology of the Friedrich-Schiller-University, Jena. 
Paraffin sections from each specimen were reviewed by a pathologist and classified 
histologically according to UICC-TNM classification (1997). All Fuhrmann grading 
spectra (1-3) are represented (Table 3). Additionally, for all patient samples the 
histological classification was confirmed with a CGH-Analysis (Appendix I) that 
verified all 56 cases. A total of ten ccRCC samples and six pRCC samples were 
analyzed with cDNA-microarrays whereas 20 ccRCC samples and 20 pRCC samples 
were analyzed with SELDI-TOF technology (Table 3). 
For the immunohistochemistry experiments carried out at the department of 
Urology a total of 68 tumor samples were analyzed, including 41 ccRCC (which 
includes those that were also analyzed via microarray and qPCR), 19 pRCC (which 
includes those that were also analyzed via microarray and qPCR), five 
chromophobe RCC, and three oncocytomas.  
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Table 3 Overview of patient samples. A Papillary renal cell carcinoma B. Clear cell renal cell carcinoma (pT= 
extension of primary tumor, pN=infiltration of lymphnodes, pM=metastasis) 
pTX: Primary tumor cannot be assessed, pT0: No evidence of primary tumor, pT1: Tumor 7 cm or less, limited to kidney,pT2: Tumor greater than 7 cm, limited to 
kidney, pT3: Tumor extends into major veins/adrenal/ perinephric tissue; not beyond Gerota's fascia, pT3a: Tumor invades adrenal/perinephric fat, pT3b: Tumor 
extends into renal vein(s) or vena cava below diaphragm, pT3c: Tumor extends into vena cava above diaphragm, pT4: Tumor invades beyond Gerota's fascia; pN - 
Regional lymph nodes, pNX: Regional nodes cannot be assessed, pN0: No regional lymph node metastasis, pN1: Metastasis in a single regional lymph node, pN2: 
Metastasis in more than one regional lymph node, pM - Distant metastasis, pMX: Distant metastasis cannot be assessed, pM0: No distant metastasis, pM1: Distant 
metastasis. 
A. Clear cell renal cell carcinoma 
Patient Appearance Grading pT: extension of primary tumor 
pN: infiltration of 
lymph nodes 
pM: 
metastasis Analysis 
1 Tubulary - 1 - - cDNA-array 
2 Azinary, tubulary 2 - - - cDNA-array 
3 - 2 3b 0 - cDNA-array 
4 Azinary, tubulary 2 - - - cDNA-array 
5 solid, compact, tubulary 2 3a 0 x cDNA-array 
6 Solid 3 - - - cDNA-array 
7 Azinary, tubulary 2 - - - cDNA-array 
8 Trabeculary 2 - - - cDNA-array 
9 Azinary, tubulary 2 - - - cDNA-array 
10 - 2 - - - cDNA-array 
11 Aleveolary 1 - - - cDNA-array  
12 Tubulo-azinary 2 1 0 - SELDI-TOF 
13 Azinary, trabeculary 2 - - - SELDI-TOF 
14 Solid, tubulo-papillary 2 2 0 x SELDI-TOF 
15 - 2 3a 0 0 SELDI-TOF 
16 Trabeculary, azinary 2 2 0 x SELDI-TOF 
17 Solid, azinary 1 3b 0 x SELDI-TOF 
18 Solid 2 2 2 x SELDI-TOF 
19 Azinary, trabeculary 1 1 - - SELDI-TOF 
20 Compact 2 3a 1 x SELDI-TOF 
21 Solid, azinary 1 3b 0 x SELDI-TOF 
22 - 2 1 0 x SELDI-TOF 
23 Trabeculary, azinary 2 2 0 x SELDI-TOF 
24 Solid, compact 2 2 X x SELDI-TOF 
25 Compact, trabeculary 2 1 0 x SELDI-TOF 
26 Comact, zystical 2 1b X 1 SELDI-TOF 
27 Solid - 3a 0 x SELDI-TOF 
28 Complex 3 3b - - SELDI-TOF 
29 Compact 2 2 X x SELDI-TOF 
30 Trabeculary 2 4 0 x SELDI-TOF 
B. Papillary renal cell carcinoma 
Patient Appearance Grading pT: extension of primary tumor 
pN: infiltration of 
lymph nodes pM:metastasis Analysis 
1 Papillary 2 1a - - cDNA-array 
2 Papillary 3 1 0 - cDNA-array 
3 Papillary 2 1b 0 X cDNA-array 
4 Tubulo-papillary - 1 - - cDNA-array 
5 Papillary - 3a - - cDNA-array 
6 Tubulo-papillary 1 3a 0 X cDNA-array 
7 Papillary - 1b - - SELDI-TOF 
8 Tubulo-papillary, solid 3 2 1 x SELDI-TOF 
9 Papillary - 3a - - SELDI-TOF 
10 Papillary 1 1a 0 x SELDI-TOF 
11 Papillary - 1 - - SELDI-TOF 
12 Papillary 2 1a x x SELDI-TOF 
13 Papillary - 2 - - SELDI-TOF 
14 Papillary - - - - SELDI-TOF 
15 Papillary 2 2 x x SELDI-TOF 
16 Tubulo-papillary 2 - - - SELDI-TOF 
17 Papillary 2 1 x x SELDI-TOF 
18 Tubulo-papillary, alveolary 2 2 0 x SELDI-TOF 
19 Tubulo-papillary 2 - 0 x SELDI-TOF 
20 Tubulo-papillary 2 2 0 x SELDI-TOF 
21 Tubulo-papillary 2 1 0 x SELDI-TOF 
22 Papillary, solid 2 2 0 x SELDI-TOF 
23 Papillary 2 - - - SELDI-TOF 
24 Tubulo-papillary 2 2 - - SELDI-TOF 
25 Solid, Trabeculary 2 - - - SELDI-TOF 
26 Solid, Compact 1 1 (3) 0 x SELDI-TOF 
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4.2.2 CELL LINES AND NATIVE LYMPHOCYTES 
For the functional analysis three RCC cell lines, one T-lymphocyte cell line as well 
as primary lymphocytes isolated from peripheral blood were used. A description of 
the established RCC cell lines, A498, CAKI1, CAKI2, and MOLT-4 and their cell 
culture conditions is given in Table 4. The cells were cultured at 37°C and 5% CO2. 
Table 4 Overview of cell lines used for cell culture experiments. 
Cell Line Cell Type Growth Conditions Growth Properties 
CAKI1 Human Kidney Carcinoma DMEM + 10% FCS Adherent 
CAKI2 Human Kidney Carcinoma DMEM + 10% FCS Adherent 
A498 Human Kidney Carcinoma RPMI + 10% FCS Adherent 
MOLT 4 T-Lymphocytes RPMI + 10% FCS  Suspension 
Lymphocytes were isolated from peripheral blood with lymphocyte separation 
medium according to manufacturer’s instructions. Stimulation of lymphocytes was 
carried out by adding 12 µg/ml phytohemagglutinin A (PHA-L). The cells were 
cultured at 37°C and 5% CO2. Lymphocytes were cultivated 72 h before adding 50 
ng/ml recombinant soluble CD70 (rmsCD70) to the cell culture. 
4.3 METHODS 
4.3.1 TRANSLATIONAL PROFILING 
For the translational approach a total of 20 clear cell and 20 papillary renal cell 
carcinoma tissue samples were used. This analysis was done to profile the protein 
patterns of both tumor-subtypes. The profiling was carried out using SELDI-TOF 
protein chips. Before applying the sample to the protein chip a cell lysis and 
protein extraction as well as a protein chip preparation was performed (chapter 
4.3.1.1). 
4.3.1.1 SELDI-TOF 
CELL LYSIS AND PROTEIN EXTRACTION. The cells were lysed using a specially developed 
lysis buffer (Buffer D; 64). Approximately 0.5 mg of frozen tissue was cut into slices 
in a cryostat in order to mechanically disrupt the cell membranes. Buffer D (200 µl) 
was placed immediately onto the slices. Samples were incubated on ice for 30 min 
and then centrifuged at 15000 rpm at 4°C for 15 min. The supernatant was used for 
subsequent protein chip analyses. 
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Buffer D 
0.1 M Na-Phosphat 
5 mM EDTA 
2 mM MgCl2 
3 mM β - 2 – Mercaptoethanol 
freshly added: 
1% CHAPS 
500 µM Leupeptin 
0.1 mM PMSF 
 
PROTEINCHIP ARRAY PREPARATION AND ANALYSIS. The extracted proteins from ccRCC and 
pRCC tissues were analyzed on a strong anion exchange array with quaternary 
amine functionality (Q10). The protein binding to the array was performed using a 
bioprocessor. First, array spots were equilibrated three times by applying 150 µl 
binding/washing buffer for 5 min at room temperature with vigorous shaking. After 
equilibration, samples were immediately applied to the spots (100 µg per spot) 
diluted in binding buffer and incubated with vigorous shaking for 30 min at room 
temperature. After removal of the samples, each well was washed three times with 
150 µl binding/washing buffer, followed by washing them twice with 150 µl water 
to remove the buffer salts and the samples were subsequently allowed to airdry. 
After two applications of 1 µl saturated sinapinic acid, mass analysis was performed 
in a ProteinChip System 4000 Series (PCS 4000 TOF – MS Personal) according to an 
automated data collection protocol. This includes an average of 195 laser shots to 
each spot with a laser intensity of 200 µA and 270 µA, respectively, depending on 
the measured region (low: 2–20 kDa and high: 20–200 kDa, respectively). The 
detector sensitivity was 9. Normalization of all spectra was performed using total 
ion current. 
 
Binding/washing buffer    Saturated Sinapic Acid 
100 mM Tris Buffer (pH 8.5)    dissolved in 
0.05% Triton x-100     50% Acetonitrile 
       0.5% Trifluoroacetic acid 
4.3.1.2 BIOINFORMATICAL ANALYSIS OF SELDI-DATA 
The bioinformatical analysis was done with two methods based on different 
statistical evaluations. First, the biomarker wizard software was used for 
calculation of p-values based on the Mann-Whitney U test for non-parametric data 
sets (65). Second, the program XL-miner, a cluster and rule-based data mining 
algorithm, was used to find specific protein sets that distinguish between the 
classifications (66). 
 
NORMALIZATION. Normalization of the protein expression was based on two 
assumptions. First, the average protein expression should be the same for all 
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samples and second, differences are due to sample preparation or handling. 
Therefore the average protein expression of each sample was calculated and 
subtracted from every expression value of that particular sample. Since a Lilliefors 
test showed that the data were rather log-normal than normal distributed all 
expression values were log2-transformed prior to this normalization procedure. 
 
SOFTWARE AIDED DATA INTERPRETATION WITH BIOMARKER WIZARD. Data interpretation was 
performed with the ProteinChip Software (version 3.0) to summarize generated 
protein profiles of all normal and tumor tissues. Cluster analysis of the detected 
signals and the determination of respective p-values were carried out with the 
Biomarker Wizard Program (Version 3.0; Ciphergen Biosystems Inc., Fremont CA). 
For p-value calculation, spectra with at least 10 signals in the range between 2 kDa 
and 20 kDa exhibiting a signal noise-to-ratio (S/N) of at least 5 were selected and 
analyzed with the Mann-Whitney U test for non-parametric data sets (65). 
 
SOFTWARE AIDED DATA INTERPRETATION WITH XL-MINER. Statistical analysis of the 
differentially expressed proteins was performed with the Software XL-miner. This 
program is a cluster and rule-based data mining algorithm (66). The CE software 
was used for the processing of raw spectra and the calculation of p-value and 
cluster plots according to the manufacturer’s instruction. This cluster and rule 
based data mining method consists of a clustering algorithm , a rule extraction and 
rating step and a rule base construction step (67). All these steps are supervised 
with respect to the given sample classification (e.g. tumor versus normal tissue). 
Additionally the data were normalized in a pre-processing step. 
First, the pre-processed protein expressions were clustered into two clusters – “low 
expressed” and “high expressed” – for each peak. Clusters were generated 
automatically using a supervised fuzzy clustering algorithm (68). For this purpose 
the median expressions of the given sample classes (e.g. the two classes: normal 
samples and tumor samples) were taken as the cluster borders. All samples with 
expression values below the lowest border were assigned to cluster “low 
expressed” with a membership of 1 and accordingly all samples with expression 
values above the highest border were assigned to cluster “high expressed” with a 
membership of 1. 
Second, the rule extraction and rating was carried out to find those features 
(peaks) with the most similar membership distribution compared to the given 
sample class distribution. For this purpose, “rules” are generated. Such rules 
consist of a condition part that is formed by one of the generated clusters and a 
conclusion part that is formed by one of the given sample classes. They can be 
written in the form: IF patient belongs to cluster ‘peak X high expressed’ THEN 
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patient belongs to class ‘tumor’. Combining all generated clusters and all given 
sample classes leads to a complete set of uni-conditional rules. These rules are 
logical hypotheses that have to be rated to find whether they are true or not. In 
this work the rules were rated using a statistically based rule rating measure 
introduced by Kiendl and Krabs that assesses the difference between the 
probability for the conclusion in the whole data set and the probability for the 
conclusion under the respective condition (69). Rules with a rule rating measure 
greater than zero were then ranked in a rule list.  
Third, with the rule base construction a small subset of rules is found which forms 
a rule-base that is used for automatic classification of new patient samples. A rule-
base contains at least one rule for every possible classification outcome. To classify 
a new patient sample the cluster memberships (condition part of the rules) of all 
rules out of the rule base that point to the same classification outcome (conclusion 
part of the rules) are added and the sample is assigned to the class with the 
highest sum. To construct a rule base that gives a good representation of the data 
set investigated all combinations of rules were permuted and the rule base with 
the smallest classification error and the smallest number of rules was chosen. The 
rules included in the chosen rule base represent markers that can distinguish 
between the sample classes under investigation. This rule base serves as a basis for 
the calculation of sensitivity (true positives / (true positives + false negatives) and 
specificity (true negatives / (true negatives + false positives) of the found rules. 
4.3.2 TRANSCRIPTIONAL PROFILING 
Transcriptional profiling is a method used for monitoring gene expression by 
measuring the amounts of transcribed mRNAs. This is possible due to rapid 
advances in high-throughput measurement technologies, like cDNA-microarrays. 
Here, transcriptional profiling was performed on clear cell and papillary renal cell 
carcinoma (ccRCC and pRCC) with pre-designed PIQORTM microarrays (Miltenyi 
Biotec GmbH). First, the total RNA was extracted from the tissue followed by an 
amplification of the mRNA (chapter 4.3.2.1). The hybridization, scanning, and 
evaluation of the microarrays was carried out according to Miltenyi Biotec´s 
standard protocol (chapter 4.3.2.1). A confirmation of the found regulations was 
done on the RNomic level using quantitative PCR (qPCR) and on the proteomic level 
using immunohistochemistry (IHC; chapter 4.3.2.2). 
4.3.2.1 CDNA-MICROARRAYS 
TOTAL RNA EXTRACTION. Approximately 2-4 mg tissue was used for each RNA 
extraction. Samples were reduced to small slices by cutting the frozen tissue with a 
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cryostat. Total RNA was isolated by standard methods using the commercially 
available RNeasy RNA Isolation Kit. Qualitative integrity test of purified total RNA 
was done by capillary electrophoresis using a Bioanalyzer 2100. The amount of RNA 
was measured with an UV-spectrophotometer. Only those samples that showed no 
RNA degradation were further analyzed. 
 
LINEAR AMPLIFICATION OF RNA. Linear amplification of RNA was done using a 
previously developed method (70). For the first strand synthesis 2 µg total RNA was 
added to the First Strand Mix. The mixture was incubated at 65°C for 5 min and 
cooled down to 42°C before adding 2 µl SSII RT (400 U). The samples were 
incubated again at 42°C for 1 h and put on ice. For the second strand synthesis, all 
reagents and tubes had to be ice cold. All components of the Second Strand Mix 
were added and samples were incubated at 16°C for 2 h. For the clean-up of 
dscDNA QIAquick was used according to the manufacturer’s protocol. After the 
clean-up, samples were dried in a speed vac and resuspended in 8 µl RNase-free 
H2O. 
First Strand Mix     Second Strand Mix  
4 µl 5 x First Strand Buffer   30 µl 5 x Second Strand Buffer 
2 µl 0.1 M DTT     4 µl DNA Polymerase I (40 U) 
1 µl 100 pmol/µl T7-(T)24 primer   3 µl 10 mM dNTPs 
1 µl 10 mM dNTPs    1 µl E. coli DNA Ligase (10 U) 
0.7 µl RNase H (2 U) 
91.3 µl DEPC H2O 
For the amplified RNA (aRNA) synthesis a Megascript T7 in vitro transcription Kit 
was used. All reagents had to be at room temperature. A NTP Mix was prepared and 
added to the samples together with 2 µl Enzyme Mix. The mixture was incubated in 
a thermocycler at 37°C for 6 h. 
NTP mix (per tube) 
2 µl ATP solution (75 mM)  
2 µl GTP solution (75 mM)  
2 µl CTP solution (75 mM)  
2 µl UTP solution (75 mM)  
2 µl 10 x Reaction Buffer 
The samples were cleaned again using a RNeasy Kit according to manufacturer’s 
instructions. Samples were now labeled to generate fluorescently labeled first 
strand cDNA. A total of 2 µg aRNA was used for the labeling reaction. Control RNA 
1, Control RNA 2, and (10x) Hexanucleotide Mix (each 2 µl) were added to the 
samples. aRNA samples were quantified by spectrophotometry and quality was 
assessed again by capillary electrophoresis (Bioanalyzer 2001). Again only those 
samples that showed no degradation and with an average length of 300 bp per 
aRNA were further analyzed. 
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TYPES OF MICROARRAYS. For the microarray experiments two different types of arrays 
were used. The aRNAs derived from ccRCC were hybridized on the PIQORTM 
Immuno/Onco Array (642 cDNA probes) whereas the aRNAs derived from pRCC were 
hybridized on the PIQORTM Immunology microarray (1070 cDNA probes; Figure 5). 
 
Figure 5 Overview of cDNA – array types used for the experiments (aRNA = amplified RNA, ccRCC = 
clear cell renal cell carcinoma, pRCC = papillary renal cell carcinoma). 
Both microarrays contain genes belonging to the categories listed in Table 5. The 
overlap between these different microarrays exhibits 562 cDNA probes. 
Table 5 Gene categories present on the used microarrays (n.s.: not specified). 
Gene Category Details 
Apoptosis,  
signal transduction, stress 
caspases, MAP-kinases, TRAFs, BCL-family, HSP70- family 
death domain containing proteins, tyrosine protein kinases, pi3-kinases 
CD antigens n.s 
Cell cycle, DNA-repair cyclins, BRCA-family, P53, P73, DNA-Ligases 
Chemokine receptors n.s 
Chemokines n.s 
Complement system n.s 
Cytokines interleukines, TGFA/B, PDGFA/B, TNFα and other members of the TNF-
family, IFNg, BMPs, inhibins, TGFβ-family 
Cytokine receptors interleukin receptors, TNF receptors 
Cytokine signaling 
and regulation 
JAK/STAT, SOCS, IRAK, NFAT 
Extracellular  
matrix proteins 
collagens, matrix-metalloproteases, TIMPs, matrillins, 
integrins, laminins, thrombospondins 
Inflammation NFkB metabolism, TOLL-receptors, phospholipases A2, 
prostaglandin receptors 
HYBRIDIZATION OF MICROARRAYS. Hybridization of ImmunoOnco PIQORTM and 
Immunology PIQORTM slides was performed according to manufacturer’s guidelines 
using a GeneTAC hybridization station and hybridization chamber respectively. The 
aRNAs (2 µg) from normal and tumor tissue were reverse-transcribed by adding a 
labelling mix. Samples were then incubated at 42°C for 30 min. After addition of  
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1 µl of SuperScriptTM II Reverse Transcriptase samples were incubated again at 42°C 
for 30 min. RNaseH (0.5 µl) was added and the samples were incubated at 37°C for 
20 min to hydrolyze RNA. 
Labeling Mix 
8 µl 5x First Strand Buffer 
2 µl Primer-Mix 
2 µl low C-dNTPs (10 mM dATP, 10 mM dGTP, 10 mM dTTP, 4 mM dCTP) 
2 µl FluoroLink Cy3/5-dCTP respectively 
4 µl 0.1 M DTT 
1 µl RNasin (20 to 40 U) 
200 U of SuperScriptTM II Reverse Transcriptase 
Cy3- and Cy5-labeled samples were combined and cleaned using QIAquickTM. 
Eluents were diluted to a volume of 50 µl. Hybridization solution (2x; 50µl), pre-
warmed to 42°C, was added to the labeled samples. 
To prepare the slides for hybridization, 100 µl of prehybridization solution were 
pipetted onto the slides which were then prehybridized at 65°C for 30 min. 
Thereafter, 100 µl purified Cy3- and Cy5-labeled probes in hybridization solution 
(2x) were pipetted onto the slides thereby displacing the prehybridization solution. 
Hybridization was performed for 14 h at 65°C, followed by four washing steps 
carried out at 50°C (71). 
Image capture of cDNA arrays was done with a laser scanner (ScanArray 4000 Lite 
or GenePix 4000B respectively). ImaGene software version 4.1 was used for signal 
quantification. The signal was measured for each spot inside a circle adjusted to 
the individual spot (160 – 230 µm diameters). Background was measured outside the 
circle within specified rings 30 µm distant to the signal and 100 µm wide. Signal 
and background were taken as the average of pixels between defined low and high 
percentages of maximum intensity defined as 0/97% for signal and 2/97% for 
background. Local background was subtracted from the signal to obtain the net 
signal intensity for both fluorescent dyes, Cy5/Cy3. First, the ratio was computed 
with the intensities for both dyes. Second, the mean of ratios of two corresponding 
spots representing the same cDNA was computed. The mean ratios were then 
normalised to the median of all mean ratios. This was done by using only those 
spots with a fluorescent intensity in one of the two channels that was two times 
above the negative control. The negative control for each array was computed as 
the mean of the signal intensity of two spots representing herring sperm RNA and 
two spots representing spotting buffer only. Only genes displaying a net signal 
intensity two-fold higher than the negative controls in the control sample or 
treatment sample were used for further analysis. Normalized ratios are shown as 
Cy5 signal intensity divided by Cy3 signal intensity of the respective gene. 
Unsupervised cluster analysis (Average Linkage Clustering) was carried out using 
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“Cluster” and “Tree View” programs according to Eisen (72). All microarray 
experiments were performed according to the MIAME guidelines (73). 
4.3.2.2 CONFIRMATION OF TRANSCRIPTIONAL PROFILING 
To verify the gene expression data obtained by cDNA-microarrays two independent 
methods were used. On the RNomic level a quantitative PCR (qPCR) was 
performed. On the protein level immunohistochemistry (IHC) for selected proteins 
was carried out. 
 
QUANTITATIVE PCR. To confirm the clear cell RCC gene expression data two gene 
primer pairs for CD70 and FOSL2 as well as one reference gene primer pair for MCP 
(Table 6) were designed from the published sequence of human SCC (SCC A1: 
DDBJ/EMBL/GenBank; HSU19556) antigen cDNA. The selection criteria for the 
corresponding amplified cDNA fragment include homology to other known genes 
(85%) and uniformity of the fragment length. All selection criteria are summarized 
in detail elsewhere (73). The primer design was performed with the software 
OLIGO (version 5.0). 
Table 6 Primer sequences for quantitative PCR to confirm gene expression data (tm = melting 
temperature). 
Candidate genes Sense primer 5´-3 Antisense primer 5´- 3´ Tm (°C) 
CD70: Tumour necrosis factor  
ligand) superfamily, member 7 
AATCACACAGGACCTCAGCAGGACC AGCAGATGGCCAGCGTCACC 88,8 
FOSL2: FOS-related antigen 2 CCCTGCACACCCCCATCGTG TGATTGGTCCCCGCTGCTACTGCTT 89,8 
MCP: Membrane cofactor protein ACTACAAAATCTCCAGCGTCCAG CAACTATGGCAATAACAATCACAGC 82,2 
Specificity of the desired qPCR products was documented using gel electrophoresis 
and melting curve analysis (LightCyler Software Version 3.5, 2001, Roche Molecular 
Biochemicals). The product specific melting curves showed only single peaks and no 
primer dimer peaks or artefacts. 
To confirm the papillary RCC gene expression data four primer pairs for the genes 
CALB1, CD98, CD68, and CD37 as well as one reference gene primer pair for IL1RAP 
were purchased from Qiagen (QuantiTect Primer assay). These primer pairs were 
specifically designed and developed for qPCR (Light Cycler). 
The following steps were carried out for all primer pairs equally. The aRNAs (2 µg) 
from both tumor and normal tissue were reverse transcribed with SuperScriptTMII 
Reverse Transcriptase using 100 µM random hexamer primers according to the 
manufacturer’s protocol. Experiments were performed with a LightCycler in 
capillaries using a Quantitect SYBR Green master mix containing HotStartTaq DNA 
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polymerase and SYBR-Green I deoxyribonucleoside triphosphates used according to 
manufacturer’s instructions. The following qPCR protocol was applied for all genes: 
• initial denaturation program for activating the HotStart enzyme (15 min at 
95°C) 
• amplification and quantification program repeated 45 times (15s at 95°C; 
10s at 55°C; 30s at 72°C) with a single fluorescence measurement. 
After completion of PCR amplification, a melting curve analysis was carried out. 
The “delta-delta CT method” for comparing relative expression results in qPCR was 
applied (74). 
 
IMMUNOHISTOCHEMISTRY. Immunohistochemistry was performed on frozen sections  
(8 µm) or cells grown in 96-well plates respectively which were fixed in acetone for 
10 min. Washing of slides was performed with Tris Buffer/Tween (0.1% w/v Tween, 
TBS-T) for 5 min. Slides were overlaid with 0.1% avidin for 10–15 min followed by 
an overlay with 0.01% biotin for 10–15 min. Biotin blocking was performed using the 
biotin blocking system from DAKO. After washing with TBS-T twice for 1 min and 
incubation for 10 min, protein blocking was carried out using a blocking solution 
containing 25 ml serum from goat in 250 ml TBS, 25 ml RPMI 1640, and 250 mg 
sodium azide for 10 min. The slides were washed three times for 1 min and 
incubated for 10 min with TBS-T. The primary antibody-antigen reaction was 
performed with the primary antibody (CD70, CD27, FOSl2, CD37, and CXCR4; 
dilution 1:250 for CD70 and FOSL2, 1:200 for CD27, CD37 and CXCR4) overnight at 
4-8°C. After washing with TBS-T (for 3x1 min and 1x10 min), slides were incubated 
with the biotin coupled secondary antibody (DAKO kit 5005) for 35 min according to 
manufacturer’s instructions. Slides were washed again with TBS-T (3x1 min, 1x10 
min) and Avidin-alkaline-phoshatase (DAKO kit 5005) solution was added for 30 min. 
After washing with TBS-T (3x1 min, 1x10 min), the enzyme reaction was carried out 
adding substrate (DAKO kit 5005) solution for 7 min. Slides were washed with water 
(3x1 min, 1x10 min). Finally, sections were stained with Haemalaun solution. 
TBS         TBS-T 
50 mM Tris        50 mM Tris 
150 mM NaCl        150 mM NaCl  
H20/1L         1 % Tween 20 
         H20/1L 
4.3.3 FUNCTIONAL PROFILING 
In order to compare the two cDNA-microarray gene expression datasets for clear 
cell renal cell carcinoma and papillary renal cell carcinoma (ccRCC and pRCC), a 
functional profiling was performed. Both tumor-subtypes were searched for equally 
and differentially expressed genes which were then subjected to a functional 
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annotation analysis. This method identifies enrichments of genes belonging to a 
common pathway or sharing other biological properties. 
4.3.3.1 GENE EXPRESSION DATA PREPROCESSING AND CLUSTERING ANALYSIS 
As the datasets for ccRCC and pRCC gene expression were generated by using 
different topic-defined microarrays, the analysis has been restricted to the subset 
of 562 PIQORTM probes present on both microarrays (Figure 5). For statistical 
analysis of the microarray data the software SAM (Statistical Analysis of 
Microarrays) was used (75). First, genes with missing values in the majority of 
experiments (>60%) were discarded. Second, any missing values in the remaining 
genes were estimated by 'N-nearest neighbor imputation' (76). This analysis 
resulted in two datasets: one containing all genes that are up- or down-regulated in 
both tumor-subtypes (subsequently called “equally regulated genes”) and a second 
one containing genes that are differentially expressed between the tumor-
subtypes. A functional annotation analysis for those datasets was performed by 
screening each dataset for a significant enrichment of genes belonging to a 
common pathway or sharing other biological properties. 
4.3.3.2 FUNCTIONAL ANNOTATION ANALYSIS 
Both datasets, for equally and differentially regulated genes in both tumor-
subtypes, were subjected to a pathway annotation analysis using Miltenyi´s 
TreeRanker system (Miltenyi Biotec GmbH). This software system analyzes groups 
of genes for a statistically significant enrichment of biological pathway annotation 
terms. These annotation terms are assigned according to characteristics and 
functions specific for the respective gene. Term enrichment relative to the 
expected background distribution was scored using Fisher's exact test. Miltenyi´s 
TreeRanker system has two basic features that distinguish this software from other 
recently published approaches (77-79). In detail, annotations derived from 
fundamentally different sources (Gene ontology, gene families, sequence motifs, 
chromosomal proximity, literature keywords, etc) can be scored simultaneously for 
each given group of genes resulting in a joint statistical significance value. 
Furthermore, the scoring approach can be applied to entire hierarchical gene trees 
scoring individual sub-branch and reporting only non-redundant instances of 
significant annotation enrichment in specific clusters. In this mode a Bonferroni-
correction was applied to the significance values accounting for the multiple-
testing situations. Genes up- or down-regulated in both tumor-subtypes were 
subjected to further analysis with Interaction Explorer Software Pathway Assist 
(Version 2.5; Stratagene). The ResNet database (as of August 30, 2005) was 
searched for common cellular processes and protein complexes. 
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4.3.4 FUNCTIONAL ANALYSIS OF CD70 
In order to test whether the up-regulation of CD70 in RCC is functional for the 
tumor by provoking apoptotic cell death, lymphocyte co-culture experiments using 
the permanent RCC cell lines A498, CAKI1, and CAKI2 were performed. These 
adherent growing cells were co-cultured with the floating permanent T-cell cell 
line MOLT 4 and primary lymphocytes. For further details on culture conditions see 
chapter 4.2.2. 
4.3.4.1 EXPRESSION OF CD70, CD27, AND SIVA IN PERMANENT CELL LINES 
CD70, CD27, and SIVA gene and protein expression in the permanent cell lines and 
in the primary lymphocytes was assessed via immunohistochemistry (IHC) and 
quantitative PCR (qPCR). For further details on the protocol see chapter 4.3.2.2. 
For qPCR, a QuantiTect® Primer Assay was purchased for the genes CD27 and SIVA 
as well as for the reference gene ILRAP1. The design of the primer pair for CD70 is 
described in chapter 4.3.2.2. 
4.3.4.2 ANALYSIS OF LYMPHOCYTE APOPTOSIS 
MOLT4 cells were resuspended at a concentration of 1 x 106 cells/ml in sterile PBS 
1640 (Gibco) before being added to flasks containing a RCC cell monolayer at a 
1.5:1 tumor cell/lymphocyte ratio. Cells were co-cultivated in fetal calf serum 
(fcs)-free medium for 3 h. Floating lymphocytes were removed from the RCC cell 
monolayers and assessed for apoptosis using APO-OneTM Homogeneous Caspase-3/7 
Assay (Promega Madison, WI, USA) according to the manufacturer’s directions. 
Blocking experiments were done by adding mouse monoclonal anti-human CD70 or 
mouse monoclonal anti-human-CD27 antibodies (both Ancell) when lymphocytes 
were incubated with the RCC monolayer. Both were used at a dilution of 5 µg/mL. 
The isotype control for the CD70 antibody was purified mouse immunoglobulin G1 
(Ancell). RmsCD70 was added to 1x106 cells/ml MOLT4 cells and native lymphocytes 
at a concentration of 50 ng/ml. Cells were cultivated in fcs-free medium for 3 
hours before performing the apoptosis assay APO-OneTM (Promega). 
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5 RESULTS 
The results obtained from the protein and gene expression profiling of clear cell 
and papillary renal cell carcinoma are displayed in chapter 5.1 and 5.2. The results 
from the functional profiling of the gene expression data for both tumor-subtypes 
are shown in chapter 5.3. The results from the functional analysis of CD70 can be 
found in chapter 5.4. A combined summary of all results is given in chapter 5.5. 
5.1 TRANSLATIONAL PROFILING 
Translational profiling was carried out to find specific protein patterns for each 
tumor-subtype. The profiling was done for clear cell and papillary renal cell 
carcinoma and corresponding normal renal tissue. The resulting peak patterns were 
searched for tumor-specific candidates for marker proteins with two different 
bioinformatic analysis methods. 
 
PATTERNS OF PROTEIN EXPRESSION ARE SPECIFIC FOR CLEAR CELL AND PAPILLARY RENAL CELL 
CARCINOMA. The SELDI spectra were compared in order to see if specific protein 
patterns for each tumor-subtype could be identified. A visual comparison reveals 
clear differences in the peak patterns found for papillary renal cell carcinoma 
(pRCC), clear cell renal cell carcinoma (ccRCC), and normal renal tissue (Figure 6). 
These differences are expressed as different intensities for a determined peak or 
even as the complete absence of a peak in one spectrum. The bioinformatic 
analyses of the spectra detected masses for which the expression levels were 
significantly different between normal and tumor tissue or between the two tumor-
subtypes. These masses can be classified into four biologically relevant groups. 
These groups correspond to masses that are significantly differentially expressed: 
1. in tumor tissue (both ccRCC and pRCC) versus normal renal tissue (normal) 
2. between ccRCC and corresponding normal  
3. between pRCC and corresponding normal 
4. between ccRCC and pRCC 
In the following paragraphs these groups are explained in more detail in order of 
appearance. 
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Figure 6 Representative examples of SELDI spectra for clear cell renal cell carcinoma, papillary 
renal cell carcinoma, and normal tissue. Visual comparison alone reveals differences in protein 
expression patterns (RCC= Renal cell carcinoma, Normal= Normal renal tissue; red and green 
arrows: peaks with a clear difference between normal and one tumor subtype, blue arrow: peaks 
with no difference between the analyzed tissues). 
GROUP 1: MASSES THAT DISTINGUISH BETWEEN NORMAL RENAL TISSUE AND BOTH TUMOR-
SUBTYPES. A comparison of the protein spectra found 12 masses that have 
significantly different intensities in both clear cell renal cell carcinoma (ccRCC) 
and papillary renal cell carcinoma (pRCC) versus normal renal tissue (normal, Table 
6). These 12 peaks differentiate between tumor tissue generally and normal. The 
peaks are all regulated in the same direction for both tumor-subtypes versus 
normal. Three masses (10347 Da, 10906 Da, and 11085 Da) were detected as being 
up-regulated in the tumor tissue and nine (3339 Da, 7561 Da 7599 Da, 11863 Da, 
15125 Da, 15335 Da, 25595 Da, 30170 Da, and 31026 Da) were found to be down-
regulated. 
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Table 6 Masses found with a statistically significant difference in intensity in clear cell renal cell 
carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) compared to normal renal tissue 
(Normal). Regulation given reflects direction of expression from normal. P-value was calculated 
with the software BiomarkerWizardTM. 
Mass (Da) ccRCC versus Normal (p-value) 
pRCC versus 
Normal (p-value) Regulation 
3339.9 0.00011 0.000002 Down 
7561.43 0.00944 0.000363 Down 
7599.91 0.00944 0.03 Down 
10347.06 0.0024 0.00609 Up 
10906.25 0.00097 0.00110 Up 
11085.41 0.0311 0.0015 Up 
11863.95 0.0386 0.0442 Down 
15125.18 0.013 0.00064 Down 
15335.86 0.02 0.0008 Down 
25595.79 0.00004 0.000001 Down 
30176.43 0.00009 0.00022 Down 
31026.77 0.03 0.044 Down 
GROUP 2: MASSES THAT DISTINGUISH BETWEEN CLEAR CELL RENAL CELL CARCINOMA AND 
CORRESPONDING NORMAL RENAL TISSUE. In general, the protein pattern found for clear 
cell renal cell carcinoma (ccRCC) shows a clear difference to the protein pattern 
for normal renal tissue (normal). Twenty-two masses with statistically significant 
differences in intensities were found which distinguish between ccRCC and normal. 
Six of these proteins or peptides are up-regulated in the tumor tissue compared to 
normal tissue and 16 of these proteins or peptides are down-regulated in the tumor 
tissue (Figure 10). Two of the 16 are particularly interesting because they have a 
very significant p-value: 25595 Da (p-value: 0.00004) and 30176 Da (p-value: 
0.00009). A boxplot shows the difference in intensity of expression for these two 
peaks of interest between normal and tumor tissue (Figure 7). Interestingly, both 
masses also appear as being differentially expressed in papillary RCC (Table 6). The 
software XL-miner also identified them as being able to distinguish between ccRCC  
 
Figure 7 Boxplots of protein peaks of interest that can discriminate between clear cell renal cell 
carcinoma (ccRCC) and normal renal tissue (Normal) (p-values: for 25595 Da= 0.00004, for 30176 
Da= 0.00009). 
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and normal renal tissue. The protein set found has a sensitivity of 95% and a 
specificity of 100%. Both proteins, or peptides, are specifically and consistently 
down-regulated in ccRCC tissue compared to normal renal tissue. 
GROUP 3: MASSES THAT DISTINGUISH BETWEEN PAPILLARY RENAL CELL CARCINOMA AND 
CORRESPONDING NORMAL RENAL TISSUE. The protein expression pattern found for 
papillary renal cell carcinoma (pRCC) shows a clear difference to the protein 
pattern for normal renal tissue. As expected, a notable difference can be seen 
compared to clear cell renal cell carcinoma (ccRCC). Forty-six masses with 
statistically significant differences in intensities were found which distinguish 
between pRCC and corresponding normal tissue. Interestingly, the number of 
statistically significant peaks detected in pRCC is twice as in ccRCC (Figure 10). 
Overall, 33 of these proteins or peptides are down-regulated in the tumor tissue 
compared to normal tissue and 13 proteins or peptides are up-regulated in the 
tumor tissue (Figure 10). In both tumor-subtypes an elevated number of down-
regulated proteins or peptides were detected compared to normal renal tissue 
(Figure 10). Compared to the regulations found in ccRCC, the high number of down-
regulated protein is notable. 
 
Figure 8 Boxplots of protein peaks of interest that can discriminate between papillary renal cell 
carcinoma (pRCC) and normal renal tissue (Normal, p-values: for 25585 Da= 0.000001, for 45888 Da= 
0.0001, for 3339 Da= 0.000002). 
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A boxplot of the protein peaks of interest shows a clear difference in intensity of 
expression between normal and tumor tissue (Figure 8). Three peaks were 
identified with a very low p-value: 25595 Da (p-value: 0.000001), 45888 Da (p-
value: 0.0001), and 3339 Da (p-value: 0.000002; Figure 9). This protein set has a 
sensitivity of 95% and a specificity of 88% (Figure 9). The peak at 3339 Da exhibits 
the most striking difference in intensity between pRCC tissue and normal renal 
tissue. Interestingly, the peak at 25595 Da was also found to be significantly 
different between ccRCC and normal renal tissue. The peak at 45888 Da seems to 
be highly specific for pRCC since it has not been detected as significantly regulated 
in ccRCC. 
 
Figure 9 Set of proteins and rules that distinguish between papillary renal cell carcinoma (pRCC) 
and normal renal tissue. Rule list (α = 95) with relevant rules for the prediction of pRCC (red frame) 
and normal renal tissue (green frame). Samples are clustered horizontally, peaks vertically. All 
expression values are log-2 transformed. The specificity of the combined rule base is 88%, the 
sensitivity is 95% (black: up-regulated, white: down-regulated, grey: no obvious tendency). 
GROUP 4: MASSES THAT DISTINGUISH BETWEEN CLEAR CELL RENAL CELL CARCINOMA AND 
PAPILLARY RENAL CELL CARCINOMA. Fourteen proteins or peptides were found as being 
differentially expressed between clear cell renal cell carcinoma (ccRCC) and 
papillary renal cell carcinoma (pRCC). Five of these proteins or peptides were up-
regulated in ccRCC compared to pRCC and nine proteins or peptides were down-
regulated in ccRCC (Figure 10). As expected, the number of peaks found to be 
significantly different between the two tumor-subtypes is lower in comparison to 
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the peaks found between the tumor-subtypes and normal renal tissue (Figure 10). 
Furthermore, pRCC seems to be more different from normal renal tissue than 
ccRCC with regards to the number of statistically significant peaks. In total, more 
proteins or peptides were found to be down-regulated than up-regulated. 
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Figure 10 Number of peaks with a significant difference in intensity detected between the analyzed 
tumor and normal tissues (pRCC= papillary renal cell carcinoma, ccRCC= clear cell renal cell 
carcinoma, N= normal renal tissue). 
Two peaks could be detected with a very low p-value: one peak at 9233 Da (p-
value: 0.002) and one peak at 5829 Da (p-value: 0.00007). A boxplot of these two 
protein peaks shows the difference in intensity of expression between ccRCC and 
pRCC (Figure 11). 
 
Figure 11 Boxplots of protein peaks of interest that can discriminate between clear cell renal cell 
carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC; p-values: for 9233 Da= 0.002 for 5829 
Da= 0.00007). 
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This protein set has a sensitivity of 75% and a specificity of 100% (Figure 12). 
 
Figure 12 Set of proteins and rules that distinguish between clear cell renal cell carcinoma (ccRCC) 
and papillary renal cell carcinoma (ccRCC). Rule list (α = 85) with relevant rules for the prediction 
of pRCC (red frame) and ccRCC (green frame). Samples are clustered horizontally, peaks vertically. 
All expression values are log-2 transformed. The specificity of the combined rule base is 100%, the 
sensitivity is 79% (black: up-regulated, white: down-regulated, grey: no obvious tendency). 
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5.2 TRANSCRIPTIONAL PROFILING 
The transcriptional profiling was carried out to find specific gene expression 
patterns for each tumor-subtype. The profiling was done for clear cell and papillary 
renal cell carcinoma and corresponding normal renal tissue. A description of the 
genes found is given in the next chapter. 
MICROARRAY ANALYSIS – 325 GENES (50 %) FOUND TO BE DIFFERENTIALLY EXPRESSED IN 
CLEAR CELL RENAL CELL CARCINOMA. A total of 325 genes (50.1% of genes present) were 
found to be more than two-fold differentially expressed in at least one tumor 
sample compared to corresponding normal renal tissue. Cluster analysis was 
performed to search for commonly up- or down-regulated gene clusters and found 
several gene clusters with a very homogeneous expression pattern (Figure 13). 
 
Figure 13 Cluster analyses of genes found in clear cell renal cell carcinoma, detectable in all 
microarray experiments with an enlargement of two areas of interest with down- and up-regulated 
genes (Figure legend: T and M = tumor tissue, N = normal tissue, red color: up-regulation, green 
color: down-regulation). 
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Among the genes detected, some were previously described as differentially 
regulated, but some are possibly new marker genes for ccRCC (the entire gene list 
with all results is shown in ‘Appendix II’). A list comparing the genes found to be 
regulated in this study with genes identified by other groups is shown in Table 7. 
Table 7 Genes found as being differentially expressed in clear cell renal cell carcinoma in this study 
previously identified and described by other groups. 
Gene name Unigene Number 
Patients showing ≥ two 
fold expression (Percent) 
Previously described 
CALB1 Hs. 1285 50% Martignoni and colleagues, 2001 
CCND1 Hs. 371468 70% Stassar and colleagues, 2001 
Collagen type II Hs. 408182 50% Droz and colleagues, 1994 
Collagen type IV Hs. 407912 50% Droz and colleagues, 1994 
CXCR4 Hs. 421986 70% Schrader and colleagues 2002 
HEVIN Hs. 75445 80% Gerritsen and colleagues, 2002 
Integrin type alpha I Hs. 519305 50% Droz and colleagues, 1994 
Integrin type alpha 5 Hs. 149609 50% Droz and colleagues, 1994 
Integrin type beta 2 Hs. 375957 60% Droz and colleagues, 1994 
LINK Hs. 2799 30% Boer, and colleagues, 2001 
LOX Hs. 102267 30% Lenburg, and colleagues, 2003 
PAI1 Hs. 356427 60% Swiercz and colleagues, 1998) 
VCAM1 Hs. 109225 50% Droz and colleagues, 1994 
VEGF Hs. 135039 80% 
Gerritsen and colleagues, 2002; 
Takahashi and colleagues, 1999 
VWF Hs. 440848 60% Braybrooke and colleagues, 2000 
Regulations were confirmed for the genes collagen type II and IV as well as 
integrin, type alpha, 1 and 5, and beta, type 2. Of special interest is the gene 
CXCR4 which was already described as a potential biomarker for RCC (16). Here, 
CXCR4 was found to be up-regulated in seven of ten tumor samples. Moreover, 
several so far unknown genes for ccRCC were identified as being differentially 
expressed (Table 8).  
Table 8 Previously unidentified genes found to be differentially expressed in clear cell renal cell 
carcinoma. 
Gene Unigene Number 
Patients showing ≥ two fold 
expression (Percent) 
Induction 
(x-fold) 
Pgs2 Hs. 156316 90% 0.074 
Fosl2 Hs. 220971 90% 0.259 
Tpa Hs. 491582 90% 0.294 
CD70 Hs. 99899 80% 39 
The four most prominent genes identified are PGS2, FOSL2, TPA, and CD70. A 
down-regulation in the majority of the examined samples has been found for PGS2, 
  Results 
  
35 
FOSL2, and TPA. However, the drastic induction of the gene CD70 (average of 39-
fold) in tumor tissue is of special interest. 
MICROARRAY ANALYSIS – 602 GENES (56%) FOUND TO BE DIFFERENTIALLY EXPRESSED IN 
PAPILLARY RENAL CELL CARCINOMA. A total of 602 genes (55.7% of genes present) were 
found to be more than two-fold differentially expressed in at least one tumor 
sample compared to corresponding normal renal tissue. Cluster analysis was 
performed to search for commonly up- or down-regulated gene clusters in pRCC 
and an overview of the results is shown in Figure 14. 
 
Figure 14 Overview of up- and down-regulated genes in papillary renal cell carcinoma. A. Down-
regulated B. Up-regulated (Red color: up-regulation, green color: down-regulation). 
As with ccRCC, several of the genes found to be differentially regulated for pRCC 
had been previously described but several new possible marker genes were also 
identified (the entire gene list with all results can be found in ‘Appendix II’). Two 
genes already known to be differentially regulated, TIMP1 and THBS2, were 
confirmed as being up-regulated in pRCC (80;81). Furthermore, several previously 
identified genes (for example genes with relevance to the extracellular matrix) 
were confirmed to be differentially expressed such as CEACAM 1, C-Kit, IGFBP6, 
CXCR4, TIMP 1, MMP-9, CD34, CD44, and Gro-1. A list comparing the genes found to 
be regulated in this study with genes identified by other groups is shown in Table 9. 
Additionally, a slight but nevertheless consistent over-expression of the genes 
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TNFR1, TNFRSF10b, and CD70 was detected. These three genes were also found to 
be up-regulated in ccRCC in this study. 
Table 9 Genes found to be differentially expressed in papillary renal cell carcinoma in this study 
previously described by other groups. 
Gene name Unigene Number 
Patients showing 
 ≥ two fold expression 
(Percent) 
Previously described 
CEACAM1 Hs. 512682 50% Kammerer and colleagues, 2004 
CD36 Hs. 120949 87.5% Gerritsen and colleagues, 2002 
C-Kit Hs. 479754 50% Petit and colleagues , 2004 
CXCR4 Hs. 421986 50% 
Gerritsen and colleagues 2002; 
 Bhaskar and colleagues, 2001 
IGFBP6 Hs. 274313 50% Takahasi and colleagues, 2003 
MMP-9 Hs. 297413 25% Gerritsen and colleagues, 2002 
Nidogen Hs. 356624 50% Gerritsen and colleagues, 2002 
PECAM Hs. 514412 50% Gerritsen and colleagues, 2002 
SPARC Hs. 111779 50% Gerritsen and colleagues, 2002 
TIMP1 Hs. 522632 75% Gerritsen and colleagues, 2002 
TIMP2 Hs. 104839 87.5% Bhaskar and colleagues, 2001 
Thrombospondin 2 Hs. 371147 50% Gerritsen and colleagues, 2002 
Thrombospondin 4 Hs. 211426 62.5% Gerritsen and colleagues, 2002 
VEGF Hs. 135039 25% Gerritsen and colleagues, 2002 
A total of seven genes that have not previously been described for pRCC were 
found to be differentially expressed (Table 10). The gene with the most prominent 
down-regulation in pRCC is CALB1 (0.35-fold), but also CCL13, CXCL14, and PLCG2 
are consistently and strongly down-regulated in most samples (Table 10). All 
differentially expressed genes can be found in ‘Appendix II’.  
Table 10 Previously undescribed genes identified to be differentially expressed in papillary renal 
cell carcinoma. 
Gene Name Unigene Number 
Patients showing  
≥ two fold 
expression 
(Percent) 
Induction  
(x-fold) 
CCL13 Hs. 54460 83% 0.57 
CXCL14 Hs. 100431 83% 0.53 
CALB1 Hs. 1285 83% 0.35 
MDU1 Hs. 81874 83% 0.6 
PLCG2 Hs. 270411 50% 0.51 
CD68 Hs. 445570 83% 1.7 
CD37 Hs. 349656 83% 2.25 
The inductions of CD68, CD37, CALB1, and MDU1 expression were among the 
strongest inductions found among all 1070 analyzed genes for pRCC and were 
observed in over 80% of the performed experiments. 
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5.2.1 CONFIRMATION OF DIFFERENTIALLY EXPRESSED GENES 
CD70 OVER-EXPRESSION IN CLEAR CELL RENAL CELL CARCINOMA WAS CONFIRMED WITH 
QUANTITATIVE PCR. Quantitative PCR (qPCR) was performed with all samples that 
have been previously examined on cDNA-microarrays. Two genes were selected to 
be confirmed by qPCR: FOSL2 and CD70 (Table 11). They were chosen due to their 
high potential to discriminate between normal and tumor tissue. One study had 
previously detected CD70 as up-regulated in renal cell carcinoma (RCC) by 
microarray experiments but no confirmation with array-independent methods was 
carried out (82). The down-regulation of FOSL2 in RCC has not been reported so 
far.  
Table 11 Qualitative correlation of microarray and quantitative (qPCR) data for clear cell renal cell 
carcinoma of CD70 and FOSL2. The percentage of samples in which the respective gene is >two-fold 
regulated is shown for both expression profiling platforms (the qPCR experiments were performed in 
triplicates and the standard deviation in all experiments performed lies between 0.02 and 1.9 %). 
Regulated 
gene 
Unigene 
Number 
Patients showing ≥ two fold 
expression by microarray (Percent) 
Patients showing ≥ two fold 
expression by qPCR (Percent) 
CD70 Hs. 99899 80% 80% 
FOSL2 Hs. 220971 90% 50% 
In order to compare the quantified mRNA molecules of the candidate genes in the 
relative expression ratio model, MCP was chosen as the reference gene for ccRCC 
because it showed no significant regulation on any hybridized microarray. The qPCR 
efficiency was set to 2 (E = 2.0) for all factors. For the gene CD70, relative 
expression data derived from microarrays and LightCycler experiments is shown as 
an example in Figure 15. 
The induction of CD70 gene expression was among the strongest inductions found of 
all genes that have been analyzed. In two microarray experiments in which CD70 
was not detectable, a modest repression of the gene was found via qPCR. The 
repression of the gene FOSL2 could only be seen in 50% of the examined samples.  
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Figure 15 Comparison of CD70 expression of clear cell renal cell carcinoma (ccRCC) versus normal 
tissue analyzed either by microarray or quantitative PCR (qPCR) technology (the qPCR experiments 
were performed in triplicates and the deviation within the standard error lies between 0.02 and 
1.9%). 
ALL SELECTED GENES, CD37, CALB1, MDU1, AND CD68 COULD BE CONFIRMED WITH 
QUANTITATIVE PCR AS BEING DIFFERENTIALLY EXPRESSED IN PAPILLARY RENAL CELL 
CARCINOMA. Quantitative PCR (qPCR) was performed with the same samples 
previously examined with cDNA-microarrays. Additionally, a total of six samples 
that had not been analyzed with cDNA-microarrays were subjected to qPCR. A 
subset of genes (CD37, CALB1, MDU1, and CD68) found to be differentially 
expressed was confirmed via qPCR in over 70% of the examined samples (Table 12). 
All four genes showed a high potential to discriminate between normal and tumor 
tissue. 
Table 12 Qualitative correlation of cDNA-microarray and quantitative PCR (qPCR) data for papillary 
renal cell carcinoma of four selected genes that seem to be discriminative between normal versus 
tumor tissue. The number of patients in which the respective gene is >2-fold regulated is shown for 
both expression profiling platforms (the qPCR experiments were performed in triplicates). 
Regulated gene Unigene Number Results from cDNA-microarray (Percent) 
Results from qPCR 
(Percent) 
CD37 Hs. 349656 87.5% 75% 
CD68 Hs. 445570 87.5% 83% 
MDU1 Hs. 81874 100% 83% 
CALB1 Hs. 1285 87.5% 83% 
In order to compare the quantified mRNA molecules of the candidate genes in the 
relative expression ratio model, IL1RAP was chosen as the reference gene because 
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it showed no significant regulation on all hybridized microarrays. The qPCR 
efficiency was set to 2 (E = 2.0) for all factors. The standard deviation in all 
experiments performed lies between 0 and 3.38%. The regulations found by cDNA-
microarrays were confirmed for all four genes by qPCR (Table 13). 
Table 13 Comparison of candidate gene expression of tumor versus normal tissue analyzed either by 
microarray or quantitative PCR (qPCR) technology (the qPCR experiments were performed in 
triplicates, green color: consistent results, yellow color: deviant results, n.m = not measured). 
 CD37 x-fold induction CD68 x-fold induction MDU1 x-fold induction CALB1 x-fold induction 
Sample qPCR Microarray qPCR Microarray qPCR Microarray qPCR Microarray 
1 n.m 1.55 0.06 1.92 9 E-07 
 
0.26 n.m 0.15 
2 435 1.26 278 2.4 0.4 0.27 0.059 0.13 
3 1.2 1.4 2.4 1.14 0.01 0.16 0.1 0.17 
4 0.6 1.6 1.3 1.25 0.1 0.1 0.06 0.7 
5 14 n.m 12.8 n.m 0.3 0.27 7 E-06 
 
0.16 
6 0.07 1.63 0.62 1.68 0.1 0.35 0.003 0.22 
7 210 1.2 39 1.24 n.m 1.6 6.6 0.52 
8 27.4 1.2 5.5 3.25 0.2 0.1 0.025 n.m 
9 1.2 n.m 26.7 n.m 0.3 n.m 0.05 n.m 
10 7.5 n.m 16.1 n.m 9.2 n.m 0.0024 n.m 
11 121 n.m 12 n.m 0.2 n.m 0.0002 n.m 
12 3 n.m 1.3 n.m 0.02 n.m 0.0004 
9.00E-07 
 
9.00E-07 
 
n.m 
CD70 COULD ADDITIONALLY BE CONFIRMED AS BEING DIFFERENTIALLY EXPRESSED WITH 
IMMUNOHISTOCHEMISTRY. To test if the induction on the mRNA level in the tumor 
samples is also reflected at the protein level, the localization of three molecules 
found in this study (CD70, CD37, and FOSL2) was examined by 
immunohistochemistry (IHC). The immunohistochemical staining for CD37 and 
FOSL2 were inconsistent and showed no conclusive discrimination between normal 
and tumor tissue. A positive staining for these proteins could only be observed in 
two out of ten cases. In contrast, IHC for CD70 clearly confirmed its differential 
expression (Table 14). 
A total of 68 tumor samples were analyzed for CD70, including 41 ccRCC (which 
includes those that were also analyzed via microarray and qPCR), 19 pRCC (which 
includes those that were also analyzed via microarray and qPCR), five 
chromophobe RCC, and three oncocytomas (Table 14). 
Table 14 Results after immunostaining with anti-CD70 antibody in different tumor types and in 
corresponding normal tissue (RCC= Renal cell carcinoma, No.= number, from Junker et.al (83). 
RCC type Tumor (no./Total No.) Normal (no./Total No.) 
Clear cell 41/41 0/41 
Papillary 1/19 0/19 
Chromophobe 1/5 0/5 
Oncocytoma 0/3 0/3 
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In each tissue section, more than 80 % of the tumor cells were stained. 
Corresponding normal kidney tissues were investigated in parallel. No 
immunostaining was detected in any normal sample (Table 14 and part A of Figure 
16). Negative controls showed the expected negative results for all antibodies 
used. 
 
Figure 16 Immunostaining for CD70 on frozen sections of A. normal tissue (x200) and corresponding 
clear cell renal cell carcinoma B.1. (x200) and B.2. (x350) C. papillary renal cell carcinoma and D. 
chromophobe renal cell carcinoma (x200). Red color indicates presence of the protein of interest. 
All ccRCC samples showed high CD70 expression in least 80% of the cells (part B.1 
and B.2 of Figure 16). Staining was accentuated in the tumor cell membrane, but 
was also weakly detected within the cells (Figure 16). No immunoreactivity could 
be detected in the surrounding stroma. Only in one pRCC sample high expression of 
CD70 was found (part C of Figure 16). However, histopathological classification was 
not reliable in this case. Focal immunostaining (less than 5%) occurred in five 
additional pRCC samples. One out of five chromophobe RCC expressed CD70 at a 
high level (part D of Figure 16). However, it was difficult to classify this tumor. No 
oncocytoma showed immunostaining for CD70.  
  Results 
  
41 
5.3 FUNCTIONAL PROFILING 
The functional profiling was carried out to find functional connections between the 
regulated genes for each tumor-subtype. The profiling was done for clear cell and 
papillary renal cell carcinoma (ccRCC and pRCC) and corresponding normal renal 
tissue. In order to compare the datasets generated by transcriptional profiling only 
those genes that were present on both topic-defined cDNA-microarrays were 
subjected to the functional profiling (chapter 4.3.2.1). For the comparative 
functional analysis, the gene expression dataset of pRCC was compared with the 
gene expression dataset of ccRCC. First, a global correlation analysis was 
performed to find out whether the gene expression profiles of patients belonging to 
the same tumor-subtype cluster together. Second, each dataset was searched for 
genes similarly regulated. Third, a functional annotation analysis was performed if 
a sufficient number of regulated genes were identified (Figure 17). 
 
Figure 17 Overview of the analysis design for the functional profiling (pRCC = papillary renal cell 
carcinoma, ccRCC = clear cell renal cell carcinoma). 
GLOBAL CORRELATION ANALYSIS OF GENE EXPRESSION DATASETS SHOWS THAT TUMOR-
SUBTYPES CLUSTER SEPARATELY. The correlation between the expression profiles of 
the datasets for clear cell and papillary RCC gene expression was assessed (Figure 
18). For this purpose, all genes that were found to be expressed in at least 55% of 
the samples were used. The expression profiles of both datasets satisfactorily 
cluster in clearly separable groups (Figure 18).  
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Figure 18 Global inter-experiment correlation analysis of genes present on both topic-defined 
PIQORTM microarray compositions. Yellow color indicates good correlation between two expression 
profiles while black squares represent poor or even anti-correlation (blue). 
Two samples of the ccRCC dataset show a very divergent expression profile, neither 
matching to the other ccRCC samples nor to the pRCC samples. Additionally, one 
experiment belonging to the pRCC dataset fits better to the ccRCC dataset. A 
closer inspection of patient data (e.g. histology, age, gender, and other 
pathologically relevant data) did not reveal possible reasons for these outliers. 
GENE REGULATIONS IN PAPILLARY AND CLEAR CELL RENAL CELL CARCINOMA. The comparative 
functional analysis revealed genes that were regulated in both tumor-subtypes in 
the same direction (equally) as well as genes that were differentially regulated. 
These genes can be divided into two groups: 
1. Discriminative genes for both tumor-subtypes. 
2. Genes equally expressed in both tumor-subtypes. 
GROUP 1: DISCRIMINATIVE GENES FOR BOTH TUMOR-SUBTYPES. The differentially 
expressed genes in both tumor-subtypes comprise thirteen genes that are up-
regulated in the ccRCC samples and down-regulated in the pRCC samples (Figure 
19). This gene set distinguishes between the tumor-subtypes applying a false-
discovery rate of zero to the combined dataset. Only one gene (FOSL2) was found 
to be consistently up-regulated in pRCC and consistently down-regulated in ccRCC. 
CD70 as well as PLGF are strongly up-regulated (39-fold and 20.8-fold, respectively) 
in all ccRCC samples, but only weakly (1.2-fold and 1.1-fold, respectively) in the 
pRCC samples. FOSL2 and HEVIN exhibit the most contrary expression between the 
tumor-subtypes. 
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Figure 19 Overview of genes discriminating between the clear cell and papillary renal cell 
carcinoma datasets (Unsupervised one-dimensional clustering of log2 data using the 'Euclidean 
distance' metric, red color: up-regulated in tumor tissue, green color: down-regulated, black color: 
no regulation, grey color: not measured). 
GROUP 2: GENES EQUALLY EXPRESSED IN BOTH TUMOR-SUBTYPES. Forty-five genes were 
identified to be regulated equally in both RCC subtypes (Table 15). They were 
grouped according to their characteristics and functional annotations. The down-
regulated genes in both tumor-subtypes are mostly enzymes (ten genes) or genes 
involved in lipid and carbohydrate metabolism (Table 15). Among the up-regulated 
genes in both tumor-subtypes was a significantly relevant group of 12 genes 
representing surface markers. Both groups were subjected to a functional 
annotation analysis. 
Table 15 Overview of genes up- or down-regulated in both examined renal cell carcinoma subtypes 
(m.a. = multiple annotation, no. = number). 
Genes down-regulated in both tumor-subtypes Genes up-regulated in both tumor-subtypes 
Gene Name Unigene No. Annotation Gene Name Unigene No. Annotation 
CCNH Hs.514 DNA-metabolism TNFR1 Hs.159 surface marker 
BAMACAN Hs.24485 DNA-metabolism BAFF Hs.270737 surface marker 
HSPA1A/HSPA1B Hs.432648 DNA-metabolism/HSP70 TNFRSF10B Hs.521456 surface marker 
ANPEP Hs.1239 Enzyme PMP22 Hs.76556 surface marker 
SOD1 Hs.75428 Enzyme PDGFRB Hs.30778 surface marker 
FYN Hs.439387 Enzyme CD53 Hs.82212 surface marker 
PLAT Hs.248197 Enzyme FCGR1A Hs.77424 surface marker 
RAR Hs.307905 Enzyme CD68 Hs.445570 surface marker 
PLCL Hs.355888 enzyme/lipid 
metabolism 
CD70 Hs.177136 surface marker 
PRKCL2 Hs.349611 enzyme/lipid 
metabolism 
CD19 Hs.96023 surface marker 
PRSS11 Hs.46 enzyme/lipid 
metabolism 
FCGR2 Hs.78864 surface marker 
PIK3CB Hs.239818 enzyme/lipid 
metabolism 
CD45 Hs.306278 surface marker 
PLCG2 Hs.75648 enzyme/lipid 
metabolism 
IL8 Hs.194778 m.a 
HSPA8 Hs.1570 HSP70 IL16 Hs.82127 m.a 
HSPA9 Hs.3268 HSP70 TUBA Hs.278242 m.a 
CTGF Hs.75511 lipid metabolism CASP4 Hs.141125 m.a 
CYR61 Hs.8867 lipid metabolism BID Hs.172894 m.a 
COL18A1 Hs.413175 m.a PLGF Hs.2894 m.a 
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Continuation of Table 15 
Genes down-regulated in both tumor-subtypes Genes up-regulated in both tumor-subtypes 
Gene Name Unigene No. Annotation Gene Name Unigene No. Annotation 
COL6A1 Hs.26208 m.a CSK Hs.77793 m.a 
LTBP4 Hs.85087 m.a CX3CR1 Hs.80420 m.a 
DCN Hs.83974 m.a SPARC Hs.333175 m.a 
ATF5 Hs.9754 m.a STAT1 Hs.21486 m.a 
BACH1 Hs.154276 m.a    
FUNCTIONAL ANNOTATION ANALYSIS REVEALS MECHANISMS ENABLED IN BOTH TUMOR-SUBTYPES. 
The aim was to search for common cellular processes enabled in RCC according to 
their annotations. The relations found for the up-regulated genes are shown in 
Figure 20 and for the down-regulated genes in Figure 21. A better visualization of 
the connections found was achieved by displaying the specific functions of the 
genes rather than general annotations. 
 
Figure 20 Network analysis of the genes that are down-regulated in both tumor-subtypes (blue halo) 
to identify common cellular processes (yellow boxes) and protein complexes (hexagons; green 
arrow: activation, red arrow: inhibition, grey arrow: unknown influence). 
The genes that are down-regulated in both tumor-subtypes encode mostly for 
enzymes or are genes which encode for proteins that are related to the lipid and 
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carbohydrate metabolism (Table 15). A detailed visualization of all relations found 
is given in Figure 20. Several down-regulated genes (CTGF, ATF5, SOD1, HSPA8, 
FYN, COL18A1, and HSPA1a) were found that are related to apoptosis or cell death 
(Figure 20). There are also genes down-regulated in both tumor-subtypes that are 
related to cell motility and proliferation, like ANPEP, DCN, and CYR61 (Figure 20). 
For the 22 genes that are up-regulated in both tumor-subtypes, more complex 
connections could be detected (Figure 21). Ten out of these 22 genes have multiple 
annotations even though most of them are related to cell motility (Figure 21). 
However, more than 50% of these 22 genes up-regulated in both tumor-subtypes 
belong to the annotation “surface markers”. A closer look at the function of those 
surface markers revealed their possible involvement in apoptotic processes and 
immune response. 
 
Figure 21 Network analysis of the genes that are up-regulated in both tumor-subtypes (blue halo) to 
identify common cellular processes (yellow boxes) and protein complexes (hexagons). Most of the 
processes involved are related to apoptosis or cell death (green arrow: activation, red arrow: 
inhibition, grey arrow: unknown influence). 
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SIGNIFICANT ENRICHMENT OF SURFACE MARKERS UP-REGULATED IN BOTH TUMOR-SUBTYPES 
RELATED TO IMMUNE RESPONSE. Five out of the 12 genes (TNFRSF10B, CD70, TNFR1, 
PDGFRB, and BAFF) are directly related to immune response, apoptosis, and cell 
death and they are up-regulated in both tumor-subtypes (Figure 22). One of these, 
CD70, stands out because of its known ability to induce apoptosis and thus its 
potential involvement in the tumor immune response. The genes TNFR1 and 
TNFRSF10B are both receptors which transmit the signal for activation of apoptotic 
processes. BAFF is known to regulate the survival of B- and T-lymphocytes. 
Although the function of PDGFRB is not completely understood, it is known that it 
also plays a role in apoptotic processes. 
 
Figure 22 Schematic representation of genes equally expressed by both tumor-subtypes related to 
apoptotic processes (blue: up-regulated genes, red: down-regulated genes, yellow: affected 
processes, green arrow: activation, red arrow: inhibition, grey arrow: unknown influence). 
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5.4 FUNCTIONAL ANALYSIS 
RENAL CELL CARCINOMA CELL LINES EXPRESS THE CD70 LIGAND BUT NOT THE RECEPTOR. In 
order to test whether renal cell carcinoma (RCC) cell lines express the components 
required for CD70-initiated apoptosis, CD70, SIVA, and CD27 expression levels were 
analyzed using quantitative PCR (qPCR) and immunohistochemistry (IHC). 
QUANTITATIVE PCR. All RCC cell lines tested expressed the CD70 ligand, although 
only a negligible expression was found in the CAKI1 cell line (Table 16). In contrast, 
the A498 cell line showed a very prominent induction of CD70 compared to normal 
renal tissue. Experiments were performed in duplicates and the deviation within 
the standard error lies between 0.007-0.14%. In comparison to MOLT4 cells, the 
RCC cell lines A498 and CAKI2 show less expression of SIVA (Table 16). These 
experiments were performed in duplicates and the standard error lies between 
0.01–0.27%. 
Table 16 Expression ratios of CD70 and SIVA in cell lines used determined by qPCR. CD70 expression 
ratios in renal cell carcinoma (RCC) cell lines compared to normal renal tissue; SIVA expression 
ratios in RCC cell lines compared to MOLT4 cells (n.m. = not measured). 
Cell Line Relative expression of CD70 (x-fold) Relative expression of SIVA (x-fold) 
A498 351.52 0.23 
CAKI1 0.16 n.m. 
CAKI2 1.71 0.07 
Additionally, expression of CD70, CD27, and SIVA in native lymphocytes was 
compared to MOLT4 T-cells by qPCR (Table 17). A higher expression level for all 
three genes was found in native lymphocytes (Table 17). These experiments were 
performed in duplicates and the standard error lies between 0.05-0.23%.  
Table 17 Expression ratios of CD70, CD27, and SIVA expression ratios in native lymphocytes 
compared to permanent MOLT4 T-cells determined by qPCR. 
Gene Relative expression (x-fold) 
CD70 2.69 
CD27 22149.71 
SIVA 6.80 
IMMUNOHISTOCHEMISTRY. A confirmation at the protein level with 
immunohistochemistry (IHC) showed a clear signal for CD70 in the cell line A498. In 
both cell lines CAKI2 and CAKI1 signals could also be detected even though the 
staining was more heterogeneous compared to A498 cells (Figure 23). In contrast, 
the staining for CD27 resulted in only weak signals in all three cell lines (Figure 23). 
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For SIVA, a clearer signal could be detected in A498 cells whereas CAKI1 and CAKI2 
cells showed weaker signals (Figure 23). 
 
Figure 23 Immunostaining for CD70, CD27, and SIVA on adherent growing cell lines. A.1. A498 cells 
stained against CD70 (200x) A.2 A498 cells stained against CD27 (200x) A.3. A498 cells stained 
against SIVA (300 x) B.1. CAKI1 cells stained against CD70 (200x) B.2 CAKI1 cells stained against 
CD27 (200x) B.3. CAKI1 cells stained against SIVA (300x) C.1. CAKI2 cells stained against CD70 (200x) 
C.2 CAKI2 cells stained against CD27 (200x) C.3 CAKI1 cells stained against SIVA (300x) (Red color 
indicates presence of protein of interest). 
RENAL CELL CARCINOMA CELLS INDUCE APOPTOSIS IN MOLT-4 T-CELLS. RCC cell lines, 
CAKI1, CAKI2, and A498 were co-cultured with MOLT-4 T-cells for three hours. 
Apoptosis was assessed in T-cells with a Caspase 3/7 assay after being separated 
from the adherent growing RCC cells. Two out of these three RCC cell lines (A498 
and CAKI2) induced T-cell apoptosis, whereas no effect was observed with CAKI1 
(Figure 24). RCC induced apoptosis in MOLT-4 T-cells was 1.31-fold for A498 (n=6) 
and 1.38-fold for CAKI2 (n=4; Figure 24). 
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Figure 24 Apoptosis ratios of T-cells co-cultured with RCC cell lines CAKI1 (left), CAKI2 (middle) and 
A498 (right). The caspase activity ratio is shown relative to normal caspase activity in MOLT-4 cells 
in culture. (Figure legend: vertical stripes: no antibody added, white: anti-CD70 antibody added, grey: anti-CD27 antibody 
added, black: Isotype control added) 
In order to test whether this effect is mediated by CD70 expression and transmitted 
via CD70/CD27 interaction, blocking experiments were performed in which anti-
CD70 and anti-CD27 antibodies were added. MOLT4 T-cells co-cultured with the 
CD70-positive RCC cell lines A498 and CAKI2 were completely protected from 
induced apoptosis when anti-CD70 antibody (p-value = 0.019 for A498; p-value = 
0.046 for CAKI2) or anti-CD27 antibody (p-value = 0.0014 for A498; p-value = 0.16 
for CAKI2; Figure 24) was added to the cell cultures. Mouse immunoglobulin G1 was 
used as a negative control and had no inhibitory effect. 
RECOMBINANT SOLUBLE CD70 INDUCES APOPTOSIS IN LYMPHOCYTE CULTURE. The effect of 
recombinant soluble CD70 (rmsCD70) on lymphocytes was assessed to elucidate if 
the protein is responsible for the induced apoptosis rate. After addition of 50 ng/ml 
rmsCD70 to permanently growing MOLT4 T-cells, an average of 1.26-fold (n=5) T-
cell apoptosis was observed. Native lymphocytes showed an average of 1.34-fold 
(n=2) apoptosis (Figure 25).  
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Figure 25 Effect of recombinant soluble CD70 and anti-CD70 and anti-CD27 antibodies on the 
apoptosis rate of MOLT4 cells (left) and native lymphocytes (right). RmsCD70 was added at a 
concentration of 50 ng/ml (Figure legend: vertical stripes: no antibody added, white: anti-CD70 antibody added, grey: 
anti-CD27 antibody added, black: Isotype control added). 
In summary, the experiments with rmsCD70 and anti-CD27 and anti-CD70 antibodies 
revealed that CD70 has a direct effect on the apoptosis rate of lymphocytes. 
RmsCD70 induced apoptosis in MOLT4 T-cells was completely blocked in the 
presence of anti-CD27 antibody (p-value = 0.030) and in the presence of anti-CD70 
antibody (p-value = 0.032; Figure 25). The induced apoptosis rate in native 
lymphocytes was completely blocked after adding anti-CD27 antibody (p-value = 
0.011) and after adding anti-CD70 antibody (p-value = 0.005; Figure 25). In 
addition, the inhibitory effect of anti-CD70 antibody observed in native 
lymphocytes over-compensated the induced apoptosis. No inhibitory effect was 
observed after adding mouse immunoglobin G1. 
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5.5 SUMMARY OF RESULTS 
TRANSLATIONAL PROFILING. The patterns of protein expression found with SELDI-TOF 
technology are specific for clear cell and papillary renal cell carcinoma (ccRCC and 
pRCC). The peak patterns clearly distinguish the tumor-subtypes from each other 
and from normal renal tissue (normal). Twelve masses with a statistically 
significant difference in intensity were found for tumor versus corresponding 
normal. Twenty-two masses with a statistically significant difference in intensity 
were detected to be specific for ccRCC versus normal. Two peaks at 25595 Da and 
30176 Da show a very high discriminative potential and are possible markers for 
this tumor-subtype. Forty-six masses with a statistically significant difference in 
intensity were found to be specific for pRCC versus normal. Of these, three peaks 
(25595 Da, 45888 Da, and 3339 Da) can discriminate between pRCC and normal and 
could serve as potential markers. Since the peak at 25595 Da has been detected for 
both clear cell and papillary RCC it can be considered as a general potential marker 
for RCC which is not discriminative between the two tumor subtypes. The peak at 
45888 Da was only detected in pRCC and is absent in ccRCC. Thus it can considered 
as highly specific for pRCC. Fourteen masses with a statistically significant 
difference in intensity distinguish between ccRCC and pRCC. Two peaks at 9233 Da 
and 5829 Da distinguish with a high discriminative potential between ccRCC and 
pRCC. The respective proteins can be considered as potential markers specific for 
either ccRCC or pRCC. In summary, the translational analysis with SELDI-TOF 
technology revealed potential candidate markers for both tumor-subtypes that 
have to be identified and studied in more detail. 
 
TRANSCRIPTIONAL PROFILING. The transcriptional analysis with cDNA-arrays led to the 
identification of potential candidate markers for both tumor-subtypes. Microarray 
analyses revealed 325 genes (50.1 %) to be differentially expressed in ccRCC and 
602 genes (55.7%) to be differentially expressed in pRCC. Out of these differentially 
expressed genes those were selected that could discriminate between tumor and 
normal tissue. These genes for both tumor-subtypes were analyzed with 
quantitative PCR (qPCR) and immunohistochemistry (IHC). The gene CD70 for 
ccRCC and the genes CD37, CALB1, MDU1, and CD68 for pRCC were additionally 
analyzed on the mRNA-level and the expression data could be reproduced. 
Additionally, the specificity of CD70 was tested in IHC experiments and confirmed 
CD70 as being specifically over-expressed in ccRCC compared to other RCC 
subtypes.  
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FUNCTIONAL PROFILING. Global correlation analysis of gene expression datasets 
showed that tumor-subtypes cluster separately. Forty-five genes are regulated 
equally and 13 genes are regulated differentially in ccRCC and pRCC. Functional 
annotation analysis reveals mechanisms enabled in both tumor-subtypes. A 
significant enrichment of genes that are related to an immune response are 
regulated in both tumor-subtypes. Among them is the gene CD70. The functional 
profiling shed light on the underlying biology of both tumor-subtypes by elucidating 
common processes.  
 
FUNCTIONAL ANALYSIS OF CD70. Renal Cell Carcinoma (RCC) cell lines express the 
CD70 ligand but not the CD27 receptor. RCC cells induce apoptosis in MOLT-4 T-
cells through CD70 expression. Recombinant soluble CD70 induces apoptosis in 
lymphocytes and MOLT 4 T-cells. These analyses confirmed the over-expression of 
CD70 in RCC cells as being functional for the tumors.  
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6 DISCUSSION 
The biology of renal cell carcinoma (RCC) was studied using a model system 
composed by the two most common RCC subtypes which, despite sharing a common 
cellular origin, display discrete histological and genetical patterns. In order to 
elucidate tumor-specific and tumor-subtype specific expression profiles, 
transcriptional and translational approaches have been used. These approaches 
were chosen because they comprise the important levels of gene and protein 
expression and thus provide a global look into the processes that occur in the 
tumor cells.  
The application of these approaches led to the identification of genes and proteins 
that are differentially expressed in clear cell and papillary renal cell carcinoma 
(ccRCC and pRCC). The translational profiling resulted in specific protein patterns 
for each tumor-subtype. Through transcriptional profiling, potential specific 
marker genes for ccRCC and pRCC have been identified. Most strikingly, the over-
expression of the gene CD70 was found to be highly specific for ccRCC. Thus, CD70 
can be considered as a new marker gene for ccRCC. Finally, the gene expression 
data was additionally searched for groups of genes involved in similar processes. 
This analysis revealed a significant enrichment of genes differentially expressed in 
both tumor-subtypes which could be involved in an immune escape strategy of RCC. 
These results are particularly interesting since, despite the presence of tumor-
infiltrating lymphocytes (TILs), RCC successfully manage to suppress the immune 
system.  
Among the genes up-regulated in both tumor-subtypes was CD70, which has been 
found to be involved in the immune escape strategies of other tumors. A closer 
inspection of CD70 function within the tumor environment of RCC revealed its 
capacity to induce apoptosis in TILs and thus enable RCC to suppress the immune 
system. In summary, this study has not only identified new, tumor-subtype specific 
marker genes but has also increased our understanding of the underlying biology of 
RCC by identifying a possible mechanism by which RCC escapes immune 
recognition. 
6.1 TRANSLATIONAL PROFILING 
The aim of the translational profiling was to identify protein patterns specific for 
both ccRCC and pRCC. This was achieved by combining ProteinChip technology 
(SELDI-TOF: Surface Enhanced Laser Desorption Ionization – Time of Flight) and 
bioinformatic tools. The advantage of using proteomic tools for cancer analysis is 
the possibility to study tumor-specific expression very close to the real conditions 
within the cells. 
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Several proteomic tools are currently applied to analyze protein expression (84;85). 
The most widely used is the two-dimensional protein gel electrophoresis (2D-PAGE) 
which can display protein expression patterns to a high degree of resolution (86). 
However, 2D-PAGE can be time-consuming, the analysis is complicated and, 
compared with DNA techniques, this approach is not very sensitive. In contrast, the 
SELDI-TOF technology is more sensitive than 2D-PAGE, especially in the lower mass 
range, and it can be employed to generate protein expression patterns from whole 
tissue extracts. Finally, it enables the analysis of proteins at femtomole levels 
directly from their native sources (8, 9, 30). Previous studies applied this technique 
successfully for molecular cancer research (87-89).In this study, SELDI-TOF analyses 
of 40 tumor samples and corresponding normal renal tissue were performed in 
order to define tumor specific protein patterns for ccRCC and pRCC. The peak 
patterns clearly distinguish the tumor-subtypes from each other and from normal 
renal tissue. 
The statistical analysis revealed several peaks with discriminative power either for 
normal versus tumor tissue or between both tumor-subtypes. Interestingly, several 
peaks were found to discriminate pRCC from both normal renal tissue and ccRCC. 
No such peaks were detected for ccRCC. An interpretation of this finding is highly 
speculative, but considering the common origin of these subtypes it could point 
towards evolutionary processes in the development of the RCC subtypes. 
It was possible to identify the ccRCC tumor samples with a specificity of 100% and a 
sensitivity of 95% using bioinformatic tools. This result is consistent with two 
earlier published studies. Fetsch et al. investigated archival cytology material from 
different tumor tissues including five RCC samples of various histological subtypes 
(61). They were able to establish specific protein fingerprints allowing diagnosis of 
each tumor type in 87%. More recently, Junker et al. reported a protein set which 
identifies ccRCC with a sensitivity of 94.0% and specificity of 98.9% (62).  
Up to now, no protein pattern specific to pRCC has been identified. Here, a set of 
proteins was detected that distinguishes between normal and pRCC tissue with a 
sensitivity of 95% and a specificity of 88%. The peak found at 45888 Da is highly 
specific for pRCC since it does not appear in the pattern for ccRCC. However, since 
the proteins found are down-regulated in the tumor tissue they are not usable as 
potential biomarkers. Finally, the two protein peaks (9233 Da and 5829 Da) which 
differ in their expression levels between ccRCC and pRCC have a discriminative 
potential of 79% sensitivity and 100% specificity. A further identification of these 
protein peaks could perhaps lead to a biomarker to distinguish the two tumor-
subtypes.  
As expected, more protein peaks were found to be differentially expressed 
between normal and tumor tissue than between ccRCC and pRCC. Fourteen protein 
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peaks with statistically significant differences in intensity between the tumor-
subtypes were found which clearly separates them, even without knowing all of the 
respective proteins. Thus, the protein pattern found for pRCC shows a clear 
difference to the protein pattern for ccRCC. 
In conclusion, the differences in protein expression detected between the tumor-
subtypes are reflecting the fact that different subtypes of RCC represent 
independent tumor entities as shown by a variety of studies (3). For the first time, 
a specific protein expression pattern for pRCC was established. The patterns 
revealed promising candidate molecules for biomarkers that have to be studied in 
more detail.  
6.2 TRANSCRIPTIONAL PROFILING 
The transcriptional profiling studied gene expression in ccRCC and pRCC using cDNA 
microarrays. This technique covers the transcriptional level of expression and is 
very useful for the identification of more genes relevant for RCC development and 
progression. However, microarray data must be confirmed by array independent 
technologies like qPCR, which is used to quantify physiological changes in gene 
expression and to verify gene expression results derived from microarrays (71;90). 
Nevertheless, microarrays have already been applied successfully for biomarker 
discovery (91;92).  
In general, our knowledge about differentially regulated genes in pRCC is still 
limited (81;82) even though genes involved in ccRCC have been identified. The 
most prominent finding for RCC so far is the identification of the Von Hippel-Lindau 
tumor suppressor gene (VHL) as being involved in the development of distinct types 
of RCC. It is located on chromosome 3p25-26 and was found to be altered in up to 
75% ccRCC by mutations or hypermethylation (93). Thus, the microarray analysis 
carried out in this study revealed differentially expressed genes specific for either 
normal or tumor tissue in both tumor-subtypes. Potential candidate molecules for 
both tumor-subtypes could then be studied in more detail. 
 
POTENTIAL MARKER GENES FOR CLEAR CELL RENAL CELL CARCINOMA. In general, the gene 
expression data found for ccRCC is consistent with previously published data. The 
pattern of regulations found in this study for genes such as collagen type II, IV as 
well as integrin, type alpha, 1 and 5, and beta, type 2 were the same as seen in a 
study by Droz et al. (94). However, this study revealed two additional genes, CD70 
and FOSL2, to be differentially expressed between tumor and normal tissue in 80% 
or more of the samples. These two genes were thus subjected to further scrutiny 
with qPCR and IHC.
  Discussion 
 
56 
The discriminating potential of FOSL2 found by microarray analysis could not be 
confirmed with qPCR and was only detected focally in two cases with IHC. This is 
not surprising given the differences in sensitivity among the techniques, especially 
the high sensitivity of qPCR versus microarrays. Meanwhile, the discriminative 
potential of CD70 found by microarrays was confirmed by both qPCR and IHC. The 
over-expression was confirmed in eight of ten samples by qPCR and also IHC 
analyses for these ten samples showed a clear signal in ccRCC. In order to examine 
the specificity of CD70, IHC was carried out with more ccRCC samples as well as 
with other RCC subtypes (83). Whereas samples from chromophobe, papillary or 
oncocytoma showed no reactivity, in all additional ccRCC samples a strong protein 
expression of CD70 could be detected. 
In addition, the recently described marker CXCR4 was found by microarray 
experiments to be over-expressed by in ccRCC. CXCR4 expression in ccRCC was 
confirmed by microarray experiments in seven out of ten tumor samples. However, 
it showed heterogeneous staining in IHC (95). In contrast, the IHC experiments with 
CD70 showed conclusive results in almost all examined ccRCC samples, whereas the 
other tumor-subtypes were negative. Thus, among the genes identified by 
microarrays, the gene CD70 can be considered as a new, specific marker gene for 
ccRCC. 
Although some information about CD70 is available, the role of this gene in tumor 
development and progression remains unclear. It is a Type II transmembrane 
glycoprotein known to mediate the interaction between T-and B- lymphocytes, and 
natural killer-cell activation. It has also been implicated in processes like cell 
proliferation, signal transduction, and cell-to-cell signalling, and can also induce 
apoptosis by binding to its receptor CD27 (96;97). In addition, several studies have 
shown that CD70 can be over-expressed in malignant lymphomas and 
nasopharyngeal tumors which are both associated with Epstein-Barr virus (96). More 
recently, CD70 has been proposed as a possible target molecule for antigen-
dependent cytotoxicity in metastatic sites of RCC (98). Nevertheless, in other 
genome wide studies performed so far, with the exception of the study of Lenburg 
et al., the up-regulation of CD70 has not been detected in ccRCC (82;99). 
Given that RCC is known to be infiltrated by lymphocytes, it is tempting to 
speculate that CD70 over-expression might play a role in RCC immune escape 
through induction of lymphocyte apoptosis. This is especially the case since 
Chahlavi et al. showed that the over-expression of CD70 in glioblastoma leads to T-
cell death (100). Interestingly, the role of CD70/CD27 interactions in T- and B-cell 
activation has already led to promising treatments for cancer (97). The possible 
role of CD70 in ccRCC is discussed in chapter 6.4. 
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POTENTIAL MARKER GENES IN PAPILLARY RENAL CELL CARCINOMA. The microarray data for 
pRCC was compared with earlier studies. The results were consistent with those 
studies that had overlapping datasets. For example, the gene expressions found 
match previously published data for the genes THBS2, C-Kit, GRO-1, TIMP1, TIMP2, 
CXCR4, and IGFBP6 (12;80;81;101). 
Of special interest were the genes CD37, CALB1, CD96, and CD68 because of their 
high potential to discriminate between normal and tumor tissue. A confirmation of 
the microarray data via qPCR showed a strong correlation for all examined genes. 
In order to confirm the expression patterns found independently from the 
microarray experiments, four separate pRCC samples that had not been analyzed 
on microarrays were subjected to a qPCR analysis. Again, the expression patterns 
found with the microarrays were confirmed. However, the over-expression of CD37 
in pRCC could not be confirmed via IHC. Due to the lack of appropriate antibodies 
IHC confirmation for the other three candidate molecules is still missing. 
These candidates are known to be involved in several processes. CD68 could play a 
role in phagocytic activities of tissue macrophages, both in intracellular lysosomal 
metabolism and extracellular cell-cell and cell-pathogen interactions. CD96 
promotes natural killer (NK) cell adhesion to target cells expressing polivirus 
receptor (PVR), stimulates cytotoxicity of activated NK cells, and mediates 
acquisition of PVR from target cells (102). CALB1 buffers cytosolic calcium and may 
stimulate a membrane Ca2+-ATPase and a 3',5'-cyclic nucleotide phosphodiesterase. 
These three genes can be considered as potential marker genes for pRCC but their 
specificity and reliability needs to be confirmed on the protein level. 
 
In summary, expression profiling with cDNA-arrays of both RCC subtypes led to 
promising candidate molecules. After confirmation with two independent methods 
the gene CD70 can be considered as a new, specific marker gene for ccRCC. 
Furthermore, this approach demonstrates that it is crucial to combine cDNA-arrays 
with appropriate confirmation techniques that do not rely only on the “rnomic” 
level of gene expression but take into account as well the protein expression. 
Nevertheless, considering that one gene is not enough to characterize a tumor the 
lists of differentially expressed genes created by cDNA-arrays have to be studied as 
well from a functional point of view.  
6.3 FUNCTIONAL PROFILING 
The gene expression data for both tumor-subtypes still contains more information 
regarding functional connections between the genes found. In a functional 
approach this information was extracted by searching the data for genes that are 
involved in similar biological processes, like for example apoptosis. Even though 
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gene expression studies of RCC using microarray technologies have successfully 
identified cancer associated expression patterns and potential marker genes 
(99;103-105), no functional profiling of these gene expression data has been carried 
out for RCC so far. Therefore, functional profiling was performed to extract the 
biological information of the gene expressions found in both tumor-subtypes. 
The aim of the functional profiling was to compare the gene expression of ccRCC 
and pRCC in order to find pathways and mechanisms enabled in only one or in both 
tumor-subtypes. First, the gene expression of both tumor-subtypes was analyzed. 
Using Miltenyi´s TreeRanker system clusters of interacting genes were found to be 
coordinately or differentially up- or down-regulated. Second, a dataset with 
differentially expressed genes (a total of 13 genes) between ccRCC and pRCC was 
identified. And third, a dataset with 45 genes regulated equally in both tumor-
subtypes was found. Functional profiling revealed differences and similarities in 
the biology of both tumor-subtypes. 
 
GENES DIFFERENTIALLY EXPRESSED COMPARING THE TUMOR-SUBTYPES. The first dataset 
analyzed contained 13 genes that are differentially expressed between both tumor-
subtypes. This dataset serves to discriminate between the two RCC subtypes. 
FOSL2 and HEVIN exhibit the most contrary expression between the examined 
tumor-subtypes. FOSL2 is strongly down-regulated in ccRCC whereas HEVIN is 
down-regulated in pRCC. Unfortunately, the suppression of FOSL2 could not be 
confirmed. No additional confirmation has been carried out for HEVIN so far. 
A number of genes identified as being up-regulated in ccRCC but not in pRCC play a 
role in cell-cell recognition, like VEGFA and VCAM1. Interestingly, CD40, a gene up-
regulated in ccRCC, is also involved in an immune response by regulating B-cell 
proliferation. An up-regulation was also found for the gene TNFR2 that mediates 
most of the metabolic effects of TNF-alpha including blocking its apoptotic 
functions. 
The findings that the genes RPS7, CD151, LUMAN, and ATF4 are up-regulated in 
ccRCC but not in pRCC is congruent with previous studies that report discrete 
microarray patterns in RCC subtypes (12;99;105). In this study, differences in 
regulation between the two tumor-subtypes for CD70, PLGF, and CCND1 were 
found. The gene CCND1 showed a rather heterogeneous expression pattern and was 
not consistently expressed in all patient samples analyzed. Meanwhile, CD70 and 
PLGF were strongly up-regulated in ccRCC but nearly unaffected in the pRCC 
dataset. A closer look at the induction revealed that while both genes are only 
slightly induced in pRCC, they are more than 20- fold up-regulated in ccRCC. These 
ambiguous results for CD70 and PLGF might not only reflect the heterogeneity of 
the cell population in the examined tumor tissues, but also sample-specific 
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differences in gene expression. Consequently these genes were included in both 
the equally and differentially expressed gene datasets. 
 
GENES EQUALLY EXPRESSED IN THE TUMOR-SUBTYPES. The 45 genes equally expressed 
(23 down-regulated and 22 up-regulated) by both tumor types were analyzed via 
functional profiling. The results for the 23 down-regulated genes showed that the 
majority of these genes are enzymes (ten genes) and genes involved in lipid and 
carbohydrate metabolism (seven genes). The functional analysis revealed their 
involvement in several cellular processes like cell motility, proliferation, and 
angiogenesis. Most importantly, several of these commonly down-regulated genes 
were found to be involved in mechanisms concerning apoptosis and cell death 
(FYN, COL18A1, CTGF, SOD1, ATF, and HSPA1A). 
Most of the 22 up-regulated genes in both tumor types are surface markers. Since 
these markers play a key role in cell-cell communication and are crucial for 
adaptive and antigen-directed immunity, the analysis was constrained to identify 
the underlying functional relations between them. Among the genes found to be 
regulated are FCGR1A, FCGR2, and CD45. They are known to be regulators of T-cell 
antigen receptor signalling and could therefore be directly involved in an immune 
response of RCC (106). CD19 may be involved in growth regulation of B-cells and 
CD68 could play a role in phagocytic activities of tissue macrophages, both in 
intracellular lysosomal metabolism and extracellular cell-cell and cell-pathogen 
interactions. The gene PMP22 might be involved in growth regulation whereas 
PDGFRB is a receptor that binds specifically to PDGFB and has a tyrosine-protein 
kinase activity. 
Most interestingly, four of the twelve up-regulated surface markers, TNFRSF10B, 
CD70, TNFR1, and BAFF, belong to the tumor necrosis factor/tumor necrosis factor 
receptor related superfamily, a group of proteins that function as communicators 
between cells. Additionally, a fifth surface marker, PDGFRB, has been found to be 
up-regulated in both tumor-subtypes. These five proteins can mediate apoptosis or 
are linked directly to an immune response via their ability to regulate the reaction 
of lymphocytes to pathogens (107;108). Given the strong up-regulation of CD70 in 
ccRCC and the accumulation of up-regulated immune-regulatory genes in RCC, it is 
tempting to speculate that genes belonging to the TNF receptor family could play a 
key role in RCC immune escape. 
 
In summary, the approach used here provides information not only on the 
differences between ccRCC and pRCC, but also on the functional similarities of 
these two most common RCC subtypes reflecting their shared origin. The increased 
expression of apoptosis-inducing genes seems, at first glance, to be antithetical to 
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tumor survival. However, it is of special interest since tumor-infiltrating 
lymphocytes (TILs) are often reported for RCC. An induction of apoptosis in these 
cells could enable RCC to suppress the immune system. The gene CD70 seems to 
have the highest potential to play a role in immune escape due to its confirmed 
over-expression in RCC and, its role in the immune escape strategies in other tumor 
types. Thus, further investigation of CD70 was undertaken to see if it is involved in 
the immune escape strategy of RCC by inducing apoptosis in TILs. 
6.4 FUNCTIONAL ANALYSIS 
The aim of the functional analysis was to examine the function of CD70 over-
expression in RCC given that cancer patients, including those with RCC, are known 
to have impaired antitumor immune responses. It is also known that despite the 
presence of tumor-infiltrating lymphocytes (TILs), RCC can successfully escape 
immune recognition. But even though RCC is generally considered an immune-
regulatory tumor only, a few mechanisms for its immune-suppression have been 
identified. These findings include that one way for these tumors to evade the 
immune system is via induction of apoptosis in T-cells through FasL expression 
(62;109-112).  
A closer look into the CD70/CD27 pathway reveals that the interaction of CD70 with 
its receptor, CD27 can also lead to T-cell apoptosis, probably due to persistent 
stimulation (Figure 26; 113). Since CD27 lacks the death domain, the apoptotic 
signal is transmitted via the apoptotic protein SIVA (114). It is also known that 
CD70 belongs to the tumor necrosis factor family. Most notably, members of this 
family have central roles in adaptive and antigen-directed immunity when they 
coordinate the response of lymphocytes to pathogens (107). 
The functional analysis of CD70 expressed by RCC cell lines or recombinant soluble 
CD70 (rmsCD70) showed that it can be responsible for apoptotic cell death in 
lymphocytes. Both tumor cell lines expressing CD70 were capable of inducing 
apoptosis in lymphocytes, whereas the non-expressing tumor cell line CAKI1 had no 
measurable apoptotic influence on the lymphocytes. Furthermore, the addition of 
rmsCD70 in physiological concentrations to both, permanent and native 
lymphocytes in culture increased the apoptosis rate significantly. The involvement 
of CD70 was shown by blocking experiments with antibodies against CD70 ligand 
and CD27 receptor.  
Interestingly, RCC can induce expression of immune-suppressive mediators such as 
prostaglandin E2 by peripheral blood mononuclear cells (115). It has already been 
speculated that this, in combination with CD70 expression, may skew the immune 
system to a prominent humoral response or, even worse, complete immune 
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escape/successful immune-suppression (56). The findings of this study support this 
hypothesis. 
 
Figure 26 CD27 pathway. Binding of CD70 Ligand to CD27 receptor can lead to apoptosis as well as 
to proliferation (www.proteinLounge.com, modified). 
In a different study the role for CD70 expression has already been examined for 
glioblastoma (116). CD70 expression by glioma cells leads to apoptosis of peripheral 
blood mononuclear cells and enhancement of the level of soluble CD27. Hence, 
CD70 expressed by glioma cells evoked immune inhibition rather than immune 
stimulation. On the other hand, a study carried out by Aulwurm et al. suggests that 
immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis 
in rodent glioma models and confer long-lasting antiglioma immunity in vivo (117). 
These differing findings suggest that the effects carried out after activating the 
CD70/CD27 pathway are highly complex and should be investigated in more detail. 
Little is known so far about possible interaction partners of CD70 and CD27 that 
may have regulatory functions for the pathway. 
Recent data for CD70 leads to the assumption that apoptosis mediated by the 
CD70/CD27 pathway involves the apoptotic protein SIVA (Figure 26; 97;116). In this 
  Discussion 
 
62 
study, CD27 as well as SIVA expression was shown for permanent and native 
lymphocytes whereas no expression was found in the permanent RCC cell lines. In 
addition, no CD27 expression was found in ccRCC by cDNA-microarrays or qPCR or 
IHC analysis. These findings point to a specific activation of the CD70/CD27 
pathway by the tumor cells in TILs. 
 
Figure 27 Schematic representation of apoptosis induction via CD70 expression in renal cell 
carcinoma (RCC) cells. A. Apoptosis induction through cell-cell contact. CD27 receptor is expressed 
by lymphocytes and CD70 ligand is membrane-bound in RCC cells. Apoptosis is induced after binding 
of death-domain substitute SIVA which initiates caspase activation. B. Apoptosis induction without 
cell-cell contact. Membrane-bound CD70 ligand is cleaved and binds to CD27 receptor. Apoptosis is 
induced after binding of death-domain substitute SIVA which initiates caspase activation. 
However, it remains unclear how the apoptotic signal is transmitted. The 
experimental design of this study suggests two possible ways. One is the induction 
of the apoptotic signal through direct lymphocyte - RCC cell contact (Figure 27, 
Part A). Another possible mechanism is the cleavage and release of CD70 to the 
surrounding environment. No direct cell-cell contact would be necessary (Figure 
27, Part B). However, from what we know it seems more likely that the cells have 
direct contact while transmitting the signal since the release of CD70 to the 
environment has not been demonstrated so far. 
In conclusion, the functional analysis provides evidence for a possible mechanism 
used by RCC to eliminate lymphocytes and prevent an immune response via the 
over-expression of CD70. It was shown here that soluble CD70 as well as CD70 
expressed by RCC cell lines leads to apoptosis in lymphocytes. Thus, this study 
identified a new, potential mechanism for RCC to successfully escape immune 
recognition. 
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7 CONCLUDING REMARKS 
This study shows that the combination of transcriptional and translational profiling 
represents a powerful tool for the molecular dissection of cancer. The upgrade of 
these approaches with functional profiling also addresses functional connections 
between the regulations found and underlines the need of comprehensive 
approaches for marker gene discovery that reflect the complexity of tumor 
development and behavior. Most importantly, the comparative study of the model 
system composed by two renal cell carcinoma (RCC) subtypes sharing a common 
cellular origin resulted in a gain of knowledge about RCC biology and shed more 
light onto the processes responsible for tumor development and behavior. 
Tumor-specific gene and protein regulations as well as potential tumor-specific 
marker genes in clear cell and papillary renal cell carcinoma (ccRCC and pRCC) 
were identified. The most striking discovery is the identification of the gene CD70 
as a new, highly specific marker gene for ccRCC. This gene was then further 
characterized regarding its function and found to be responsible for lymphocyte 
apoptosis. Thus, this study identified a new, potential mechanism for RCC to 
suppress the immune response. 
In addition, this study also led to topics that need to be addressed in further 
studies. No possible protein interaction partners for CD70 or its receptor CD27 have 
been described so far. Their function in the tumors could be influenced by 
secondary proteins that have regulatory effects. The activation of the CD70/CD27 
pathway in RCC should be confirmed in mouse models to elucidate whether this 
mechanism is enabled in vivo as well. In this context, the question of whether CD70 
is released by the tumor cells or if it remains membrane-bound before binding to 
CD27 receptor still needs to be addressed.  
However, our view into the processes involved in tumor development and tumor 
behavior is still restricted to one expression level at one time-point due to 
methodological limitations. Future investigations would be improved if the data 
derived from the expression approaches could be better integrated to give a more 
comprehensive view of all layers of regulations that characterize the tumor. This 
would allow also for a better understanding of tumor development and behavior 
and thus tumor biology. 
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8 DEUTSCHE KURZFASSUNG 
Die Biologie von Nierenzellkarzinomen (NZK) ist bisher nur unzureichend 
verstanden. NZK sind die häufigsten malignen Tumoren der Niere und lassen sich in 
fünf Subtypen einteilen: klarzellige, papilläre und chromophobe NZK sowie 
Sammelgang-Karzinome und Onkozytome. Am häufigsten werden klarzellige und 
papilläre NZK diagnostiziert, die beide aus dem proximalen Tubulus der Niere 
entstehen. Trotz des gemeinsamen Ursprungs sind sie sowohl histologisch als auch 
genetisch eindeutig voneinander unterscheidbar und stellen somit ein optimales 
Untersuchungsmodell dar, um tumor-spezifische und tumorsubtyp-spezifische 
Muster zu erkennen. Das Ziel dieser Arbeit ist, potentielle Markergene für 
klarzellige und papilläre NZK zu identifizieren, ihre Spezifität und Relevanz für den 
Tumor zu bestimmen und damit das Tumorverhalten und die Tumorentstehung von 
NZK besser zu charakterisieren. 
Der hierfür verwendete Ansatz bezieht sowohl die translationale als auch die 
transkriptionale Ebene ein und gewährleistet somit eine umfassende Analyse der 
Protein- und Genexpression beider Tumorsubtypen. Auf translationaler Ebene 
wurden mit Hilfe von SELDI-TOF Technologie (Surface Enhanced Laser Desorption 
Ionisation – Time of Flight) spezifische Proteinmuster für beide Tumorsubtypen 
erstellt. Erstmalig konnten spezifische Regulationen des Proteoms für papilläre NZK 
identifiziert werden. Auf transkriptionaler Ebene wurden zahlreiche differentiell 
exprimierte Gene mittels cDNA-microarrays detektiert. Für ausgewählte Gene, 
deren differentielle Expression in NZK bisher unbekannt war, erfolgte eine 
Validierung auf RNA- und Proteinebene. Hier konnte das Gen CD70 als 
überexprimiert in klarzelligen NZK identifiziert werden und ist ein neues, 
spezifisches Markergen für diesen Tumorsubtyp. Die Genexpressionsmuster beider 
Tumorsubtypen wurden weiterhin einer bioinformatorischen Analyse unterzogen, 
um biologische Zusammenhänge in der Funktion der regulierten Gene zu 
detektieren. Es wurde eine Gruppe von Genen identifiziert, deren Mitglieder 
apoptotische Prozesse induzieren können. Diese Gene sind sowohl in klarzelligen als 
auch in papillären NZK gleichermaßen reguliert, jedoch scheint die Induktion von 
Apoptose auf den ersten Blick antithetisch zum Tumorverhalten zu sein. Eine 
Induktion von Apoptose in den tumorinfiltrierenden Lymphozyten, die sehr häufig in 
NZK zu finden sind, würde es aber den Tumoren ermöglichen, das humane 
Immunsystem zu unterdrücken. Zu den apoptose-induzierenden Genen in dieser 
Gruppe gehört auch das Gen CD70, dessen Funktion mit Hilfe von 
Zellkulturexperimenten untersucht wurde. Diese Experimente zeigten, dass CD70 
Apoptose in Lymphozyten induziert. Die Induktion von Apoptose durch 
Überexpression von CD70 in NZK ist ein potentieller, bisher unbekannter 
Mechanismus, mit dem NZK dem humanen Immunsystem entkommen können. 
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10 EQUIPMENT AND CHEMICALS 
10.1 EQUIPMENT 
Translational Profiling 
Determination of protein concentration 
• Halfmicrocuvettes, Sarstedt 
SELDI TOF MS Technology  
• ProteinChip System 400 
 
Transcriptional Profiling 
RNA isolation and RNA amplification 
• Bioanalyzer 2100, Agilent Technologies 
• Cryostat, CM 1850, Leica 
• Peltier Thermal Cycler PTC-200, MJ Research 
• DNA120 Speed Vac, Thermo Savant 
Microarrays 
• PIQORTM Immuno/Onco-Chip, human, antisense, Miltenyi Biotec GmbH 
• PIQORTM Immunology Chip, human, antisense, Miltenyi Biotec GmbH 
• GenePix Scanner 4000B, Axon 
• ScanArray 4000 Lite, Perkin Elmer 
• Hybridization chamber, PIQORTM HybChamb, Miltenyi Biotec GmbH 
• GeneTAC hybridization station, Perkin Elmer 
• ImaGene software version 4.1, BioDiscovery 
• Wash container, Milian Laboratories supplies 
Quantitative PCR 
• LightCycler, Roche 
• LightCyclerCapillaries, Roche 
Immunohistochemistry  
• Cryostat, CM 1850, Leica 
 
Functional Analysis 
Cell Culture 
• Culture Flasks 7 cm2, 25 cm2 and 75 cm2, Greiner Bio-One GmbH 
• CO2-Incubator Typ BB 6000, Heraeus sepatech 
• Invers-Microscope, Telaval 3, Zeiss 
• 0 Series (PCS 4000 TOF – MS Personal), Ciphergen 
• CM10 Chip, Ciphergen 
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Apoptosis 
• SpectraMax, Gemini, Molecular Devices 
• FIA-Plate, Black, 96 well plates, Greiner Bio-One GmbH 
Centrifuges and Vortexer 
• Millipore Microcentrifuge MC-13, Amincon Bioseparation 
• C-1200 Mini Centrifuge, National Labnet Co 
• Appligene, Oncor 
• Universal 30 RF, Hettich 
• Megafuge 1.0, Heraeus sepatech 
• MS1 Minishaker, IKA 
• REAX top, Heidolph 
• Biofuge Stratos, Heraeus 
Other Equipment and Consumables 
• Tubes, different types, Sarstedt and Eppendorf 
• Tips, unsealed and sealed, 10 µl, 100 µl, 200 µl and 1000 µl, Gilson and 
Biozym 
• Falcon tubes 15 ml and 50 ml, Greiner Bio One GmbH 
• Scale BP 61, Sartorius 
• WPA biowave S 2100 Diode Array Spectrophotometer, Biochrom AG 
• Waterbath, Memmert 
10.2 CHEMICALS 
Translational Profiling 
Cell lysis and protein extraction 
• Sodium phosphate, Merck 
• EDTA, Sigma 
• Magnesiumchloride, Sigma 
• ß-2-Mercaptoethanol, Sigma 
• CHAPS, Roche 
• Leupeptin, Serva 
• PMSF, Roth 
Determination of protein concentration with Bradford  
• Bradford Staining solution, Bio Rad 
SELDI 
Energy absorbing Matrix: 
• Sinapic Acid, SPA, Ciphergen 
  Equipment and Chemicals 
  
76 
CM10 Chip: 
• ACN, Aldrich 
• trifluoroacetic acid, Aldrich 
 
Transcriptional Profiling 
RNA Isolation and Amplification 
• E.coli DNA Ligase, Gibco BRL 
• DNA Polymerase I, Gibco BRL 
• Ribonuclease H, Gibco BRL 
• Superscript II RNase H-Reverse Transcriptase including 5 x First Strand 
Buffer, 0.1 M DTT, reverse transcriptase, Invitrogen 
• MEGAscript T7 Kit, Ambion 
• QIAquick
 
PCR Purification Kit, Qiagen  
• RNeasy
 
Mini Kit, Qiagen  
• Hexanucleotide Mix (10x), Roche Diagnostics 
Microarrays 
• Superscript™II RNase H-ReverseTranscriptase (RT) including 5× First Strand 
Buffer and 0.1 M DTT, Invitrogen 
• 100 mM dNTP set, Invitrogen 
• OligoDT and random hexamers, Birch-Hirschfeld, Friedrich-Schiller 
University, Jena 
• Ribonuclease H (RNaseH, 2.2 U/µL), Invitrogen 
• FluoroLink™ Cy3-dCTP, GE Healthcare 
• FluoroLink™ Cy5-dCTP, GE Healthcare 
• CyScribe GFX, GE Healthcare 
• Ethanol (EtOH), Merck KGaA 
• Prehybridization solution, Miltenyi Biotec GmbH 
• 2x hybridization solution, Miltenyi Biotec GmbH 
• QiaQuick, Qiagen 
Quantitative PCR 
• SuperScriptTMII Reverse Transcriptase, Invitrogen 
• Random hexamer primers, Birch-Hirschfeld, Friedrich-Schiller-University 
• QuantiTect Primer Assay, Qiagen 
• QuantiTect SYBRGreen PCR-Kit, Qiagen 
Immunohistochemistry 
• Acetone, J.T. Baker 
• Sodium azide. Sigma 
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• Biotin blocking system, DAKO kit 5005 (containing biotin and Avidin-alkaline-
phosphatase) 
• Haemalaun solution, Merck 
• Tween 20, Roche 
 
Functional Analysis 
Cell Culture 
• Trypsin/EDTA-Solution, Biochrom AG 
• Lymphocyte separation medium, PAA Laboratories GmbH 
• Phytohemagglutinin A (PHA-L); Biochrom AG 
• Recombinant soluble rmsCD70, Alexsis Biochemicals 
• PBS, Gibco 
Media 
• DULBECCO´S MEM (1x), Biochrom AG 
• RPMI 1640, Invitrogen 
• Fetal Bovine Serum, Serum Med, Biochrom AG 
• Amnio MaxTM C-100 Basal Medium, GIBCO BRL 
Apoptosis 
• APO-OneTM Homogeneous Caspase-3/7 Assay, Promega Madison 
Antibodies 
• Mouse monoclonal anti-human Anti-CD70 antibody, AncellTM 
• Mouse monoclonal anti-human Anti-CD27 antibody, AncellTM 
• Mouse polyclonal anti-human anti- SIVA antibody, Abnova, Taiwan 
• Mouse immunoglobulin G1, AncellTM 
• Recombinant soluble CD70, Alexsis Biochemicals 
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temperature). ........................................................................................................22 
Table 7 Genes found as being differentially expressed in clear cell renal cell carcinoma in this study 
previously identified and described by other groups (no. = number).....................................34 
Table 8 Genes found to be differentially expressed in clear cell renal cell carcinoma not previously 
identified (no. = number). .........................................................................................34 
Table 9 Genes found to be differentially expressed in papillary renal cell carcinoma in this study 
previously described by other groups (No. = number). ......................................................36 
Table 10 Genes identified to be differentially expressed in papillary renal cell carcinoma not previously 
described (No. = number). .........................................................................................36 
Table 11 Qualitative correlation of microarray and quantitative (qPCR) data for clear cell renal cell 
carcinoma of CD70 and FOSL2.. ...................................................................................37 
Table 12 Qualitative correlation of microarray and quantitative PCR (qPCR) data for papillary renal cell 
carcinoma of four selected genes that appeared to allow discrimination between normal versus 
tumor tissue...........................................................................................................38 
Table 13 Comparison of candidate gene expression of tumor versus normal tissue analyzed either by 
microarray or quantitative PCR (qPCR) technology...........................................................39 
Table 14 Results after immunostaining with anti-CD70 antibody in different tumor types and in 
corresponding normal tissue (RCC= Renal cell carcinoma, No.= number, from Junker et.al (81). .39 
Table 15 Overview of genes up- or down-regulated in both examined renal cell carcinoma subtypes 
(m.a. = multiple annotation, no. = number). ..................................................................43 
Table 16 Expression ratios of CD70 and SIVA in cell lines used determined by qPCR. 47 
Table 17 Expression ratios of CD70, CD27, and SIVA expression ratios in native lymphocytes compared to 
permanent MOLT4 T-cells determined by qPCR. ..............................................................47 
11.2 LIST OF FIGURES 
Figure 1 Overview of classical and new approaches for biomarker discovery and identification (qPCR = 
quantitative PCR; IHC = immunohistochemistry)................................................................3 
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Figure 24 Apoptosis ratios of T-cells cocultured with RCC cell lines CAKI1 (left), CAKI2 (middle) and 
A498 (right). ..........................................................................................................49 
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(RCC) cells.. ...........................................................................................................62 
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12 APPENDICES 
Appendix I: Results of CGH-Analyses 
A. Papillary renal cell carcinoma 
Patient CGH-Analysis Patient CGH-Analysis 
1 dim(y), enh(7,17) 14 enh(3,7,16q,17), dim(Y) 
2 dim(8p11pter, Xp, Y),  
enh(2q22q34, 3p12qter, 9q22pter, 12q24pter) 
15 enh(3,7,12,16,17,Xp) 
3 dim(1p,20,y), enh(17) 16 enh(3,7,12), dim(Y) 
4 enh(7,12,17) 17 enh(7), dim(Y) 
5 enh(3q,7) 18 enh(7, 12), dim(y) 
6 dim(9q22qter,17p), enh(8p12qter, 11q14q23,17q) 19 dim(14q22pter), enh(7,12,13,17) 
7 enh(7) 20 dim(5q,10q24), enh(7,12,17) 
8 enh(3p13qter,7) 21 enh(7,16,17), dim(Y) 
9 enh(3q,7,16,17,20) 22 enh(3,4,5q,7q,12q,14,15,16q,20) 
10 enh(7,8,17) 23 enh(16,17), dim(X) 
11 dim(y); enh(3,7,10,16,17) 24 enh(3q,7,17q23qter) 
12 enh(3, 7), dim (11q13qter) 25 dim(3p12pter), enh(4q22q28), dim(Y) 
13 enh(7) 26 enh(7,17), dim(Y) 
 
B. Clear cell renal cell carcinoma 
Patient CGH-Analysis 
1 dim(3) 
2 dim(3p21pter,8p,14q21q24), enh(5q21qter) 
3 dim(3p13pter), enh(5q,7) 
4 dim(3p,4q13q28,7q,10q22,14q13qter,16q17p), enh(2q32pter,5q31qter,6q,13q22qter) 
5 dim(1p34qter,2p22pter,3,4,6,8,9,13,14,15,18q,x), enh(16q21pter,19,20) 
6 dim(3p), enh(4, 5, 13, 21) 
7 dim(3p13pter,14,17,20), enh(2,21) 
8 dim(3p12pter,14,15,17,20,y), enh(2,7,11,12,21) 
9 dim(3p13pter, 10q23qter)  
10 dim(3p14p24,8p,9q21qter,14,17,18,y), enh( 8q,9q21pter) 
11 dim(3p,8p) 
12 dim(3,8,13,14,18) 
13 enh(5q23pter), dim(3p14p22) 
14 dim(3p14pter) 
15 dim(3p21pter,14q,18q,y); enh(5,7) 
16 dim(3p13,9q17p), enh(13q21q31) 
17 dim(3p21pter,14q21qter,20,22q,y), enh(4p13q28,5p23q) 
18 dim(3q21pter,4,6q,9,10,14,y); enh(6q,7,12,16,17,20,22) 
19 dim(3p?,8p), enh(5q22qter) 
20 dim(3p14pter,9q,14q24qter); enh(5,7,12) 
21 dim(1p,3,6,9,11,14); enh(1q) 
22 dim(3p14pter; 9q31qter,14); enh(5,7,12) 
23 dim(3p13pter,9q22qter,14q,15q,18); enh(5q33qter,20) 
24 dim(3p21pter,9,14,15,22,y): enh(4,5,6q,7) 
25 dim(3p14pter,8p,14q11q24,17p), enh(5q33qter) 
26 dim (3p21pter) 
27 dim(3p13pter, 14) enh(5) 
28 dim(3p13, 9q17p), enh(13q21q31) 
29 dim(2q33, 3pter21, 4, 9, 13, 14,18q), enh(5p, 7, 17q, 20) 
30 dim(3p14pter, 8p, 14q21qter, 18), enh(3q25qter, 4p, 4q31qter, 5, 7, 8q, 12) 
31 n.m 
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Appendix II: Ratio List of All Genes Present On the Microarrays 
 
A: Clear Cell Renal Cell Carcinoma 
Ratio list of all genes present on the microarray Each gene is annotated with gene name(s) and corresponding 
SwissProt or Unigene numbers. In addition the respective experiments are indicated. (tumor: Cy5 labelled; normal 
tissue: Cy3 labelled). For each gene the normalized Cy5/Cy3 ratio (representing the mean of two corresponding spots 
per gene) is indicated. If a ratio is shown for a certain genen in the gene list, this indicates that a more than two-fold 
signal intensity above the average signal intensities of the background in at least one of the two channels (Cy3 or Cy5) 
could be observed. No ratio (-) indicates, that the signal intensities of the respective gene did not meet the 
requirements mentioned above and thus could not be reliable detected in that particular experiment. 
 
Gene name UniGene 266 271 275 277 333 493 258 261 269 274 
ABR  Hs.118021 - - - - - - - - - - 
AC15 Hs.166563 0.96 0.98 0.91 1.02 1.08 0.4 0.72 0.81 0.88 0.62 
ACTA2 Hs.195851 1.44 0.51 1.34 3.25 0.32 1.57 0.2 2.46 1.32 1.76 
AF6  Hs.100469 - - 1.49 1.91 - - - - - - 
AGRIN Hs.273330 0.73 0.77 1.11 0.4 0.49 0.87 0.86 0.86 0.67 1 
AGTRL1 Hs.9305 1.22 - - - - - - - - - 
ALCAM Hs.10247 0.86 1.12 - 0.9 1.64 0.66 0.43 0.61 0.41 - 
AMP Hs.61418 0.73 1.04 - 0.92 1.14 1.06 0.79 1.1 0.74 0.87 
ANPEP Hs.1239 0.1 0.32 1.28 0.06 0.01 0.92 0.09 0.39 0.38 0.7 
AP1  Hs.78465 0.66 0.89 0.81 - 0.64 1.11 1.02 0.8 1.26 0.7 
APC Hs.75081 2.33 1.35 1.18 1.15 0.66 0.56 0.79 0.93 1.17 0.63 
APRIL  Hs.54673 0.47 1.8 0.81 0.73 0.73 1.48 1.17 0.85 0.44 0.44 
ASB-1 Hs.153489 - - - - - 1.16 0.51 - - - 
ASB-3  Hs.9893 1.48 - - - - - 1.53 - - - 
ATF1:  Hs.36908 - - - - - - - - - 0.91 
ATF3 Hs.460 2.6 - - - - - 6.74 - - - 
ATF4  Hs.181243 1.39 1.69 1.51 1.74 1.74 1.25 1.09 1.37 0.76 1.06 
ATF5  Hs.9754 0.55 0.64 0.88 0.37 0.82 1.19 0.56 0.76 1 0.65 
ATF6 Hs.5813 0.95 0.94 0.73 0.77 0.73 0.8 0.75 0.67 0.82 0.68 
BACH1  Hs.154276 1.58 0.87 - - - 0.56 1.56 0.8 1.14 0.89 
BAD  Hs.76366 0.53 1.24 1.26 0.52 0.7 1.55 - 0.36 0.76 0.84 
BAFF  Hs.270737 2.32 2.02 0.79 6.22 - 1.17 3.94 4.16 2.95 4.61 
BAMACAN Hs.24485 0.99 0.91 1.09 0.64 0.36 0.81 0.81 0.92 0.61 0.53 
BARD1 Hs.54089 0.92 0.89 0.96 0.94 - 0.76 0.79 0.71 0.44 0.52 
BAX Hs.159428 0.85 0.98 1.03 0.98 0.74 1.42 1.08 1.82 1.29 1.76 
BCL10 Hs.193516 - 1.49 - - - - - - - - 
BCL2  Hs.79241 - 1.37 - 1.29 - - 1.61 1.24 - - 
BCL2A1  Hs.227817 - 0.85 - - - 1.28 0.92 - 0.58 - 
BCL2L1  Hs.305890 0.64 1.18 0.6 0.22 1.27 0.73 0.57 0.65 - 0.75 
BCL2L2  Hs.75244 1.26 0.92 - - - - - 0.75 - - 
BCL3 Hs.31210 1.54 - - - - - - - - - 
BID Hs.172894 1.43 1.59 1.12 1.75 - 1.27 1.18 1.7 1.93 2.4 
BIGLYCAN Hs.821 2.27 1.41 0.59 0.69 - 0.85 1.58 4.25 2.34 0.5 
BIK  Hs.155419 - - - - - - - - - - 
BIP Hs.75410 0.65 0.66 0.95 1.22 1.01 0.73 1.2 1 0.81 0.91 
BMP1  Hs.1274 1.16 0.48 0.73 1.23 - 0.8 1.71 1.48 1.06 3.71 
BMP2 Hs.73853 0.82 0.34 0.86 0.43 0.32 0.78 0.64 0.93 0.37 0.35 
BMP4  Hs.68879 0.87 - - - - - - - - - 
BMP6  Hs.285671 1.79 - - - - - 0.17 - - - 
BMP8 Hs.99948 - 3.06 - - - - - - - - 
BPGF1-Q6 Hs.77266 1.68 0.82 1.1 0.96 1.95 0.8 0.87 1.25 1.25 2.76 
BRCA1 Hs.194143 - - - 2.32 - - 1.8 - - - 
BSG Hs.74631 0.31 0.91 1.4 0.69 3.72 1.62 0.59 0.85 1.33 0.69 
BST1 Hs.169998 0.54 1.08 0.85 0.46 - 0.91 - 0.62 0.54 0.45 
C3AR1  Hs.155935 1.39 1.95 0.85 2.13 0.74 1.08 2.29 1.23 1.92 3.4 
CALB1  Hs.65425 - - - 0.0032 0.00765 - 0.0027 0.00315 - 0.00
34 CANPX  Hs.169172 - - - - - - 1.07 - - - 
CASP2 Hs.108131 0.65 1.02 - - 0.7 1.51 - 0.91 - 0.78 
CASP4_HUMAN Hs.74122 1.41 1.16 1.05 2.93 1.44 1.22 2.13 0.96 2.11 2.51 
CASP7 Hs.9216 1.38 1.32 1.43 1.08 - 0.89 1.42 0.82 1.23 - 
CASP8 Hs.381231 1.51 1.21 0.93 0.84 - 0.77 1.66 1.75 3.28 2.46 
CASP9 Hs.100641 0.72 - - - - - - - - - 
CBP  Hs.270 0.44 1.07 - - 3.92 1.38 1.38 1.03 - - 
CCNC  Hs.118442 0.89 0.36 0.71 0.5 0.95 0.76 0.62 0.33 0.79 0.75 
CCND1  Hs.82932 2.75 15.16 37.07 3.04 0.86 1.41 10.15 2.57 3.09 0.93 
CCND3 Hs.83173 1.5 1.18 - 1.41 - 1.13 0.84 0.61 0.37 0.79 
CCNF_2  Hs.1973 2.86 - 0.45 - - - 0.42 1.36 0.35 - 
CCNG2 Hs.429880 1.36 2.7 0.9 0.5 2.26 0.86 0.89 0.79 - 0.7 
CCNH Hs.514 0.8 0.86 0.68 0.51 0.91 1 0.65 0.62 0.52 0.84 
CCR1 Hs.301921 1.73 2.12 - - - - 0.4 - - - 
CCR10  Hs.278446 0.58 0.73 0.97 0.42 0.42 1.33 0.69 0.74 0.58 0.53 
CCR5  Hs.54443 0.68 0.89 0.94 0.59 1.26 0.85 0.81 1.14 0.68 0.9 
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CCR6 Hs.46468 - - - - - - 2.23 - - - 
CD14 Hs.75627 3.19 3.27 0.77 4.66 1.48 1.33 2.85 2.94 3.66 5.9 
CD151  Hs.75564 0.78 1.09 0.93 1.26 1.09 1.41 1.26 1.56 1.26 2.56 
CD19 Hs.96023 2.88 3.15 0.77 4 1.2 1.36 3.24 2.54 3.78 6.17 
CD2:  Hs.89476 0.49 3.87 0.59 11.78 - 1.58 10.23 2.96 1.31 1.67 
CD24 Hs.381003 0.46 - 2.96 3.15 0.71 0.85 2.04 - 2.7 3.61 
CD33  Hs.83731 1.79 1.35 - - - 0.98 - - 0.94 - 
CD34  Hs.374990 5.94 1.01 1.69 0.64 0.78 0.96 1.14 3.28 - - 
CD36 Hs.75613 39.79 22.44 9.6 - 1.21 0.48 10.92 49.23 2.71 3.69 
CD37  Hs.153053 0.59 1.25 0.67 0.64 0.46 1.79 1.23 1.35 0.66 0.69 
CD39 Hs.205353 11.53 4.42 1.03 3.81 1.69 0.65 2.16 8.59 2.69 4.54 
CD3D. Hs.95327 0.35 1.08 0.42 0.56 - 2.41 1.97 0.3 0.48 0.41 
CD3E  Hs.3003 1 - - - - - - - - 1.22 
CD4 Hs.17483 1.8 1.96 0.96 1.27 - 0.8 5.57 2.64 2.34 2.09 
CD45_EX29-31 Hs.170121 0.9 2.32 - 3.54 - 0.7 3.88 1.21 1.31 1.26 
CD47 Hs.82685 0.97 0.9 1.01 0.89 1.1 1.22 1.22 1 0.85 1.81 
CD48  Hs.901 0.63 3.8 0.51 9.87 - 1.7 5.39 7.61 1.27 3.34 
CD52 Hs.276770 0.47 1.43 0.62 4.46 1.05 2.84 5.21 3.1 0.71 3.48 
CD53  Hs.82212 1.93 3.99 0.86 6.58 1.86 1.3 6.15 6.39 3.08 7.38 
CD58  Hs.75626 0.94 1.19 0.64 0.88 0.67 1.45 1.73 0.81 0.65 0.66 
CD59_HUMAN  Hs.278573 0.9 0.87 0.77 1.03 3.39 1.29 0.93 1.05 0.75 0.47 
CD63 Hs.433996 0.63 0.91 1.84 0.83 1.98 1.22 1.23 1.14 1.31 1.32 
CD68.  Hs.246381 2.19 3.89 2.75 2.14 - 1.08 2.18 2.39 2.38 4.29 
CD72 Hs.116481 - 2.45 - 0.77 - 0.71 - - - - 
CD74. Hs.84298 1.7 2.99 1.56 2.64 1.45 1.27 2.17 3.26 2.4 2.52 
CD79A Hs.79630 0.12 - - - - 1.66 - - - - 
CD79B Hs.89575 0.77 0.66 1.2 - - 1.69 3.74 - - - 
CD83 Hs.79197 0.63 - - - 2.12 - 0.86 - - - 
CD86 Hs.27954 - - - - - 0.92 - - - - 
CD8A  Hs.85258 - 0.58 - - - 0.84 - - - - 
CD8B Hs.2299 - - - - - 1.02 - - - - 
CD9 Hs.1244 0.78 2.06 1.15 1.06 2.18 2.18 0.84 0.9 0.48 0.75 
CD97 Hs.3107 1.17 1.96 0.87 3.05 - 1.32 2.04 1.51 1.56 2.23 
CDH5 Hs.76206 7.48 1.43 2.94 1.1 0.89 0.57 1.47 3.11 0.94 0.68 
CDKN1A Hs.179665 2.02 0.7 0.53 0.25 - 0.68 0.6 0.55 - 0.35 
CDKN1B) Hs.238990 1.58 1.93 1.06 1.05 0.88 0.78 0.71 1.13 0.8 - 
CEBPB Hs.99029 1.91 0.69 0.57 1.8 - 1.19 2.32 1.8 2 3.32 
CEBPG Hs.2227 1.46 - 0.61 - - 1.09 0.6 0.72 0.73 1.12 
CISH6 Hs.169836 2.44 - - - - - - 2.29 - - 
CLARP Hs.195175 1.21 0.95 0.98 0.68 0.29 1.11 1.11 0.89 0.61 0.64 
C-MAF Hs.30250 - - - - - - - 5.89 - - 
COL12A1 Hs.101302 0.64 0.65 0.85 0.71 0.84 0.58 0.52 0.61 0.6 0.74 
COL15A1 Hs.83164 9.88 0.39 0.53 - - 0.49 3.16 2.33 2.88 1.6 
COL16A1 Hs.26208 0.1 - - - - - - - - - 
COL18A1_1 Hs.78409 0.74 0.33 0.8 0.4 0.28 0.73 0.63 0.83 0.38 0.43 
COL18A1_2 Hs.78409 0.62 1.36 0.92 0.67 1.09 1.29 0.84 0.81 0.66 0.52 
COL1A1 Hs.172928 0.77 0.17 0.09 5.09 1.36 0.55 1.07 1.81 9.17 4.73 
COL1A2 Hs.179573 1.12 0.26 - 3.01 - 0.43 1.01 1.05 4.81 3.28 
COL3A1 Hs.119571 0.99 - 0.17 3.68 3.27 0.55 1.15 1.36 3.69 4.22 
COL4A1 Hs.119129 6.36 0.33 1.47 2.52 1.17 0.48 3.53 3.96 3.02 2.74 
COL4A2 Hs.75617 3.26 0.43 1.43 2.08 0.78 0.8 2.37 2.62 1.53 1.81 
COL4A3 Hs.530 0.05 - - - - - - - - - 
COL5A1 Hs.146428 0.91 - - - - 0.53 - - 3.56 - 
COL5A2 Hs.82985 2.84 0.6 1.52 2.4 1.57 0.39 1.78 2.1 3.38 2.05 
COL6A1 Hs.108885 0.95 - 0.85 0.57 3.18 0.88 - 0.4 - 0.66 
COL6A2 Hs.159263 1.85 0.7 1.38 3.5 - 0.65 1.35 1.24 2.51 2.22 
COL7A1 Hs.1640 0.32 0.03 - - - - - - - - 
COL8A1 Hs.114599 0.7 0.62 1.65 0.84 0.59 1.63 1.27 2.98 0.9 - 
COL9A1 Hs.154850 0.8 - - - - - - - - - 
COL9A3 Hs.53563 0.47 - - - - - - - - - 
CONTGF Hs.194678 0.93 1.5 1.17 1.31 - 0.95 1.02 - 2.25 0.6 
CREB1 Hs.79194 1.84 0.83 - - - - - 1.29 - - 
CREBPA Hs.149 0.94 0.89 1.11 0.85 0.6 0.82 0.52 0.95 0.78 1.12 
CREB-RP Hs.42853 1.22 1.03 - - - 0.92 0.61 1.01 - 0.53 
CREM Hs.155924 1.64 0.79 - 1.27 0.52 1.1 1.44 1.39 0.81 0.57 
CSF1R Hs.174142 2.57 1.99 0.83 2.22 - 0.74 1.9 6.25 1.18 4.33 
CSF2RA Hs.182378 1.19 1.74 0.74 1.51 - 0.97 1.97 2.7 1.97 1.91 
CSF3R Hs.2175 - 1.9 - - - - - - - - 
CSK Hs.77793 0.91 1.48 1.21 2.56 0.81 1.2 1.59 2.54 1.08 2.15 
CTGF Hs.75511 0.35 0.07 0.06 0.1 0.35 0.75 0.14 0.26 0.83 0.27 
CX3CR1 Hs.78913 - 3.61 - 0.91 - - 3.19 8.12 1.64 4.68 
CXCR4 Hs.89414 2.56 4.53 1.21 12.11 1.11 1.43 5.34 9.4 3.52 8.65 
CYPA Hs.342389 0.7 1.05 1.36 - - 1.79 1.25 1.93 0.88 2.22 
CYR61 Hs.8867 0.56 0.1 0.22 0.33 0.25 0.81 0.72 0.74 1.1 0.58 
DAF Hs.1369 1.14 - - 0.52 1.95 0.89 0.72 0.68 0.79 1.56 
DDR1 Hs.75562 0.19 0.45 0.69 0.37 0.99 1.04 1.33 0.7 0.28 0.7 
DDR3 Hs.180338 0.99 - - - - 1.39 - - - - 
DPP4 Hs.44926 0.78 1.04 - 0.49 - 0.97 0.89 0.42 - 0.08 
E4BP4 Hs.79334 2.14 1.24 1.78 1.47 - 0.77 0.88 2.73 2.66 0.54 
EDG1 Hs.154210 6.3 2.55 2.12 1.73 - 0.77 2.67 4.77 - 0.92 
EDG2 Hs.75794 - - - - - - 1.76 - - - 
ENG Hs.76753 2.79 0.94 1.13 - 0.55 - 1.07 1.7 0.79 0.62 
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ENIGMA Hs.102948 1.47 0.44 0.54 0.73 - - - 1.49 1.23 - 
FAK1 Hs.740 2.56 0.95 1.37 0.67 0.67 0.66 0.71 0.88 - - 
FBLN1_1 Hs.79732 0.15 - 0.08 - - 0.69 0.02 - - - 
FBLN2 Hs.198862 3.98 - - - - - - 1.27 - - 
FBXW1B Hs.21229 1.16 - - 0.73 2.08 0.51 0.51 0.81 - - 
FCGR1A Hs.77424 4.66 3.27 1.14 6.74 1.91 1.19 3.88 1.35 6.02 8.77 
FCGR2C_HUMAN Hs.78864 1.83 1.82 0.51 13.68 0.95 1.31 2.97 2.51 3.59 4.78 
FCGR3A_HUMAN Hs.176663 3.57 9.19 2.77 8.46 - 0.69 6.84 6.7 26.61 15.7
7 FGR Hs.1422 1.31 1.32 - - - - - - - - 
FIBRILLIN1 Hs.750 1.47 0.34 0.61 1.41 1.64 0.77 0.85 1.43 1.4 2.04 
FIBROMODULIN Hs.230 - - - - - - - - 2.64 5.22 
FIBRONECTIN Hs.287820 3.2 1.11 2.72 3.58 1.11 0.55 1.74 3.58 6.9 5.02 
FIP2 Hs.278898 0.82 1.01 1.46 1 0.29 1.12 1.16 0.72 0.91 0.85 
FKHR Hs.170133 1.06 - - - - - - 0.86 - - 
FKHRL1 Hs.380831 1.17 1.41 1.66 1.11 - - 0.8 0.83 1.03 0.6 
FLT3 Hs.385 - - - - - - 0.69 - - - 
FOSL2 Hs.301612 0.23 0.23 0.1 0.08 0.21 0.96 0.05 0.42 0.12 0.19 
FRE Hs.153684 2.32 1.86 0.92 2.51 - 0.81 1.28 2.69 2.72 0.58 
FREAC1 Hs.155591 0.85 1.01 - 0.49 1.27 1.17 1.08 1.44 0.73 0.94 
FRIZZLED3 Hs.40735 0.73 0.86 0.97 1.02 1.21 1.71 0.99 1.56 0.74 1.53 
FTH Hs.62954 0.71 1.09 2.38 0.63 1.52 1.21 0.99 1.08 1.69 0.97 
FY Hs.183 1.99 - 0.14 - 0.66 1.83 0.62 1.69 - 0.71 
FYN Hs.169370 1.9 0.83 0.91 0.41 - 1.06 0.85 0.53 - - 
FZD4 Hs.19545 1.5 0.76 0.82 1.27 1.08 0.74 0.84 1.02 - 0.61 
FZD6 Hs.114218 1.05 0.7 0.52 0.99 1.38 - 1.04 0.65 0.58 0.91 
GADD153 Hs.129913 0.88 1.65 - 1.41 5.76 1.63 1.01 0.77 0.48 0.67 
GADD34 Hs.76556 0.85 0.96 1.06 1.08 0.7 1.36 1.19 0.89 0.83 1.11 
GADD45 Hs.80409 0.58 1.08 0.83 0.32 1.23 1.64 0.27 0.61 0.58 0.83 
GAP1 Hs.119274 0.48 0.66 - 0.62 - - 0.69 - - - 
GAPD Hs.169476 1.71 1.96 3.5 1.86 2.32 1.58 1.6 2.04 2.6 2.74 
GAS2 Hs.129818 - - - - 5.65 - 0.91 - - - 
GAS3 Hs.103724 3.9 6.18 - 1.61 - 1.96 0.93 3.22 1.6 1.29 
GDF15_2 Hs.296638 0.36 0.74 0.3 0.13 1.89 1.57 0.48 0.27 0.15 0.22 
GDF3_1 Hs.86232 1.04 - - - - - - - - - 
GJA1_2 Hs.74471 2.92 1.67 1.07 1.02 0.67 0.71 2 1.93 1.25 1.53 
GM-CSF Hs.1349 - - - - - - - - - - 
GNA13 Hs.1666 1.48 2.71 - 2.61 - - 0.93 0.8 - - 
GNAI1_1 Hs.203862 1.79 1.42 - 3.84 - - 0.83 1.19 - 0.75 
GNAI3 Hs.73799 1.46 0.77 0.78 1.26 0.54 0.75 1.01 0.89 0.87 1.22 
GNAQ Hs.380144 2.61 4.52 2.54 1.13 - 0.75 1.54 2.11 1.8 0.9 
GRB2 Hs.381152 0.86 0.63 1.01 0.69 0.56 0.96 0.72 0.83 1.49 0.83 
GREMLIN Hs.40098 0.35 - - - - - - - - - 
GRO1_HUMAN Hs.789 - - - - - - - - 1.29 - 
HCK Hs.89555 1.84 1.98 1.04 17.58 2.15 0.85 8.22 3.1 1.7 8.58 
HEVIN Hs.75445 12.76 4.29 2.57 3.38 16.9 1.08 3.07 7.78 1.24 1.86 
HLF Hs.250692 0.64 - - - - - - - - - 
HPRT Hs.82314 - - - - - - - - 0.91 3.05 
HSC73 Hs.180414 0.65 0.49 0.82 0.54 0.94 0.97 0.59 0.43 0.74 0.7 
HSP70.1 Hs.8997 0.68 0.86 1.29 0.35 0.6 1 0.39 0.75 0.45 0.42 
HSPA1L Hs.80288 1.52 - - - - - - - - - 
HSPA9 Hs.3069 0.51 0.99 0.7 0.5 1.4 1.02 0.49 0.53 0.63 0.5 
HSPG2 Hs.211573 3.03 - 2.37 - - 0.46 1.48 3.96 - 1.29 
HSR.1 Hs.44581 1.13 - - - - - - - 0.88 1.64 
IAP1 Hs.127799 0.73 5.82 0.89 2.43 0.96 0.48 3.31 2.53 6.05 1.99 
ICAM1 Hs.168383 0.7 0.86 0.72 0.45 0.43 0.85 0.61 0.73 0.68 0.91 
ICAM3 Hs.99995 0.59 1.14 0.78 1.53 1.12 1.99 1.08 1.24 0.76 1 
IFNGR1 Hs.180866 1.87 1.67 0.96 1.73 1.39 1.15 1.56 1.49 2.82 2.85 
IKBA Hs.81328 1.01 2.54 1.55 1.33 0.33 1.49 1.1 2.23 0.61 0.56 
IKBB Hs.9731 0.66 0.91 - - - - - - - - 
IKBE Hs.182885 - 1.01 0.99 - - 1.28 4.97 - 1.73 3.26 
IKKA Hs.198998 1.21 - - - - - 0.55 0.49 0.8 0.58 
IKKB Hs.226573 0.57 0.35 - - 1.68 0.64 0.38 0.37 0.6 0.38 
IKKG Hs.43505 0.96 1.13 - - - - 0.51 0.8 - 0.54 
IL11 Hs.1721 2.06 1.1 0.6 1.11 - 0.79 1.24 3.05 2.8 0.67 
IL15_1 Hs.168132 - 1.22 - 1.29 - 0.78 1.59 - - - 
IL16 Hs.82127 0.79 1.76 0.74 5.02 - 1.6 2.25 3.05 1.62 1.75 
IL18 Hs.83077 0.27 0.66 0.5 0.51 4.92 1.45 1.38 0.85 1.11 2.5 
IL1B Hs.126256 - 2.87 - - - 1.53 2.61 - 1.45 0.77 
IL1R1 Hs.82112 0.85 0.61 - 0.66 - - 0.43 - - 0.81 
IL1R2 Hs.25333 2.3 - - 0.49 - - 0.09 - 0.71 5.55 
IL2RG Hs.84 0.76 1.64 0.49 3.32 - 1.26 2.69 1.62 - 0.95 
IL3RA Hs.172689 2.77 0.69 1.11 0.61 0.75 1.23 1.29 1.75 0.49 0.59 
IL4 Hs.73917 - 0.63 - 0.55 - 1.37 0.75 0.71 0.45 0.85 
IL4R Hs.75545 1.77 1.34 0.92 - - 1 1.05 1.1 - 0.74 
IL5RA Hs.68876 - - - - - - - - 0.94 3.54 
IL6 Hs.93913 2.76 - - - - 1.02 1.29 1.48 1.38 1.8 
IL6R Hs.193400 - 1.14 - 0.75 - - 0.64 0.61 0.75 - 
IL6ST Hs.82065 0.89 0.93 - 0.47 0.75 0.77 0.53 0.49 - 0.43 
IL7 Hs.72927 - 0.89 - 1.44 - 1.41 0.82 0.75 0.83 0.92 
IL7R Hs.362807 0.17 - - - - - 1.43 - - - 
IL8_HUMA Hs.624 0.7 0.72 - - 0.64 1.31 1.18 1.54 1.31 1.32 
IL8RB-IL8RA_HUMAN Hs.194778 Hs.846 0.48 - - - - - - 0.33 0.52 - 
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ILF Hs.296281 0.94 - - - - - - - - - 
INTEGRINA7 Hs.74369 2.92 - - - - - - - - - 
INTEGRINA8 Hs.91296 0.42 - 3.68 - - - - 1.09 - - 
INTEGRINB5 Hs.149846 - - - - - - - - 0.64 - 
INTEGRINB6 Hs.57664 0.51 0.04 0.08 - - - 0.63 0.88 - 0.7 
INTEGRINB7 Hs.1741 0.43 2.48 0.97 1.37 1.31 1.21 1.37 1.74 0.64 0.6 
INTEGRINB8 Hs.355722 - - - - - - - - - 0.98 
IQGAP1 Hs.1742 1.94 1 0.81 0.89 3.05 0.4 1.14 1.3 1.36 1.61 
IQGAP2 Hs.78993 0.56 0.73 - - 2.79 - 0.2 0.22 - - 
ITGA1_1 Hs.116774 2.54 0.99 1.13 1.36 2.28 0.54 2.13 3.44 5.03 1.24 
ITGA1_2 Hs.116774 1.92 0.66 1.62 1.66 1.17 0.46 1.45 1.7 2.04 1.22 
ITGA3  Hs.265829 0.76 0.83 0.66 0.71 - - 0.91 1.22 2.33 2.19 
ITGA4 Hs.40034 - 1.61 - - - - 1.62 - - - 
ITGA5  Hs.149609 7.05 1.32 - 2.49 0.93 0.61 2.48 2.72 1.35 2.25 
ITGA6 Hs.227730 3.29 1.04 1.52 0.87 2.56 0.65 1.23 0.84 - 0.35 
ITGAE Hs.851 0.61 - - - - 1.63 0.92 0.73 0.53 0.92 
ITGAV Hs.295726 1.27 0.89 - 0.95 3.52 - 0.98 0.78 1.62 1.66 
ITGB1  Hs.287797 2.41 0.71 0.85 - 0.76 0.48 1.34 1.57 2.5 1.86 
ITGB2 Hs.83968 1.67 2.61 1.21 4.34 1.21 0.98 4.5 3.67 2.97 6.25 
ITGB3 Hs.87149 0.54 0.12 - - 1.09 - 0.54 0.32 - - 
ITGB4 Hs.85266 1.31 0.75 - 1.04 - - - 1.14 - 2.29 
JUNB Hs.198951 4.37 1.74 0.81 0.65 0.9 1.07 1.31 1.29 0.86 0.96 
KAI1 Hs.323949 0.25 0.49 0.26 - 1.64 0.8 0.29 0.36 0.84 3 
KIAA0170  Hs.277585 0.95 - 1.06 - - - - 0.46 0.71 0.48 
KIAA0538 Hs.184367 2.07 - - 1.24 - - - - - - 
KIAA0646 Hs.24439 0.6 0.48 0.57 0.39 0.54 0.94 0.52 0.34 0.37 - 
KIAA1041 Hs.26023 1.15 0.65 1.03 2.92 0.36 1.5 8.63 1.21 2.33 0.42 
KIT Hs.81665 - - - - 11.97 - - - - - 
KLRD1 Hs.41682 1.88 - - - - 0.96 12.85 - - - 
LAMA3 Hs.83450 0.72 1.08 0.81 - - - 0.73 0.89 0.9 0.5 
LAMA4 Hs.78672 7.51 2.41 1.98 7.44 4.43 0.5 1.62 6.21 13.5 8.06 
LAMA5 Hs.11669 0.92 0.52 1.3 1.69 0.95 1.07 1.37 1.42 - 1.48 
LAMB1 Hs.82124 1.01 0.25 0.43 0.24 0.48 0.62 0.39 0.76 0.37 0.71 
LAMB3 Hs.75517 - - - - - 0.71 - - 0.82 - 
LAMG1 Hs.214982 1.69 0.7 1.08 1.38 - 0.75 1.17 1.98 0.65 1.44 
LAMP1 Hs.150101 0.52 0.43 - 0.34 0.79 0.93 0.35 0.43 0.9 0.34 
LAMP2 Hs.8262 0.61 1.09 1.09 0.97 1.73 1.15 0.65 0.77 0.64 0.54 
LAP18 Hs.250811 0.58 0.48 0.66 0.55 0.44 1.29 0.56 0.72 0.33 0.81 
LCK Hs.1765 0.49 - - - - 1.57 1.33 - - - 
LCP2 Hs.2488 3.54 3.03 0.51 - - 0.71 - - 3.31 0.92 
LIG3 Hs.100299 0.41 0.79 0.77 - - - 0.38 - - - 
LIG4 Hs.166091 0.78 - - - - - - - - - 
LIM Hs.154103 1.1 0.66 0.55 0.5 0.96 0.55 0.53 0.68 0.47 0.47 
LINK Hs.2799 - - - - - - 11.32 6.74 11.98 - 
LRP1 Hs.236894 1.23 1.69 - - - - - 0.68 - 4.32 
LTBP1 Hs.241257 1.26 - - - - 0.78 - 0.86 - - 
LTBP2 Hs.83337 0.66 0.79 0.85 - 0.55 1.16 0.7 0.71 0.58 0.43 
LTBP4 Hs.85087 0.47 0.37 - - - 1.1 0.31 0.62 0.59 0.5 
LUMAN Hs.287921 0.81 1.41 1.4 1.45 1.61 1.76 1.42 0.99 0.86 1.86 
LUMICAN Hs.79914 0.29 0.04 0.03 - - 1.16 - - 0.66 - 
LYN Hs.80887 1.88 1.9 1.64 2.16 0.82 0.94 2.56 1.87 2.48 3.52 
LYSYLOXIDASE Hs.102267 - 0.39 - - - 1 - 3.07 10.03 9.65 
MAFG Hs.252229 1.04 1.1 0.93 1.12 - 1.36 0.86 0.83 - - 
MAGP1 Hs.83551 0.49 - - - - 1.4 - - 0.61 - 
MAPK14 Hs.79107 1.34 0.9 - 1.22 - - 1.01 0.83 - 0.95 
MAPK3 Hs.861 2.21 0.94 0.99 0.49 - 1.27 - 0.52 - - 
MAPK7 Hs.3080 1.29 1.04 - - - - - - - - 
MAPK9 Hs.246857 1.33 0.93 - 0.87 0.94 0.83 0.81 1.22 0.68 0.46 
MATK Hs.274 - - - - - - - - - 5.14 
MATRILIN2 Hs.19368 0.39 0.9 - 0.2 - - 0.18 1.14 - 0.5 
MATRIXGLA Hs.365706 0.49 0.3 0.41 0.68 0.46 1.69 0.44 1.02 1.01 0.36 
MCL1 Hs.86386 2 1.08 0.59 1.06 1.35 0.43 0.94 1.07 1.01 1.14 
MCP Hs.83532 1.35 1.3 0.98 0.88 1.64 0.67 0.84 0.79 0.81 0.69 
MDC9 Hs.2442 1.8 0.72 - 0.88 1.68 0.53 1.96 1.55 1.93 1.8 
MDU1 Hs.79748 0.63 0.93 - 0.39 2.28 1.66 0.25 0.4 0.36 0.21 
MEGF5 Hs.57929 1.48 - - - - - - - - - 
MFAP3 Hs.28785 0.58 0.84 1.04 0.59 0.65 1.26 0.84 0.87 0.83 0.68 
MIC2 Hs.433387 0.95 0.97 1.78 1.85 0.45 1.2 1.68 2.36 3.01 0.95 
MIP2B_HUMAN Hs.89690 0.63 0.61 0.98 0.85 - 0.99 0.52 1.3 1.01 1.01 
MME Hs.1298 0.12 0.59 1.03 0.15 - 0.55 0.25 0.19 - 0.00
91 MMP1_HUMAN Hs.83169 1.12 - - 4.71 - 4.07 - 2.36 - - 
MMP11 Hs.155324 1.24 - - 2.08 - 0.66 - - - - 
MMP15 Hs.80343 0.83 - - - 0.9 8.43 - 0.64 - - 
MMP18 Hs.154057 - - - - - - - - 2.43 3.43 
MMP2 Hs.111301 1.2 - - - - 1.01 - 2.54 4.48 1.51 
MMP7 Hs.2256 0.12 0.0087 0.0069 - 0.94 7.68 - - 1.01 - 
MMP8 Hs.73862 - - - - - - - - - - 
MMP9 Hs.151738 1.08 - - - - 5.12 - - 2.25 - 
MPP1 Hs.1861 0.73 1.37 1.19 0.77 0.78 - 0.51 0.51 0.61 0.39 
MS4A2 Hs.89751 0.08 - - - - - - - - - 
MSP58 Hs.25313 0.64 1.05 1.2 0.86 1.48 1.52 0.65 0.84 0.56 0.63 
MST1R Hs.2942 0.69 0.82 0.65 0.31 0.8 0.84 0.63 0.47 0.56 0.5 
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MUPP1 Hs.169378 1.29 2.54 0.83 - - 0.86 - 1.16 - - 
NBS1 Hs.25812 - 1.43 - - - - 1.27 - - - 
NCAM1_1 Hs.167988 - - - - 2.36 0.74 0.88 0.32 - - 
NED4 Hs.1565 0.78 1.01 - - - - - 0.65 - 1.43 
NFAT3 Hs.77810 0.82 - - - - - - - - - 
NFATX Hs.172674 1.21 1.66 1.22 0.83 0.46 0.68 0.98 1.29 0.78 0.45 
NF-E2 Hs.75643 - - - - - - - - - - 
NFE2L1 Hs.83469 1.05 1.28 1.03 0.4 0.86 0.72 0.48 0.68 0.74 0.52 
NFKB1 Hs.83428 1.08 1.57 1.61 1.2 0.9 1.31 1.35 1.5 0.93 1.28 
NFKB2 Hs.73090 0.76 0.62 - - - - - - - - 
NFKB3 Hs.75569 1.63 2.38 0.88 - 1.16 1.27 0.75 1.02 - - 
NIDOGEN Hs.348994 1.87 0.89 1.34 - - - 0.85 1.22 0.81 - 
NRF2 Hs.155396 0.61 0.44 0.58 0.48 0.65 0.74 0.91 0.6 0.59 0.54 
NT5 Hs.153952 2.23 0.98 0.86 0.41 - - 0.34 0.34 2.07 0.41 
OPN Hs.313 0.07 0.14 0.57 0.13 5.3 1.42 0.56 0.58 2.04 0.59 
OSF Hs.95821 1.28 0.64 0.75 0.78 1.91 1.06 0.98 0.97 1.17 0.72 
OSP94 Hs.71992 - - - - 2.13 - 1.56 0.44 - 0.58 
OSTEOCALCIN Hs.2558 0.61 1.82 - - - 5.04 - - - - 
P5 Hs.1846 1.38 1.59 0.92 - - 0.85 0.46 1.14 - 1.18 
P73_1 Hs.247753 0.55 0.94 0.81 0.37 0.62 1.2 0.72 0.59 0.57 0.5 
PAI1 Hs.82085 5.62 0.73 - 16.7 - 0.74 4.21 2.13 5.19 16.0
3 PAR2 Hs.154299 - 1.3 0.6 4.49 - - 0.73 0.83 0.45 1.25 
PCNA Hs.78996 1.03 1.13 1.1 1.21 1.19 1.11 1.03 0.95 1.02 1.94 
PDGA Hs.37040 - 0.7 0.79 - - 1.09 - 1.35 - 0.65 
PDGB Hs.1976 1.98 0.59 1.06 0.34 - 0.69 0.84 0.72 - - 
PDGFRB Hs.76144 2.09 1.88 - 3.53 - 0.48 1.34 1.67 6.32 1.09 
PDZK1 Hs.15456 0.18 0.68 1.74 0.4 0.02 2.43 0.55 0.5 0.33 0.05 
PESCADILLO Hs.13501 0.72 1.63 1.32 1.13 0.99 0.83 0.92 1.44 1.29 1.11 
PGS2 Hs.433989 0.06 0.02 0.01 0.09 0.12 1.61 0.00965 0.1 0.24 0.02 
PIK3C2A Hs.249235 1.44 0.99 0.97 0.78 0.86 - 0.76 0.63 0.6 0.59 
PIK3CA Hs.85701 1.62 - 1.12 0.72 - - 0.76 0.96 1.44 - 
PIK3CB Hs.239818 0.47 0.76 - 0.46 - 0.52 0.66 0.45 0.35 0.38 
PIK3R1 Hs.6241 0.84 0.87 - 0.42 - 0.68 0.49 0.73 1.92 0.98 
PIK3R3 Hs.372548 6.29 0.88 - 0.68 - - 1.26 - - - 
PKCD Hs.155342 0.6 1.09 - 0.55 4.2 1.15 0.39 0.37 0.51 0.32 
PLA2G4 Hs.211587 - 0.44 - - - - - - - - 
PLC Hs.153322 0.31 0.13 - 0.07 0.22 - 0.07 0.06 - 0.02 
PLCB1 Hs.41143 0.86 1.18 0.92 0.6 - - 1.05 0.77 0.76 0.49 
PLCG1 Hs.268177 2 0.6 - - - - 0.56 0.58 - - 
PLCG2 Hs.75648 0.43 0.22 - 0.15 5.15 1.03 0.31 0.17 - 0.22 
PLGF Hs.2894 9.86 54.43 5.32 36.77 - 1.02 7.78 29.87 27.68 5.68 
PNP Hs.120330 0.64 - - - - - - - 0.8 0.67 
PPOL Hs.177766 0.84 1.05 1.19 0.81 0.49 0.98 0.88 0.72 0.98 0.86 
PRELP Hs.76494 0.81 - - - - - - - - 3.61 
PRK2 Hs.69171 1.19 0.6 1.89 0.45 - 0.67 0.86 0.77 1.48 0.57 
PRKCB_1 Hs.77202 - 1.57 - - - 0.63 1.43 - 0.44 - 
PRKCB_2 Hs.77202 0.76 - - - 0.35 0.82 0.63 - 0.66 0.23 
PRKCH Hs.315366 4.97 1.31 1.49 4.32 - 1.02 3.09 2.1 2.12 1.16 
PRSS11 Hs.75111 1.64 0.55 - 0.35 0.41 0.83 0.52 0.79 2.37 0.66 
PTAFR Hs.46 0.9 1.76 - - - 1.04 - 2 2.34 - 
PTGD Hs.158326 0.67 - 1.28 - - 0.84 - 0.99 0.56 0.55 
PTGFR Hs.89418 0.7 - - - - - - - - - 
PTP Hs.211595 0.27 0.53 - 0.26 0.18 - 0.33 0.24 - 0.27 
PTP1C Hs.63489 0.86 1.48 1.1 1 - 1.23 1.38 1.21 0.81 1.72 
PTPN12 Hs.62 2.58 1.48 1.4 2.11 - 0.7 1.65 2.32 1.68 2.07 
PTPN3 Hs.153932 0.29 0.63 - 0.64 1.98 - 0.51 0.27 - - 
PTPN4 Hs.73826 0.9 0.36 1.02 0.45 0.57 1.02 0.76 0.34 0.32 0.38 
PVS_HUMAN Hs.171844 - - - - - 0.98 - - - - 
RAI: (RAI) Hs.324051 2.25 1.16 1.77 2.19 - 1.65 2.17 3.26 1.07 2.97 
RAR Hs.302498 0.55 0.63 - 0.31 1.12 1.69 0.39 0.35 - 0.26 
RASA1_2 Hs.758 0.61 0.85 0.4 0.35 0.5 - 0.52 0.3 0.25 0.33 
RELB Hs.858 0.98 0.87 1.15 - - - - 3.67 - 1.34 
RPS7 Hs.301547 0.68 0.75 1.16 1.67 0.72 1.73 1.38 1.21 0.77 1.04 
RRAS Hs.9651 0.86 2.26 1.14 1.5 0.7 2.05 1.42 1.49 1.14 2.76 
RYUDOCAN Hs.252189 - 0.5 - - 2.93 - - 0.36 - 0.86 
SARP2 Hs.7306 0.5 0.28 0.49 0.24 0.28 1.34 0.62 0.54 0.93 0.61 
SELE Hs.89546 1.14 0.66 0.75 - 3.21 1.42 1.11 0.79 0.52 0.83 
SELL Hs.82848 0.72 1.72 - - - 0.9 2.3 - 0.99 - 
SELPLG Hs.79283 0.8 1.86 0.85 0.94 - 1.36 1.56 1.03 1.07 3.94 
SERPINA1_1_HUMAN Hs.297681 1.07 3.25 2.59 1.56 0.27 0.97 1.12 4.02 2.61 2 
SIP1_1 Hs.101813 2.05 1.1 - - 0.49 0.85 0.54 - - - 
SIP1_2 - 2.1 - - - - - - - - - 
SIPA1 Hs.7019 1.1 0.87 1.01 0.53 1.03 0.89 1.04 0.82 0.86 0.75 
SMPD2 Hs.55235 0.47 0.66 0.95 0.72 - - 0.77 - 0.58 0.96 
SOCS1 Hs.50640 0.55 0.78 1.07 0.84 1.43 1.61 1.14 1.33 0.78 1.66 
SOCS2 Hs.110776 2.19 - - - - - 0.68 0.84 - - 
SOCS3 Hs.345728 3.57 - - - - 0.68 - - - - 
SOD1 Hs.75428 0.56 0.75 0.91 0.59 0.67 1.83 0.6 0.62 0.4 0.42 
SOS1 Hs.326392 1.02 0.56 0.99 0.56 - 0.95 0.39 0.56 0.69 0.42 
SPARC Hs.111779 4.5 1.15 2.33 1.63 3.11 0.65 3.05 2.54 6.92 2.73 
SPOCK Hs.93029 - - - - - - - - 6.41 1.11 
SRC Hs.198298 0.46 0.94 0.72 0.99 0.44 1.43 1.05 0.49 0.33 0.7 
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SSB2 Hs.334697 - - - - - - - - - 0.56 
STAT1 Hs.21486 1.28 1.06 1.23 2.35 0.49 - 1.96 1.24 1.07 1.49 
STAT2 Hs.72988 2.81 1.43 1.34 - - 1.42 7.83 1.44 1.27 0.96 
STAT3 Hs.321677 1.03 1.01 0.72 1.05 0.34 0.69 0.99 0.98 0.89 1.1 
STAT5A Hs.167503 0.73 0.8 0.68 1.13 0.23 1.39 0.58 0.75 0.87 1.16 
STAT5B Hs.244613 1.58 1.08 1.39 1.32 - 0.64 1.1 0.86 1.09 1.07 
STAT6 Hs.181015 1.15 1.36 1.52 0.82 - - - 1.43 - - 
SYCL Hs.8180 1.81 0.73 0.84 1.66 1.33 1.02 1.2 1.21 1.42 1.77 
SYK Hs.74101 0.83 - - - - - - - - - 
SYNDECAN1 Hs.82109 - 0.4 - 0.4 - 0.79 0.17 0.47 0.89 0.35 
SYNDECAN2 Hs.1501 0.99 1.16 1.6 1.25 4.65 0.66 1.05 1.01 0.66 0.61 
SYNDECAN3 Hs.158287 0.61 0.62 0.89 - - 0.88 0.79 0.61 0.53 0.5 
SYNGAP2 Hs.221922 0.66 - - - - - - - - - 
TAX1 Hs.12956 0.82 0.55 0.89 0.83 0.68 1.5 0.71 1.09 1.93 2.31 
TAX2 Hs.6454 - - - - - - - - - - 
TAX33 Hs.178215 - 2.18 2.44 1.25 3.67 2.76 1.29 0.45 - - 
TAX40 Hs.112933 - 0.96 - - - 1.97 - - - - 
TCF12 Hs.21704 1.54 1.32 - 0.69 - - 0.72 0.76 0.83 0.89 
TCF4 Hs.326198 2.2 1 1.5 1.71 0.62 0.91 2.18 2.31 1.15 1.16 
TENASCINC Hs.289114 0.66 0.19 - - - 0.85 - 0.91 0.74 - 
TFRC Hs.77356 1.25 1.41 - 0.51 2.15 - 0.76 0.54 - 0.73 
TGF1 Hs.1103 1.48 1.28 1.59 1.85 1.03 0.96 2.28 2.85 2.86 1.44 
TGF3 Hs.2025 - - 0.7 0.54 - 0.73 0.82 0.73 0.67 1.63 
TGFA55 Hs.170009 0.58 1.45 1.13 0.84 - - 1.16 0.6 0.82 0.66 
THBD Hs.2030 2.23 - 0.5 - - 0.45 0.76 - - 1.33 
THROMBOSPONDIN1 Hs.87409 0.65 0.42 0.4 0.65 - 0.63 0.54 1.69 3.01 1.79 
THROMBOSPONDIN2 Hs.108623 0.65 0.09 - 5.4 - 0.55 0.6 0.65 3.61 4.96 
THROMBOSPONDIN5 Hs.1584 0.62 - - - - - - - - - 
THY1 Hs.125359 4.22 0.33 2.07 0.3 0.08 0.71 0.36 0.26 1.13 0.3 
TIMP1  Hs.5831 1.76 0.69 0.52 6.31 0.86 1.19 4.35 3.97 5.97 5.75 
TIMP2 Hs.6441 0.73 0.83 0.97 1.06 - 1.17 0.85 1.08 0.88 1.63 
TIMP3 Hs.245188 1.1 2.51 1.22 0.46 2.21 0.97 1.03 1.07 - 0.2 
TKT Hs.71891 1.02 - - - - - - - - - 
TNFC Hs.890 0.21 0.45 - 3.02 - 1.98 1.59 0.94 0.33 0.96 
TNFR1 Hs.159 2.24 1.33 1.69 4 - - 1.5 1.42 1.69 0.77 
TNFRSF11A Hs.114676 - - - - - - 0.32 - - - 
TNFRSF1B Hs.256278 2.06 0.9 - - - 0.81 1.54 1.5 - 1.42 
TNFRSF5 Hs.25648 2.21 4.23 1.97 2.29 1.34 1.49 3.8 1.7 1.71 3.34 
TNFRSF6 Hs.82359 - 1.47 0.67 - - 0.8 2.43 0.54 - - 
TNFRSF7 Hs.180841 - 2 - - - 1.92 - - - - 
TNFSF12 Hs.26401 1.37 2.06 1.02 1.15 - 1.53 0.94 1.18 0.52 0.42 
TNFSF7  Hs.99899 - 26.71 13.35 14.51 - 4.16 39 80.4 35.73 43.0
8 TNFSF9 Hs.1524 - - - - - - - 45.53 - 2.64 
TP53BP1 Hs.170263 0.66 1.65 0.81 - - 0.86 0.8 1.15 0.74 - 
TPA  Hs.274404 0.5 0.28 0.48 0.08 0.06 0.91 0.19 0.28 0.07 0.09 
TRAIL Hs.83429 1.27 0.71 1.13 1.3 0.22 1.92 1.31 1.33 3.3 2.56 
TRAILR1_HUMAN Hs.249190 0.99 1.18 1.18 2.27 - 1.4 1.62 1.27 - 1.09 
TRAILR2 Hs.51233 1.86 1.86 1.29 3.33 2.92 0.63 2.56 2.25 1.53 1.76 
TRAILR3_HUMAN Hs.119684 1.89 - - - - 1.22 0.61 0.97 - 2.6 
TRAILR4_HUMAN Hs.129844 - - - - - - 0.7 2.35 - 0.52 
TRAIN Hs.283615 - 0.98 - - - - - - - - 
TUBA_HUMAN Hs.278242 1.26 1.68 1.34 1.9 2.04 1.12 2.54 2.07 1.39 4.03 
TUBB1-TUBB5_HUMAN Hs.356729 Hs.179661 1.92 1.09 1.39 2.12 0.81 0.75 1.62 2.5 1.49 2.41 
UPA Hs.77274 0.86 - 0.9 0.77 - - 0.65 1.18 - - 
UVRAG Hs.13137 - - - - - - 0.77 - - - 
VAV2 Hs.352272 - - - 0.26 - - - - - - 
VCAM1 Hs.109225 0.83 2.92 1.06 1.53 - 1.89 3.07 3.14 3.95 7.91 
VEGC Hs.79141 2.67 0.78 0.71 - 1.21 0.82 0.67 0.85 0.62 - 
VEGF_1 Hs.73793 14.67 9.11 29.07 7.44 1.21 0.88 9.43 7.18 16.38 3.02 
VEGFD Hs.11392 0.11 - - - - - - - - - 
VERSICAN Hs.81800 0.92 - - - - 0.66 - 14.92 7.03 - 
VWF Hs.110802 10.88 4.33 1.57 8.11 3.81 0.48 13.22 4.77 - - 
WSB-1 Hs.187991 0.85 0.92 1.01 0.43 0.31 0.92 1.44 0.91 1.7 1.9 
WWP2  Hs.166119 0.82 0.79 0.7 0.4 0.88 0.59 0.48 0.56 - 0.43 
XBP1 Hs.149923 0.91 2.14 0.78 2.1 1.76 1.06 1.87 1.16 0.5 1.18 
XRCC Hs.98493 0.96 0.9 1.34 1.31 0.66 1.42 0.83 1.17 0.55 0.56 
ZO1 Hs.74614 1.67 0.51 1.11 0.45 0.91 0.88 0.69 0.74 - 0.35 
 
B. Papillary Renal Cell Carcinoma 
Ratio list of all genes present on the microarray:  
Gen Name UniGene 2828 3204 3230 2060 2810 3026 
AATK: (AATK OR AATYK Hs.514575 1.78 - - 0.91 - 0.84 
ABCP2:(ABCB2 OR TA Hs.352018 1.75 0.88 - 0.84 1.54 - 
ABCP3: (ABCB3 OR TAP Hs.502 1.22 0.58 - 0.88 1.24 - 
ABF1: (ABF-1) ACTIVA Hs.42474 1.12 0.86 - 1.28 1.34 1.77 
ABIN-2: (ABIN-2) A2 Hs.325630 0.87 1.93 - 0.52 1.40 1.21 
ABIN-3: (ABIN-3) A2 Hs.208206 0.88 - - - 0.93 1.12 
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ABR: (ABR) ACTIVE BR Hs.434004 0.94 - - 1.65 1.29 1.38 
AC15: (RFC1 OR RFC14 Hs.166563 1.24 1.10 - 0.79 0.67 1.13 
ACTA2: (ACTA2 OR ACT Hs.208641 0.89 0.79 2.86 1.57 0.26 0.66 
ACTB: (ACTB) BETA1 Hs.426930 2.24 0.77 1.38 1.16 2.18 1.82 
ACVR1: (ACVR1 OR ACV Hs.150402 0.84 1.66 - 0.96 - 0.94 
ACVR2: (ACVR2) ACTIV Hs.389846 0.84 - - 1.19 - 1.10 
ACVRL1: (ACVRL1 OR A Hs.410104 0.92 - - 0.96 0.57 0.79 
ADAM8: (ADAM8 OR MS2 Hs.86947 1.33 0.90 - 1.12 1.47 0.94 
ADCY8: (ADCY8) ADENY Hs.120330 0.78 - - 1.51 1.26 0.92 
AF6: (MLLT4 OR AF6) Hs.511773 0.92 - - 1.35 0.85 0.94 
AFX1: (AFX1 OR AFX O Hs.512585 1.28 0.95 - 0.90 1.24 0.96 
AGGRECAN1: (AGC1 OR Hs.2159 0.90 - - 0.50 - 1.98 
AGRIN: (AGRN) AGRIN Hs.273330 0.90 0.88 - 1.23 0.93 1.35 
AGTRL1: (AGTRL1 OR A Hs.438311 0.79 - - 1.24 - 1.18 
AID: (AID) ACTIVATIO Hs.149342 0.87 - - - 1.36 0.78 
AIF1: (AIF1 OR IBA1) Hs.76364 1.24 - - 1.78 1.43 1.25 
AIM2: (AIM2) INTERFE Hs.105115 1.23 - - 1.65 1.22 0.80 
AIOLOS: (ZNFN1A3) ZI Hs.258579 1.25 - - 1.24 1.31 0.99 
AKT: (AKT1 OR RAC OR Hs.368861 1.44 0.68 - 0.32 1.17 0.55 
ALCAM: (ALCAM) CD166 Hs.10247 1.46 - - 1.70 1.00 1.35 
ALG2: (PDCD6 OR ALG2 Hs.24087 0.57 0.95 - 0.56 1.13 1.23 
ALOX12-PS2: (ALOX12- Hs.378695 - - - - - 1.91 
ALOXE3: (ALOXE3) EPI Hs.232770 0.99 - - 2.49 0.86 1.37 
ALR: (ALR) ALR. Hs.387381 0.89 - - - - 0.92 
AMBP: (AMBP OR ITIL Hs.76177 0.73 0.99 - 0.22 1.63 0.73 
AMP: (MFAP1) MICROFI Hs.61418 0.83 0.59 - 0.48 0.79 1.00 
AMSH: (STAMBP OR AMS Hs.12479 0.78 - - 0.58 0.79 0.92 
ANPEP: (ANPEP OR PEP Hs.1239 0.66 0.87 - 0.48 0.69 0.13 
AOC3: (AOC3 OR VAP1) Hs.198241 0.60 - - - - 0.79 
AP1G2: (AP1G2) ADAPT Hs.343244 0.84 - - 0.99 0.79 1.19 
APAF1: (APAF1) APOPT - - - - - 0.85 - 
APRIL: (TNFSF13 OR A Hs.54673 0.99 0.63 - 1.43 1.34 1.34 
ARHGAP1: (ARHGAP1 OR Hs.138860 1.23 0.96 0.62 1.68 1.24 0.92 
ASB-1: (KIAA1146) KI Hs.512609 0.95 - - 0.73 0.96 0.79 
ASB-2: (ASB2) ANKYRI Hs.182416 1.17 0.70 - 0.47 0.85 0.82 
ASB-3: (ASB3) ANKYRI Hs.40763 0.58 - - 0.59 0.98 0.75 
ASB-4: (WUGSC:H_GS3 Hs.413226 1.00 - - 0.66 1.17 - 
ATF1: (ATF1) CYCLIC- Hs.36908 0.98 1.60 - 1.32 1.22 1.00 
ATF2: (ATF2 OR CREB2 Hs.80285 0.92 0.90 - - 0.90 0.85 
ATF3: (ATF3) CYCLIC- Hs.460 0.58 0.77 - - 0.74 0.63 
ATF4: (ATF4) CYCLIC- Hs.181243 0.74 0.44 0.93 0.57 0.63 0.67 
ATF5: (ATF5 OR ATFX) Hs.9754 1.15 0.80 - 1.00 0.86 0.77 
ATF6: (ATF6) CYCLIC- Hs.433046 0.87 1.86 - 0.52 0.72 0.95 
ATFA: (ATF7 OR ATFA) Hs.405395 0.84 0.62 - - 1.20 0.77 
B2M: (B2M) BETA-2-MI Hs.48516 0.62 0.70 0.75 2.55 0.69 2.72 
B7-H1: B7-H1 (PD-1-L Hs.443271 1.24 0.93 - 1.16 1.33 0.96 
B7-H3: TRANSMEMBRANE Hs.77873 - - - - 0.86 0.89 
BACH1: (BACH1) TRANS Hs.154276 0.89 0.44 - 0.44 0.93 0.87 
BAD: (BAD OR BBC6 OR Hs.76366 1.50 1.47 - 0.45 1.76 0.77 
BAFF: (TNFSF13B OR T Hs.270737 1.19 0.84 - 3.78 1.29 1.27 
BAG-1: (BAG1) BAG-FA Hs.377484 0.41 0.63 - 0.17 1.42 0.68 
BAG-3: (BAG3 OR BIS) Hs.15259 1.76 - - 0.44 0.82 0.57 
BAK1-BAK2: (BAK1 OR Hs.93213 - - - - - 0.86 
BAMACAN: (BAM OR SMC Hs.24485 0.85 - - 0.37 0.68 0.90 
BARD1: (BARD1) BRCA1 Hs.54089 1.16 - - 1.78 1.48 1.23 
BAX: (BAX) APOPTOSIS Hs.159428 1.26 1.38 - 0.73 1.14 - 
BAXBETA_HUMAN: (BAX) Hs.159428 0.82 - - 1.25 0.87 - 
BCL1: (BCL-1 OR BC Hs.193516 0.99 0.99 - 1.79 - 1.37 
BCL2: (BCL2 OR BCL-2 Hs.79241 Hs.501181 1.34 1.39 0.78 1.27 1.52 1.65 
BCL2A1: (BCL2A1 OR B Hs.227817 - 0.56 - - 1.00 1.16 
BCL2L1: (BCL2L1 OR B Hs.305890 - - - 0.85 - 0.92 
BCL2L2: (BCL2L2 OR B - 1.44 0.93 0.72 1.14 1.47 0.99 
BCL2NEW_1: (BCL2L13 Hs.84063 1.31 1.23 0.66 0.89 1.43 1.68 
BCL2NEW_2: (BCL2L13 Hs.410026 1.32 0.92 0.65 1.17 1.33 0.96 
BCL3: (BCL3) B-CELL Hs.310922 1.25 0.84 - 0.76 1.26 0.84 
BCL6: (BCL6 OR ZNF51 Hs.310922 1.15 - - 1.55 1.16 0.94 
BCL-XL: (BCL2L1 OR B Hs.31210 - - - 0.92 - 1.79 
BCL-XS-XL: (BCL2L1 O Hs.155024 0.98 - - 0.56 0.94 0.74 
BETA-TRCP: (FBW1A OR Hs.69771 1.17 0.93 - 1.17 1.40 0.93 
BF: (BF) COMPLEMENT Hs.748 1.20 0.88 0.68 0.97 1.18 0.96 
BFGFR_1_HUMAN: (FGFR Hs.300825 0.94 - 0.43 - 0.97 0.85 
BID: (BID) BH3 INTER Hs.821 1.00 - - 1.52 1.12 0.97 
BIGLYCAN: (BGN) BONE Hs.155419 - - - 2.15 - 1.15 
BIK: (BIK OR BIKLK O Hs.310769 0.83 1.24 - - 0.77 0.82 
BIP: (HSPA5 OR GRP78 Hs.289107 1.36 0.76 0.62 0.26 1.46 1.23 
BM3B: (GDF1 OR BMP3 Hs.389900 - - - 1.16 - 1.58 
BM45: (39341K13RI Hs.8750 Hs.512788 0.90 0.46 - 0.28 0.91 0.81 
BMP1: (BMP1 OR PCP-3 Hs.2171 1.52 - - 1.82 2.25 - 
BMP1: (BMP1) BONE Hs.1274 1.15 - - 1.33 1.34 0.97 
BMP15: (BMP15 OR GDF Hs.158317 1.10 - - - - 1.19 
BMP2: (BMP2 OR BMP2A Hs.247820 0.93 1.16 - 0.89 1.45 1.12 
BMP3: (BMP3 OR BMP-3 Hs.73853 - 0.45 - - - 1.27 
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BMP4: (BMP4 OR BMP2B Hs.121507 0.77 - - 0.68 1.36 0.93 
BMP5: (BMP5) BONE MO Hs.68879 0.93 - - 1.86 0.97 1.58 
BMP6: (BMP6 OR BMP-6 Hs.1104 0.66 0.68 - 1.31 - 1.99 
BMP7: (BMP7 OR BMP-7 Hs.285671 - 1.77 - - - 0.72 
BMP8A-BMP8B_HUMAN: ( Hs.170195 1.13 - - 1.23 1.29 0.99 
BMPR1A: (BMPR1A OR A Hs.409964 Hs.494158 0.68 0.99 - 0.85 1.13 0.96 
BMPR1B: (BMPR1B) BON Hs.2534 1.35 - - - 0.76 0.98 
BNIP3: (BNIP3 OR NIP Hs.87223 0.72 - - 0.37 1.27 0.86 
BNIP3L: (BNIP3L OR B Hs.79428 0.63 - - 0.52 0.93 1.12 
BPGF1-Q6: (BPGF-1 OR Hs.132955 1.39 1.18 - 1.16 1.16 1.15 
BRCA1: (BRCA1) BREAS Hs.77266 1.48 0.78 - 1.95 - 1.38 
BRCA2: (BRCA2) BREAS Hs.194143 - 0.29 - - - - 
BSG: (BSG) BASIGIN P Hs.34012 1.26 0.68 - 0.25 1.17 0.38 
BST1: (BST1 OR BP3 O Hs.501293 1.67 1.00 - 0.78 1.46 0.87 
BTG1: (BTG1) BTG1 PR Hs.169998 0.24 - - 0.75 0.82 0.71 
BTG2: (BTG2 OR PC3) Hs.255935 0.82 0.63 - 0.46 0.73 0.82 
BTG3: (BTG3 OR TOB5 Hs.75462 0.33 1.33 - 0.47 1.15 0.89 
BTK: (BTK OR ATK OR Hs.77311 1.33 - - 1.17 - 1.98 
BY55: (BY55) NATURAL Hs.159494 - - - - 1.14 0.98 
C1QA: (C1QA) COMPLEM Hs.81743 2.65 1.22 - 7.64 1.41 0.83 
C1S: (C1S) COMPLEMEN Hs.9641 0.92 1.15 2.35 0.89 0.41 0.87 
C2: (C2) COMPLEMENT Hs.458355 1.34 0.92 - 1.22 1.44 0.82 
C3: (C3) COMPLEMENT Hs.2253 1.38 0.81 0.68 0.90 1.25 0.85 
C3AR1: (C3AR1 OR C3R Hs.284394 1.20 - - 6.49 1.17 1.13 
C3F: (C3F) C3F. IDEN Hs.155935 1.76 1.43 - 0.53 1.26 0.67 
C4: (C4A AND C4B) CO Hs.300423 1.36 0.46 - - 0.63 0.48 
C4BPA: (C4BPA OR C4B Hs.150833 1.89 - - - 0.99 0.85 
C5R1_1: (C5R1 OR C5A Hs.1012 0.99 1.65 0.66 2.30 1.16 1.42 
C8G: (C8G) COMPLEMEN Hs.2161 0.95 0.52 0.56 0.31 0.89 0.69 
CALB1: (CALB1 OR CAB Hs.1285 0.22 0.70 0.16 - 0.52 0.17 
CALB2: (CALB2 OR CAB Hs.65425 1.14 1.22 - 1.39 1.31 0.87 
CALM2: (CALM2 OR CAM Hs.106857 0.48 0.44 - 0.49 0.82 2.66 
CANPX: (CAPN6 OR DJ9 Hs.425808 - - - - - - 
CAPN1: (CAPN1 OR CAN Hs.169172 1.27 - - 0.85 0.62 0.86 
CAPN2: (CAPN2 OR CAN Hs.356181 0.52 1.32 0.51 0.37 1.43 1.46 
CARD4: (NOD1) CARD4/ Hs.350899 1.00 0.63 - 0.46 0.99 0.92 
CASP1: (CASP1 OR IL1 Hs.19405 1.13 0.78 0.90 2.21 1.27 - 
CASP1_HUMAN: (CASP1 Hs.2490 - - - - - 1.32 
CASP14: (CASP14) CAS Hs.5353 - - - - 0.98 1.16 
CASP2: (CASP2 OR ICH Hs.248226 1.36 1.14 0.67 1.12 1.52 0.97 
CASP3: (CASP3 OR CPP Hs.433103 1.15 - - 2.14 0.85 1.67 
CASP4_HUMAN: (CASP4 Hs.141125 1.36 0.93 - 2.90 1.16 2.21 
CASP6: (CASP6 OR MCH Hs.74122 1.82 0.89 0.72 0.68 1.37 0.84 
CASP7: (CASP7 OR MCH Hs.3280 0.83 0.82 - 0.88 0.87 0.85 
CASP8: (MCH5 OR CASP Hs.9216 1.41 1.65 0.79 1.11 1.46 - 
CASP9: (CASP9 OR MCH Hs.243491 1.53 - - 0.90 0.94 0.92 
CBL: (CBL OR CBL2) S Hs.329502 - 0.94 - - - 1.20 
CBL-AP: (CAP OR SH3P Hs.41324 1.13 - - 0.97 0.94 0.87 
CBLB: (CBLB) SIGNAL Hs.108924 0.94 - - 1.78 - 1.24 
CBP: (PSCDBP OR CBP) Hs.436986 0.69 0.62 - 3.79 - 1.17 
CCL1_HUMAN: (SCYA1) Hs.270 0.96 0.67 - 0.70 1.14 0.82 
CCL11: (SCYA11) EOTA Hs.72918 1.18 0.92 0.77 0.92 1.58 0.83 
CCL13_HUMAN: (CCL13 Hs.54460 0.23 0.43 0.95 0.19 1.23 0.40 
CCL15-CCL14_HUMAN: ( Hs.414629 0.29 0.86 0.82 0.49 0.66 - 
CCL16_HUMAN: (CCL16 Hs.20144 Hs.272493 1.14 0.76 - 0.69 1.15 0.90 
CCL17: (SCYA17 OR TA Hs.10458 1.85 0.84 0.61 1.15 1.78 0.91 
CCL18_HUMAN: (CCL18 Hs.66742 2.83 0.63 2.58 11.35 1.13 2.33 
CCL19: (SCYA19 OR MI Hs.16530 0.27 1.40 0.78 1.26 0.93 1.52 
CCL2: (SCYA2 OR MI Hs.50002 0.92 - - 0.62 0.92 0.97 
CCL2_HUMAN: (SCYA2 O Hs.303649 1.88 0.49 1.20 1.35 0.67 1.99 
CCL21: (SCYA21 OR SC Hs.75498 0.43 - - 0.90 0.99 1.24 
CCL22: (SCYA22 OR MD Hs.57907 0.95 0.74 - 0.69 1.34 1.23 
CCL23_HUMAN: (CCL23 Hs.97203 0.65 1.67 - 2.87 0.99 1.43 
CCL24: (CCL24 OR SCY Hs.169191 1.17 0.99 0.59 1.32 1.32 0.99 
CCL26_HUMAN: (CCL26 Hs.247838 0.71 - - 1.23 1.14 1.44 
CCL27: (SCYA27 OR IL Hs.131342 0.83 - - - 1.80 1.15 
CCL3-CCL3L1: (CCL3 O Hs.225948 0.63 0.44 0.67 0.90 0.73 - 
CCL3L1-CCL3: (CCL3L1 Hs.512683 Hs.73817 0.78 1.00 0.72 1.55 1.22 - 
CCL4: (SCYA4 OR MIP1 Hs.512683 Hs.73817 0.76 0.63 0.84 1.87 1.20 0.89 
CCL5: (SCYA5) SMALL Hs.75703 0.83 0.64 - 2.23 1.33 0.72 
CCL7: (SCYA7 OR MCP3 Hs.489044 Hs.241392 1.43 0.47 0.69 0.54 1.18 0.73 
CCL8_HUMAN: (SCYA8 O Hs.251526 0.89 - - - 1.11 0.84 
CCNB2: (CCNB2) CYCLI Hs.271387 2.43 - - 1.72 1.18 1.16 
CCNC: (CCNC) CYCLIN Hs.194698 0.62 1.69 - 0.65 0.88 - 
CCND1: (CCND1 OR PRA Hs.435450 - - - - - 0.92 
CCND3: (CCND3) CYCLI Hs.371468 0.93 - - 0.44 0.59 0.74 
CCNE1: (CCNE1 OR CCN Hs.83173 1.15 1.18 - 1.39 1.51 1.15 
CCNF_2: (CCNF) G2/MI Hs.244723 1.33 1.37 - 1.31 1.42 1.82 
CCNG2: (CCNG2) CYCLI Hs.1973 0.66 1.26 - 0.52 0.51 0.83 
CCNH: (CCNH) CYCLIN Hs.13291 1.45 - - 0.38 1.14 1.13 
CCR1: (CCR1 OR CMKBR Hs.514 - - - - - 0.92 
CCR1: (CCR1 OR GPR Hs.301921 1.27 - - 1.31 1.31 1.80 
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CCR2-CCR5_BAD: (CCR2 Hs.278446 1.34 0.93 - 1.40 1.42 0.99 
CCR3: (CCR3 OR CMKBR - 1.22 - - - - 1.24 
CCR4: (CCR4 OR CMKBR Hs.506190 - - - - 0.94 1.21 
CCR5-CCR2: (CCR5 OR Hs.184926 0.69 - - - 0.78 1.16 
CCR6: (CCR6 OR CMKBR Hs.54443 Hs.395  0.65 0.50 - 1.27 0.79 1.17 
CCR7: (CKR7 OR CMKBR Hs.46468 1.55 - - 1.79 0.97 1.33 
CCR8: (CCR8 OR CMKBR Hs.1652 - 0.93 - - - 1.62 
CCR9: (CCR9 OR CMKBR Hs.113222 0.99 - - 1.54 1.12 1.66 
CD14: (CD14) MONOCYT Hs.225946 3.58 1.12 - 7.70 1.17 0.79 
CD151: (CD151) PLATE Hs.75627 1.16 0.72 - 0.25 0.95 0.51 
CD16_HUMAN: (FCGR3A Hs.512857 1.96 0.17 - 17.34 1.48 1.32 
CD164: (CD164 OR MMG Hs.372679 0.44 0.32 - 0.19 0.85 0.59 
CD19: (CD19) B-LYMPH Hs.43910 1.27 0.96 - 1.34 1.40 0.97 
CD1A_HUMAN: (CD1A) T Hs.96023 1.45 1.40 - 1.22 1.41 0.99 
CD1B_HUMAN: (CD1B) T Hs.1309 1.23 - - 1.25 1.20 0.99 
CD1C_HUMAN: (CD1C) T Hs.1310 1.40 - - 0.95 0.82 0.87 
CD1D_HUMAN: (CD1D) T Hs.1311 1.25 - - 2.16 0.99 1.22 
CD1E_HUMAN: (CD1E) T Hs.1799 1.28 0.95 0.65 0.97 1.39 0.81 
CD2: (CD2) T-CELL SU Hs.249217 0.57 - - 11.12 0.76 1.43 
CD22: (CD22) B-CELL Hs.89476 1.33 0.97 - 1.39 1.44 0.99 
CD24: (CD24 OR CD24A Hs.278694 0.53 - - 1.13 0.69 4.92 
CD28: (CD28) T-CELL- Hs.262150 1.47 1.00 - 1.49 1.45 1.96 
CD29_HUMAN: (CD29) Hs.375108 1.32 - - 1.68 0.93 1.12 
CD33: (CD33) MYELOID Hs.1987 1.13 0.44 - 1.84 0.85 2.00 
CD34: (CD34) HEMATOP Hs.83731 1.17 1.85 - 0.73 1.29 0.94 
CD36: (CD36 OR GP4 O Hs.374990 1.27 0.71 - 1.49 1.28 0.92 
CD36L2: (SCARB2 OR C Hs.443120 0.87 - - 1.33 1.15 1.00 
CD37: (CD37) LEUKOCY Hs.349656 1.63 1.64 - 5.36 1.20 1.44 
CD38: (CD38) ADP-RIB Hs.153053 0.93 1.37 - 3.58 - 1.17 
CD39: (ENTPD1 OR CD3 Hs.174944 0.88 0.65 - 2.73 0.94 1.49 
CD3D: (CD3D OR T3D) Hs.444105 0.38 - - 6.30 0.76 1.25 
CD3E: (CD3E OR T3E) Hs.95327 0.98 1.59 - 1.85 1.35 1.48 
CD3Z-CD3H: (CD3Z OR Hs.3003 0.74 - - - - 1.44 
CD4: (CD4) T-CELL SU Hs.97087 0.86 0.72 0.46 1.64 1.55 1.41 
CD44_EX11-13_HUMAN: Hs.17483 - - - - - 0.98 
CD44_EX13-15_HUMAN: Hs.306278 1.00 - - - 0.87 0.95 
CD44_EX16-2_HUMAN: Hs.306278 2.93 1.15 - 4.20 0.96 1.26 
CD44_EX3-5_HUMAN: (C Hs.306278 1.68 1.54 - 3.44 1.25 1.11 
CD44_EX7-9_HUMAN: (C Hs.306278 0.97 0.91 - 1.83 0.96 0.94 
CD44_EX9-11_HUMAN: ( Hs.306278 1.19 - - 1.82 1.12 1.27 
CD45_EX1-11: (PTPRC Hs.306278 0.86 1.24 - 1.39 - - 
CD45_EX29-31: (PTPRC Hs.444324 0.78 - - 9.85 - 0.90 
CD47: (CD47 OR IAP) Hs.444324 0.61 0.69 0.41 0.92 0.78 1.67 
CD48: (CD48 OR BCM1 Hs.446414 0.46 1.16 - 1.87 0.55 2.53 
CD5: (CD5 OR LEU1) T Hs.901 0.76 - - - 0.71 1.27 
CD52: (CDW52 OR CD52 Hs.58685 0.26 - - 14.69 0.59 2.11 
CD53: (CD53 OR MOX44 Hs.276770 0.84 - - 8.26 1.44 1.94 
CD58_HUMAN: (CD58 OR Hs.443057 0.53 1.30 - 1.17 1.38 1.83 
CD59_HUMAN: (CD59) C Hs.75626 0.35 0.37 - 0.60 1.98 1.24 
CD6: (CD6) T-CELL DI Hs.278573 - 0.33 - - - - 
CD63: (CD63 OR MLA1) Hs.436949 0.65 1.00 1.33 0.75 2.48 1.94 
CD68: (CD68) MACROSI Hs.445570 1.68 1.25 - 3.25 1.24 1.14 
CD69: (CD69) EARLY A Hs.246381 - 1.26 0.95 3.33 - 1.36 
CD7: (CD7) T-CELL AN Hs.82401 0.84 - - - 0.95 1.13 
CD72: (LY-32 OR LYB- Hs.36972 - - - 6.19 - 1.59 
CD74: (CD74 OR DHLAG Hs.116481 0.98 0.93 - 3.25 1.12 0.33 
CD79A: (CD79A OR IGA Hs.446471 1.37 0.94 - 1.93 1.54 1.78 
CD79B: (CD79B OR IGB Hs.79630 - 1.15 - 2.69 - 1.52 
CD8: (CD8 OR CD28L Hs.89575 - - - 1.56 - 1.53 
CD81: (CD81 OR TAPA1 Hs.838 0.62 0.50 - 0.46 0.95 0.65 
CD83: (CD83) ANTIGEN Hs.54457 - - - 1.23 - 0.51 
CD84: (CD84) LEUKOCY Hs.79197 0.82 1.22 - 1.73 - 1.31 
CD86: (CD86 OR CD28L Hs.398093 1.14 - - 6.72 - 1.51 
CD8A: (CD8A OR MAL O Hs.27954 0.92 1.77 - - 0.89 1.15 
CD8B: (CD8B OR LYT-3 Hs.85258 1.44 0.81 0.32 1.51 1.48 1.15 
CD9: (CD9 OR MIC3) C Hs.2299 Hs.405667 0.72 0.82 - 1.55 0.64 1.38 
CD96: (TACTILE OR CD Hs.387579 1.69 1.12 - 1.77 1.58 1.96 
CD97: (CD97) LEUCOCY Hs.142023 1.46 0.70 - 0.93 0.81 0.75 
CDH3: (CDH3 OR CDHP) Hs.3107 1.14 - - - 0.92 0.89 
CDH5: (CDH5) VASCULA Hs.191842 1.24 1.36 - 1.00 1.30 0.99 
CDKN1A: (CDKN1A OR C Hs.76206 - - - 1.50 - - 
CDKN1B: (CDKN1B OR K Hs.370771 - - - - - - 
CDM: (BCAP31 OR BAP3 Hs.238990 0.58 0.52 - 0.53 1.33 0.41 
CEA_HUMAN: (CEACAM5 Hs.381232 1.56 0.69 0.43 1.58 1.45 1.42 
CEACAM1: (CEACAM1 OR Hs.220529 - - - 0.38 - 0.53 
CEBPB: (CEBPB OR TCF Hs.512682 1.73 - - 1.78 0.91 0.98 
CEBPG: (CEBPG) CCAAT Hs.99029 1.17 0.94 - 0.74 1.32 0.93 
CFH: (HF1 OR HF OR C Hs.2227 1.15 0.94 - 0.71 1.47 0.93 
CGA: (CGA OR CGA1) G Hs.278568 1.12 - - 1.24 - 0.99 
CHESS1: (CHES1) CHEC Hs.119689 1.18 - - - - 1.18 
CIS4: (SOCS4 OR SOCS Hs.211773 0.84 0.75 - 0.63 1.75 0.89 
CISH: (CISH OR G18 O Hs.8257 0.72 - - 0.55 0.89 0.76 
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CISH6: (SOCS5 OR CIS Hs.355724 1.12 - - 1.29 0.72 1.19 
CLARP: (CFLAR OR CLA Hs.436657 - - - 0.52 0.70 0.49 
CLU: (CLU) CLUSTERIN Hs.159553 0.11 2.20 - 0.75 0.87 1.44 
CMKLR1: (CMKLR1 OR D Hs.113207 0.97 - - 2.37 - 0.96 
CMKRL2: (CMKRL2 OR D Hs.75110 - - - 0.73 0.98 1.98 
CNR1: (CNR1 OR CNR) Hs.524920 0.98 - - 1.23 - 1.18 
CNTF: (CNTF) CILIARY Hs.179729 1.20 1.77 0.57 1.46 1.33 0.99 
COL11A1: (COL11A1) C Hs.439168 - 1.21 - 2.55 - 1.40 
COL11A2: (COL11A2) C Hs.390171 1.59 1.34 - 1.23 1.54 1.61 
COL12A1: (COL12A1) C Hs.101302 - - - - - 1.67 
COL13A1: (COL13A1 OR Hs.211933 - - - - - 1.11 
COL15A1: (COL15A1) C Hs.409034 0.76 - - 1.23 - 0.91 
COL16A1: (COL16A1) C Hs.26208 0.90 - - 1.22 - 1.29 
COL17A1: (COL17A1) P - - 1.62 - 2.68 - 1.74 
COL18A1_1: (COL18A1) Hs.413175 0.66 0.85 - 0.23 0.78 0.55 
COL18A1_2: (COL18A1) Hs.413175 - - - 0.55 1.51 0.79 
COL1A1: (COL1A1) C Hs.172928 0.88 0.80 - 0.92 - 1.59 
COL1A1: (COL1A1) COL Hs.232115 16.32 1.37 - 5.22 1.13 0.95 
COL1A2: (COL1A2) COL Hs.408182 7.55 - - 5.12 - 2.23 
COL2A1: (COL2A1) COL Hs.443625 1.33 1.39 - 1.47 1.28 1.00 
COL3A1: (COL3A1) COL Hs.437173 3.32 0.89 - 2.55 0.44 1.67 
COL4A1: (COL4A1) COL Hs.407912 1.13 0.82 0.97 0.78 0.94 0.89 
COL4A2: (COL4A2) COL Hs.407817 0.92 0.84 - 0.58 1.47 1.20 
COL4A3: (COL4A3) COL Hs.169825 Hs.497023 0.89 1.36 - 1.25 1.75 1.62 
COL4A5: (COL4A5) COL Hs.408 1.58 1.34 - 0.89 1.28 0.92 
COL4A6: (COL4A6) COL Hs.433695 0.92 - - - - 0.98 
COL5A1: (COL5A1) PRO Hs.283393 2.43 - - 1.82 0.97 1.19 
COL5A2: (COL5A2) COL Hs.415997 2.94 0.86 - 0.92 1.45 0.84 
COL6A1: (COL6A1) COL Hs.420269 2.26 1.19 - 0.32 0.86 0.54 
COL6A2: (COL6A2) COL Hs.233240 5.44 - - 0.92 1.19 0.54 
COL6A3: (COL6A3) COL Hs.1640 - 1.14 - 2.00 - 1.15 
COL7A1: (COL7A1) COL Hs.114599 0.47 0.98 - 0.67 0.90 0.76 
COL8A1: (COL8A1) COL Hs.353001 1.64 - - 1.34 - 1.17 
COL8A2: (COL8A2) COL Hs.149809 1.46 - - 1.74 1.56 1.34 
COL9A1_1: (COL9A1) C Hs.418012 1.70 - - 2.86 0.99 1.63 
COL9A2: (COL9A2) COL Hs.126248 0.97 0.95 - 0.64 1.22 0.86 
COL9A3: (COL9A3) ALP Hs.1584 1.33 1.27 - 1.43 1.46 1.11 
COP1: (COP1) COP1 PR Hs.412957 0.94 - - 0.44 0.74 1.23 
CR1-CR1L: (CR1 OR C3 Hs.334019 Hs.89688 0.83 - - - - 0.96 
CR2: (CR2 OR C3DR) C Hs.73792 - 1.32 - - - 0.96 
CREB1: (CREB1) CAMP- Hs.22315 0.74 - - - 0.87 0.88 
CREBPA: (CREB1 OR CR Hs.149 1.14 - - - 0.92 0.92 
CREB-RP: (CREBL1 OR Hs.42853 0.92 - 0.54 - 0.83 1.49 
CREL: (REL) C-REL PR Hs.44313 0.79 - - - 0.92 0.86 
CREM: (CREM) CAMP RE Hs.231975 0.69 1.66 - 0.67 0.77 0.99 
CRK: (CRK) PROTO-ONC Hs.511822 0.83 - - 0.69 1.19 1.12 
CRKL: (CRKL) CRK-LIK Hs.5613 1.54 - - 1.39 1.32 - 
CSF1: (CSF1 OR CSFM) Hs.173894 - - - - - 1.15 
CSF1R: (CSF1R OR CSF Hs.174142 - - - - - 1.51 
CSF2RA: ((CSF2RAX OR Hs.520937 1.83 1.55 0.86 1.95 1.42 0.92 
CSF2RB: (CSF2RB OR I Hs.285401 1.17 0.66 - 0.95 1.36 0.72 
CSF3: (CSF3) GRANULO Hs.2233 2.00 1.19 - 0.43 1.53 0.93 
CSF3R: (CSF3R OR GCS Hs.381027 1.21 1.14 - 1.29 1.26 0.84 
CSK: (CSK) TYROSINE- Hs.77793 1.52 - - 1.25 1.15 - 
CTGF: (CTGF OR HCS24 Hs.434488 0.91 - - 0.75 0.26 0.53 
CTLA4: (CTLA4 OR CD1 Hs.410037 1.53 - - 2.53 - 1.26 
CTSD: (CTSD) CATHEPS Hs.247824 - - - 2.16 0.49 0.55 
CX3CL1: (SCYD1 OR FK Hs.343475 0.96 0.88 0.57 0.75 1.24 0.88 
CX3CR1: (CX3CR1 OR G Hs.80420 0.80 - - 2.82 - 1.53 
CXCL1: (SCYB1 OR I Hs.78913 1.19 1.16 - 2.19 1.34 1.46 
CXCL11: (SCYB11 OR S Hs.413924 0.84 0.85 - 1.31 1.33 1.32 
CXCL12: (SDF1) STROM Hs.103982 1.43 - - 0.33 0.53 0.52 
CXCL13: (BLC OR BCA1 Hs.436042 1.13 0.59 - 0.64 1.58 0.92 
CXCL14: (SCYB14 OR N Hs.100431 0.22 0.46 0.64 0.17 1.31 0.38 
CXCL16: (911K24R Hs.24395 0.92 - - 2.58 1.34 1.26 
CXCL6_HUMAN: (CXCL6 Hs.82407 0.84 0.59 0.77 0.64 1.23 1.64 
CXCL7: (SCYB7 OR PPB Hs.164021 1.99 0.72 - 1.19 1.32 0.99 
CXCR4: (CXCR4 OR LES Hs.198252 0.20 0.58 - 14.66 0.47 1.52 
CYPA: (PPIA OR CYPA) Hs.421986 0.99 0.97 0.59 0.49 2.13 2.34 
CYR61: (CYR61 OR IGF Hs.356331 1.59 0.51 - 0.24 0.76 0.38 
DAF: (DAF OR CR OR C Hs.8867 0.76 1.22 - 1.47 0.54 1.50 
DAPK1: (DAPK1 OR DAP Hs.408864 0.96 - - - 1.75 0.93 
DAPK2: (DAPK2) DEATH Hs.244318 0.96 - - 1.71 - 0.97 
DCIR_HUMAN: (DCIR) D Hs.129208 0.73 - - 2.83 - 1.77 
DCP1: (DCP1 OR DCP O Hs.115515 1.37 0.92 - 1.25 1.46 0.97 
DDR1: (EDDR1 OR CAK Hs.156316 0.32 0.63 - 0.14 1.43 2.28 
DDR3: (TNFRSF25 OR T Hs.298469 1.16 1.22 0.55 1.19 1.46 0.89 
DLL1: (DLL1) DELTA-L Hs.423573 1.46 1.38 0.95 1.37 1.33 1.72 
DPP4: (DPP4 OR ADCP2 Hs.440905 0.57 1.33 - 0.75 0.56 0.47 
DR6: (TNFRSF21 OR DR Hs.368657 0.97 0.79 - - 1.68 0.85 
E2F1: (E2F1 OR RBBP3 Hs.44926 1.38 0.65 - 0.43 1.55 0.68 
E2F5: (E2F5) TRANSCR Hs.159651 0.89 - - 0.92 1.13 1.17 
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E4BP4: (IL3BP1 OR E4 Hs.96055 1.45 1.54 - 0.79 1.13 0.92 
EBCTF: (EBF) EARLY B Hs.447905 0.87 1.10 - 0.91 0.90 0.86 
EBI2: (EBI2) EBV-IND Hs.79334 0.54 1.20 - 6.53 1.45 1.32 
ECE1: (ECE1) ENDOTHE Hs.120785 1.99 0.89 - 1.60 1.17 1.15 
ECE2: (ECE2) ENDOTHE Hs.784 1.25 - - 1.25 0.88 1.77 
ECT2: (ECT2) ECT2 PR Hs.232688 - - - - - 1.24 
EGR1: (EGR1 OR ZNF22 Hs.129801 1.52 - - 1.18 1.27 0.77 
EGR2: (EGR2 OR KROX2 Hs.293257 1.20 - - 0.60 0.92 0.78 
EGR3: (EGR3 OR PILOT Hs.326035 0.98 - - 0.79 0.95 0.84 
EMR1: (EMR1) CELL SU Hs.1395 1.26 - 0.46 1.23 0.99 - 
ENG: (ENG OR END) EN Hs.74088 1.17 0.87 0.39 0.27 0.73 0.87 
ENIGMA: ENIGMA PROTE Hs.2375 1.75 - - 0.74 1.15 0.49 
ENOS: (NOS3) NITRIC- Hs.76753 1.89 0.82 - 0.94 1.26 0.85 
EPHB2: (EPHB2 OR EPT Hs.436339 1.82 1.25 - 0.66 0.99 0.88 
EPOR: (EPOR) ERYTHRO Hs.446303 0.89 - - 0.48 1.15 0.80 
ESR1: (ESR1 OR NR3A1 Hs.125124 1.45 0.94 - 1.30 1.21 0.81 
ESR2: (ESR2 OR NR3A2 Hs.127826 0.98 0.94 - 0.53 1.16 1.69 
ETS1: (ETS1) C-ETS-1 Hs.1657 1.66 - - 0.42 0.99 0.74 
ETS2: (ETS2) C-ETS-2 Hs.443150 1.26 0.50 - 1.18 1.27 0.75 
F2R: (F2R OR PAR1 OR Hs.18063 1.18 0.82 0.50 - - 0.98 
F3: (F3 OR CF3 OR CF Hs.292477 1.27 0.75 - 1.34 - 0.58 
FADD: (FADD OR MORT1 Hs.128087 1.28 - - 1.15 1.39 1.34 
FAIM: (FAIM) FAS APO Hs.62192 0.63 0.99 0.74 0.42 1.31 0.95 
FAK1: (FAK1 OR FAK O Hs.86131 1.55 0.78 - 0.87 0.54 1.42 
FAST1: (FOXH1 OR FAS Hs.173438 1.27 - - 1.68 1.27 0.97 
FBLN1_1: (FBLN1) FIB Hs.434281 1.74 0.82 - 0.99 0.86 0.96 
FBLN2: (FBLN2) FIBUL Hs.159251 1.19 0.85 - 1.28 0.49 0.83 
FBXW1B: (FBXW1B OR F Hs.445240 - 0.97 - 1.36 - 0.92 
FBXW2: (FBXW2 OR FBW Hs.198862 1.26 0.86 - 0.62 1.16 1.16 
FCER2: (FCER2 OR IGE Hs.226434 1.18 1.58 - 1.58 - 0.87 
FCGR1A: (FCGR1A OR F Hs.280385 2.97 0.98 - 15.40 1.47 1.39 
FCGR2_HUMAN: (FCGR2A Hs.444354 1.12 - - 36.78 1.65 1.49 
FCP1: (FCP1) SERINE Hs.1416 1.17 0.96 - 0.63 0.79 1.53 
FGR: (FGR OR SRC2) P Hs.77424 Hs.516104 0.94 - - 1.89 1.26 0.74 
FIBRILLIN1: (FBN1 OR Hs.352642 Hs.126384 1.76 1.16 - 0.88 0.54 1.22 
FIBRILLIN2: (FBN2) F Hs.4076 - - - - - 1.27 
FIBROMODULIN: (FMOD Hs.1422 1.25 0.51 - 1.39 1.35 0.99 
FIP2: (FIP2 OR NEMO2 Hs.750 1.13 0.98 - 0.28 0.92 1.18 
FKHL16: (FOXM1 OR FK Hs.79432 0.96 0.32 - 1.38 - 0.68 
FKHR: (FOXO1A OR FKH Hs.442844 0.48 0.90 - 0.43 0.93 1.91 
FKHRL1: (FOXO3A OR F Hs.390162 0.88 - - 0.48 1.42 0.60 
FLAP: (ALOX5AP OR FL Hs.239 Hs.479302 Hs.511941 1.26 - - 1.77 1.68 0.94 
FLASH: (CASP8AP2 OR Hs.170133 1.13 0.99 - 0.59 1.52 1.98 
FLASHLIKE: FLASH REL Hs.14845 0.91 1.59 - 0.86 1.32 0.86 
FLT3: (FLT3 OR STK1 Hs.100194 - 1.00 - - - 0.89 
FLT3LG: (FLT3LG) SL Hs.122843 0.86 1.96 - 0.97 0.99 1.18 
FN1: (FN1 OR FN) FIB Hs.279763 Hs.201550 7.46 - - 6.47 0.56 1.46 
FOS_1: (FOS) P55-C-F Hs.385 0.98 1.43 - 0.38 0.65 1.47 
FOSB: (FOSB OR GS3) Hs.428 1.45 - - 1.42 1.29 0.67 
FOXG1A-FOXG1B: (FOXG Hs.418138 1.16 0.88 0.32 0.64 1.12 1.69 
FRA1: (FOSL1 OR FRA1 Hs.25647 0.78 0.49 - 2.38 0.82 0.92 
FRA2: (FOSL2 OR FRA2 Hs.75678 6.66 1.37 0.42 4.28 1.85 1.90 
FRAP: (FRAP) FKBP-RA Hs.283565 1.65 0.61 0.20 - 0.82 7.37 
FTH: (FTH1 OR FTH OR Hs.301612 2.28 - - 1.25 2.51 0.94 
FUT3: (FUT3 OR LE) G Hs.386249 Hs.525266 Hs.169277 0.98 2.37 0.72 0.34 1.12 1.33 
FYN: (FYN) PROTO-ONC Hs.439387 0.45 - - - 0.90 - 
G22P1: (G22P1) ATP-D Hs.338207 0.85 - - 0.34 0.63 0.87 
GADD153: (DDIT3 OR C Hs.448738 0.87 0.55 - 0.55 1.53 0.79 
GADD34: (GADD34) APO Hs.169238 1.37 0.36 - 0.84 1.43 0.89 
GADD45: (GADD45A OR Hs.390567 0.67 0.92 0.65 0.16 0.70 0.90 
GAPD: (GAPD) (GAPDH) Hs.169744 1.95 1.33 - 0.63 4.26 0.48 
GAS2: (GAS2) GROWTH- Hs.392171 Hs.355867 - 1.15 0.76 - - - 
GAS3: (PMP22 OR GAS3 Hs.76556 1.23 1.30 - 2.12 0.89 1.46 
GATA3: (GATA3) TRANS Hs.80409 1.34 - - - 0.99 1.92 
GATA4_HUMAN: (GATA4) Hs.169476 1.12 - - 0.42 0.93 0.59 
GDIA1: (ARHGDIA OR G Hs.135665 2.36 0.66 - 0.33 1.25 0.68 
GEM: (GEM OR KIR) GT Hs.372031 0.69 0.58 - 0.99 0.77 0.54 
GG2-1: (GG2-1 OR MDC Hs.169946 0.73 - - 0.74 0.96 0.97 
GITRL: (TNFSF18 OR A Hs.243987 1.57 - - 0.53 1.60 1.16 
GL5: (GL5) B7-LIKE Hs.159161 0.78 - - - 0.95 0.83 
GM-CSF: (CSF2 OR GMC Hs.79022 0.97 1.33 - - - 1.11 
GN6ST: (GN6ST OR CHS Hs.17839 0.82 0.42 - 1.58 0.82 1.17 
GP1BA: (GP1BA) PLATE Hs.248197 1.18 0.74 0.68 1.33 1.38 1.23 
GP9: (GP9) PLATELET Hs.1349 1.27 1.17 - 1.27 1.14 0.89 
GPCR25: (GPCR25 OR T Hs.8786 - - - 3.52 - 1.41 
GPR17: (GPR17) PUTAT Hs.1472 0.79 - - 1.78 0.94 1.14 
GPR31: (GPR31) PROBA Hs.1144 1.35 - - 1.60 1.42 1.16 
GPR5: (CCXCR1 OR XCR Hs.131924 1.25 - - 1.59 1.26 1.18 
GRAIL: (GRAIL) CDNA: Hs.46453 0.60 - - - 0.91 0.84 
GRB1: (GRB1) GROWT Hs.248124 0.95 - - 1.47 1.65 1.20 
GRB2: (GRB2 OR ASH) Hs.248116 0.80 0.68 0.43 1.80 0.98 1.44 
GRL: (GRL OR NR3C1) Hs.512118 1.26 0.76 0.59 1.48 1.83 1.96 
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GRO1_HUMAN: (CXCL1 O Hs.411366 0.30 0.78 - - 0.70 1.22 
GRO2_HUMAN: (CXCL2 O Hs.126608 0.81 0.58 - 0.67 1.33 0.86 
GSTM1: (GSTM1 OR GST Hs.789 0.28 - - 0.23 1.98 - 
GZMB: (GZMB OR CTLA1 Hs.75765 - - - 2.82 - - 
HCK: (HCK) TYROSINE- Hs.301961 Hs.279837 Hs.348387 1.14 0.64 - 1.95 1.24 0.94 
HES1: (HES1 OR HRY O Hs.1051 0.50 - - 0.25 1.85 0.63 
HEVIN: (HEVIN) HIGH Hs.89555 0.15 0.26 - 0.29 0.58 0.62 
HEXA: (HEXA) BETA-HE Hs.250666 0.95 - - 0.48 0.76 0.73 
HFH4: (FOXJ1 OR FKHL Hs.75445 1.37 1.17 - 0.97 1.19 0.93 
HGF: (HGF OR HPTA) H Hs.411157 Hs.513009 1.13 1.58 - 1.29 1.45 1.48 
HGFALIKE: (HGFALIKE) Hs.370041 0.80 1.55 - 0.68 0.97 1.87 
HHAVCR-1: (HHAVCR-1 Hs.396530 1.29 - - 1.49 1.49 1.19 
HHEX: (HHEX OR PRHX Hs.422542 1.28 1.53 0.68 1.32 1.39 1.12 
HIF1A: (HIF1A) HYPOX Hs.129711 2.99 0.88 1.19 1.45 1.11 1.86 
HJ1: (JAG1) JAGGED 1 Hs.118651 1.16 1.29 - 1.23 1.12 1.13 
HJ2: (HJ2 JAGGED2) N Hs.412416 1.24 0.60 - 1.54 1.27 2.57 
HLA-DQA_HUMAN: (HLA- Hs.409202 0.70 - - 6.80 0.89 1.61 
HLF: (HLF) HEPATIC L Hs.387679 Hs.289095 - - - - - 1.25 
HLX1: (HLX1) HOMEOBO Hs.250692 1.18 1.22 0.60 1.42 1.18 1.28 
HMOX1: (HMOX1 OR HO1 Hs.74870 2.27 0.76 - 1.12 1.34 0.85 
HMOX2: (HMOX2 OR HO2 Hs.202833 0.97 - - 0.46 0.99 1.14 
HNF3A: (FOXA1 OR HNF Hs.284279 0.83 0.99 - 1.46 0.99 1.87 
HNF3B: (FOXA2 OR HNF Hs.70604 Hs.163484 1.84 - - 0.76 0.99 1.13 
HNF3G: (FOXA3 OR TCF Hs.155651 0.92 0.87 - 1.13 - 0.98 
HPRT: (HPRT1 OR HPRT Hs.36137 1.74 1.33 - 1.76 1.25 1.12 
HR2R: (HH2R) HISTAMI Hs.412707 - - - 1.41 - 0.76 
HRAS: (HRAS) HRAS SU Hs.247885 0.78 0.69 0.45 0.96 1.25 1.11 
HRAS1: (HRAS1 OR HRA Hs.36761 1.43 - - 0.49 1.16 1.25 
HRH1: (HRH1) HISTAMI Hs.37003 1.30 0.37 0.42 1.39 1.21 0.72 
HSC73: (HSPA8 OR HSP Hs.1570 1.59 0.82 0.66 0.30 1.22 0.79 
HSF4: (HHSF4) HEAT S Hs.180414 0.78 1.15 - - - 0.97 
HSP15: (HSP15 OR H Hs.75486 1.91 0.67 0.29 0.44 0.98 3.93 
HSP7.2: (HSPA2 OR H Hs.36927 1.77 0.53 - 2.49 1.45 0.45 
HSPA1A: ((HSPA1A OR Hs.432648 0.46 - - 0.22 0.64 1.51 
HSPA1L: (HSPA1L) HEA Hs.75452 Hs.274402 0.83 0.74 - - 0.82 1.39 
HSPA4: (HSPA4 OR HSP Hs.80288 0.81 1.26 - 0.42 1.27 - 
HSPA6-HSPA7: (HSPA6 Hs.90093 0.86 0.52 - 1.48 1.14 0.81 
HSPA9: (HSPA9B OR HS Hs.3268 0.82 0.43 0.31 0.20 0.99 0.65 
HSPCA: (HSPCA OR HSP Hs.184233 0.69 0.66 - 0.93 1.62 0.69 
HSPD1: (HSPD1 OR HSP Hs.446579 0.71 0.57 - 0.13 0.74 1.00 
HSPG2: (HSPG2) BASEM Hs.79037 5.88 - - 3.44 0.67 1.89 
HSR.1: (HSP7-4 OR H Hs.211573 Hs.470489 0.72 - - 0.85 1.60 1.14 
HTLF: (HTLF) HUMAN T Hs.430666 1.16 - - 0.94 0.93 1.16 
HTRIP: (HTRIP OR TRA Hs.103126 0.97 - - - - - 
IAP1: (BIRC2 OR API1 Hs.127799 21.24 0.95 0.74 1.34 0.57 - 
IAP2_1: (BIRC3 OR AP Hs.49215 16.29 - - 0.62 1.36 1.14 
IAP4_2: (BIRC5 OR AP Hs.386467 0.71 - - - 1.38 1.12 
IBSP: (IBSP OR BNSP) Hs.433303 - - - - - 1.49 
ICAM1: (ICAM1 OR ICA Hs.353214 - 0.93 0.66 - - 0.85 
ICAM2: (ICAM2 OR ICA Hs.56247 1.48 1.22 - 0.95 1.35 1.17 
ICAM3_HUMAN: (ICAM3) Hs.14155 3.70 - - 1.28 2.15 0.90 
ICOS: (ICOS) ACTIVAT Hs.391392 1.45 - - 0.48 0.99 - 
ID4: (ID4) DNA-BINDI Hs.415359 1.22 0.80 0.66 1.22 1.27 1.20 
IDD: (IDD OR DGCR2 O Hs.20315 - - - - - 1.21 
IFIT1: (IFIT1 OR IFI Hs.458414 0.52 0.55 - 0.26 0.81 1.31 
IFITM1_HUMAN: (IFITM Hs.174195 Hs.374650 0.21 0.89 - 1.31 0.28 0.54 
IFITM2-IFITM3_HUMAN: Hs.37026 0.56 0.22 - 1.34 0.94 0.81 
IFNA1_HUMAN: (IFNA1 Hs.211575 - - - - 0.97 0.85 
IFNA2_HUMAN: (IFNA2) Hs.181315 0.88 0.74 - 1.36 0.98 1.28 
IFNAR1: (IFNAR1 OR I Hs.86958 Hs.512211 1.75 1.75 1.18 1.17 1.21 1.20 
IFNAR2: (IFNAR2 OR I Hs.93177 1.49 - - 0.53 1.25 0.83 
IFNB1: (IFNB1 OR IFN Hs.856 1.29 1.62 0.76 1.32 1.40 0.99 
IFNG: (IFNG) INTERFE Hs.180866 1.45 - - 3.12 1.12 1.59 
IFNGR1: (IFNGR1 OR I Hs.409200 0.95 - - 3.32 0.73 1.85 
IFNGR2: (IFNGR2 OR I Hs.349109 1.35 - - 3.47 1.30 1.18 
IGF2: (IGF2) INSULIN Hs.401316 1.12 0.69 0.52 1.85 1.44 - 
IGFBP1: (IGFBP1 OR I Hs.274313 1.19 0.86 - 1.38 1.33 1.24 
IGFBP6: (IGFBP6 OR I Hs.31323 0.45 - - 0.98 2.26 7.43 
IKAP: (IKAP OR IKBKA Hs.81328 1.00 0.53 - 0.65 0.96 1.83 
IKBA: (NFKBIA OR NFK Hs.9731 0.39 0.94 - 0.45 0.65 0.87 
IKBB: (NFKBIB OR IKB Hs.458276 1.37 0.82 - 0.60 1.68 0.67 
IKBE: (NFKBIE OR IKB Hs.198998 0.87 - - 1.18 0.59 0.99 
IKBR: (NFKBIL2) IKAP Hs.413513 1.23 0.67 0.67 0.55 1.13 0.89 
IKKA: (IKK ALPHA OR Hs.43505 0.96 1.27 - 0.74 0.93 0.95 
IKKB: (IKKB OR IKBKB Hs.193717 1.56 - - 0.88 0.93 0.96 
IKKG: (IKBKG OR NEMO Hs.327 - - - 0.65 0.94 0.90 
IL11: (IL11) INTERLE Hs.418291 - 0.74 0.23 2.35 - 1.34 
IL12A: (IL12A OR NKS Hs.1721 - 0.41 - 2.41 - 1.21 
IL12B: (IL12B OR NKS Hs.673 0.89 - - 1.90 1.14 1.15 
IL12RB1: (IL12RB1 OR Hs.674 1.52 - - - 0.97 0.88 
IL12RB2: (IL12RB2) I Hs.223894 0.94 - - - 0.88 1.75 
IL13: (IL13 OR NC3 Hs.413608 1.16 1.15 0.63 1.74 1.43 1.18 
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IL13RA1: (IL13RA1 OR Hs.845 0.73 - - 1.26 1.13 1.14 
IL14: (IL14) HYPOTHE Hs.285115 1.48 1.32 - 1.29 1.40 1.34 
IL15_3_HUMAN: (IL15) Hs.168132 0.77 - - 0.98 - 0.80 
IL16: (IL16) INTERLE Hs.170359 1.27 0.86 0.71 2.38 1.34 1.18 
IL17: (IL17 OR CTLA8 Hs.41724 1.43 - - 2.77 1.15 1.58 
IL17F: (IL17F OR IL2 Hs.272295 0.84 0.71 - 1.65 0.86 1.11 
IL17R: (IL17R) INTER Hs.129751 0.83 - - 1.14 1.26 1.12 
IL18: (IL18 OR IGIF) Hs.83077 1.65 - - 1.27 1.27 1.73 
IL18BP: (IL18BP) INT Hs.325978 1.16 - - 2.00 0.99 0.92 
IL18R1: (IL1RRP OR I Hs.159301 0.84 - - - 0.98 1.10 
IL1A: (IL1A) INTERLE Hs.1722 0.87 1.18 - 1.10 1.17 0.94 
IL1B: (IL1B) INTERLE Hs.126256 - - - 1.36 0.83 1.49 
IL1R: (IL1RA OR IL Hs.82112 1.27 - - 5.79 0.93 1.88 
IL1R1: (IL1R1 OR IL1 Hs.25333 0.72 - - - 0.72 1.83 
IL1R2: (IL1R2 OR IL1 - 1.13 - - 1.28 - 1.55 
IL1RAP: (IL1RAP) IL- Hs.66 0.89 0.92 - 0.90 1.15 0.90 
IL1RB: (IL1RB OR C Hs.66 1.16 0.82 0.70 0.95 0.93 0.85 
IL1RL1: (IL1RL1 OR S Hs.416814 0.65 - - - 0.99 - 
IL1RL2: (IL1RL2 OR I Hs.81134 1.12 0.87 0.51 1.59 1.17 - 
IL1RN: (IL1RN OR IL1 Hs.89679 - 0.91 0.58 4.26 - 0.94 
IL2: (IL2 OR IL-2) I Hs.302014 - - - - - 1.65 
IL21: (IL21) INTERLE Hs.210546 - - - - - 1.38 
IL21R: (IL21R OR NIL Hs.110915 1.85 - - 1.63 0.92 0.81 
IL22R: (IL22R) IL-22 Hs.130058 - - - - - 1.18 
IL2RA: (IL2RA OR IL2 Hs.75596 1.25 0.83 - - - 0.97 
IL2RB: (IL2RB) INTER Hs.84 0.46 1.15 - - 0.69 1.15 
IL2RG: (IL2RG) CYTOK Hs.694 0.56 - - 7.96 - 0.88 
IL3: (IL3 OR IL-3 OR Hs.460433 1.25 - - 1.23 1.56 1.13 
IL3RA: ((IL3RAX OR I Hs.73917 - 1.93 0.72 1.52 - 0.98 
IL4: (IL4 OR IL-4) I Hs.75545 - - - - - 1.31 
IL4R: (IL4R OR IL4RA Hs.2247 - 1.70 - 1.54 - 1.29 
IL5: (IL5 OR IL-5) I Hs.68876 1.18 1.17 - 1.45 1.54 1.13 
IL5RA: (IL5RA OR IL5 Hs.512234 0.99 0.38 - 2.27 - 1.98 
IL6: (IL6 OR IFNB2 O Hs.193400 - - - 2.89 - 1.54 
IL6R: (L6RA OR IL6R) Hs.71968 - 0.48 0.20 1.41 - 1.17 
IL6ST: (IL6ST) INTER Hs.72927 1.14 0.96 - 1.22 1.51 1.32 
IL7: (IL7 OR IL-7) I Hs.362807 - 0.99 0.71 1.54 - 1.47 
IL7R: (IL7R) INTERLE Hs.624 - - - 1.74 - 1.15 
IL8_HUMAN: (IL8) INT Hs.194778 Hs.846 - - - 4.35 - 1.43 
IL8RA-IL8RB: (IL8RA Hs.846 Hs.194778 - 0.70 - 1.52 - 1.35 
IL8RB-IL8RA: (IL8RB Hs.960 0.93 - - 1.26 1.22 1.37 
IL9: (IL9) INTERLEUK Hs.407506 0.86 1.32 - 1.62 1.15 1.14 
ILF: (ILF1 OR ILF) I Hs.727 1.80 0.74 - 1.74 1.29 1.43 
INHA: (INHA) INHIBIN Hs.1735 - 0.89 - - - 1.54 
INHBA: (INHBA) INHIB Hs.374664 3.19 - - 3.89 - 1.14 
INHBB: (INHBB) INHIB Hs.334575 1.37 - - 0.97 1.42 1.30 
INHBC: (INHBC) INHIB Hs.439046 0.93 1.39 - 1.36 - 1.00 
INOS: (NOS2A OR NOS2 Hs.1742 1.30 0.90 - 1.59 1.34 1.11 
INTEGRINA7: (ITGA7) Hs.373980 1.68 0.63 - 1.37 1.26 1.17 
INTEGRINA8: (ITGA8) Hs.182018 1.47 1.64 - 1.40 1.49 1.12 
INTEGRINA9: (ITGA9) Hs.424542 1.98 - - 0.92 1.39 0.96 
INTEGRINB5: (ITGB5) Hs.142295 1.12 0.77 - 0.63 1.11 0.83 
INTEGRINB6: (ITGB6) Hs.268552 0.59 - - 0.95 0.74 1.10 
INTEGRINB7: (ITGB7) Hs.80645 0.61 - - 0.77 0.95 0.77 
INTEGRINB8: (ITGB8) Hs.75254 0.68 - - - 1.28 0.89 
IP4P-BII: INOSITOL P Hs.334450 0.99 - - 0.64 0.97 1.80 
IPLA2: (IPLA2) CALCI Hs.355827 0.65 1.50 - 0.43 0.83 1.26 
IQGAP1: (IQGAP1) RAS Hs.166120 1.56 0.65 0.30 1.66 1.17 1.63 
IQGAP2: (IQGAP2) RAS Hs.314676 0.77 - - - 0.65 1.57 
IRAK1: (IRAK1 OR IRA Hs.439320 0.90 - - 1.67 0.77 0.69 
IRAK2: (IRAK2) INTER Hs.158237 0.83 0.92 - - 0.87 0.65 
IRAK-4: (IRAK-4) (LO Hs.387725 1.57 - - 1.47 1.20 0.90 
IRAK-M: (IRAK-M) IL- Hs.411312 - - - - - 0.92 
IRF1: (IRF1) INTERFE Hs.265829 0.84 0.83 - 1.12 0.87 0.69 
IRF3: (IRF3) INTERFE Hs.145140 1.30 - - 0.48 1.74 1.96 
IRF5: (IRF5) INTERFE Hs.149609 1.14 0.72 - 1.49 0.82 1.38 
IRF6: (IRF6) INTERFE Hs.212296 0.79 - - 1.17 1.00 0.87 
IRF7: (IRF7) INTERFE Hs.74369 Hs.51483 0.99 - - 1.74 0.96 1.90 
ITCH: (AIP4 OR ITCH) Hs.171025 0.98 0.88 - 0.96 1.49 0.93 
ITGA1_2: (ITGA1) INT Hs.222 0.73 1.24 - 0.99 - 0.97 
ITGA1_HUMAN: (ITGA1 Hs.389133 1.53 - - 1.20 1.27 1.29 
ITGA2: (ITGA2) INTEG Hs.174103 0.82 - - 1.51 1.44 0.77 
ITGA2B: (ITGA2B OR I Hs.172631 0.68 0.83 - - 0.87 1.18 
ITGA3: (ITGA3) INTEG Hs.436873 1.56 - - 1.85 1.36 - 
ITGA4: (ITGA4 OR VLA Hs.385521 Hs.381264 - - - - - 0.92 
ITGA5: (ITGA5 OR FNR Hs.287797 0.97 1.92 - 1.96 0.88 1.85 
ITGA6: (ITGA6) INTEG Hs.375957 - 0.75 0.52 1.58 - 1.52 
ITGAE: (ITGAE) INTEG Hs.87149 0.59 - - 1.34 1.53 1.22 
ITGAL: (ITGAL OR CD1 Hs.85266 0.68 1.45 - 0.77 0.98 1.25 
ITGAM: (ITGAM OR CR3 Hs.149846 - 1.17 - 2.84 - 1.19 
ITGAV: (ITGAV OR VNR Hs.57664 1.46 0.79 - 1.52 1.55 1.38 
ITGAX-ITGAD_HUMAN: ( Hs.1741 1.20 - - 1.44 1.48 1.33 
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ITGB1: (ITGB1 OR FNR Hs.355722 4.31 2.33 - 0.65 0.43 0.79 
ITGB2: (ITGB2 OR CD1 Hs.420257 1.78 0.82 1.88 5.60 1.22 1.14 
ITGB3: (ITGB3 OR GP3 Hs.76716 0.69 - - 0.63 1.36 0.98 
ITGB4: (ITGB4) INTEG Hs.76415 1.52 - - 1.18 1.00 - 
ITIH1: (ITIH1 OR IGH Hs.211576 1.68 0.71 0.73 0.77 1.23 0.90 
ITIH3: (ITIH3) INTER Hs.66392 0.96 - - - 1.00 0.89 
ITIH4: (ITIH4 OR IHR Hs.433445 1.84 0.40 - 0.45 1.49 0.87 
ITK: (ITK OR LYK OR Hs.436004 0.54 - - - 1.30 1.45 
ITSN: (ITSN) INTERSE Hs.434374 0.92 - - 1.30 - 1.16 
JAK1: (JAK1 OR JAK1A Hs.210387 1.32 - - 2.12 0.67 - 
JAK2: (JAK2) TYROSIN Hs.247700 1.32 0.78 - 1.34 1.17 1.33 
JAK3: (JAK3) TYROSIN Hs.78465 1.63 0.90 - 0.55 1.16 1.33 
JM2: (FOXP3 OR IPEX) Hs.400124 1.29 0.56 - 1.31 1.37 0.81 
JUN: (JUN) TRANSCRIP Hs.323949 0.75 1.31 - 0.18 0.63 0.89 
JUNB: (JUNB) TRANSCR Hs.80976 0.87 0.52 0.62 0.47 0.65 0.65 
KAI1: (KAI1 OR CD82 Hs.86998 1.35 0.49 - 0.95 1.31 1.24 
KI67: (MKI67) ANTIGE Hs.81665 1.35 0.63 - 1.43 1.29 0.71 
KIAA827: (NFAT5 OR Hs.1048 1.41 0.94 - 1.32 1.32 0.94 
KIT: (KIT OR SL) MAS Hs.268510 Hs.387787 0.90 0.77 - 1.53 1.13 1.68 
KITLG: (KITLG OR MGF Hs.41682 0.76 0.92 - - 0.87 1.31 
KLRC4: (KLRC4 OR NKG Hs.77741 0.99 - - 1.24 0.89 1.46 
KLRD1: (KLRD1 OR CD9 Hs.8878 1.37 - - 1.55 1.48 0.89 
KNG-KNT1-KNT2: (KNG) Hs.276238 - 1.00 0.63 - - 1.74 
KNSL1: (KNSL1 OR EG5 Hs.445201 1.19 - - 1.30 1.19 - 
KSR1: (KSR1 OR HB) K Hs.409523 0.92 1.61 - - - 1.28 
L1CAM: (L1CAM OR CAM Hs.500930 Hs.270364 - - - 1.36 - 0.95 
LAG3: (LAG3 OR FDC) Hs.445120 0.76 - - 0.73 0.93 1.23 
LAMA1: (LAMA1 OR LAM Hs.83450 1.14 - - - 0.96 0.93 
LAMA2: (LAMA2 OR LAM Hs.437536 0.50 1.25 - 1.18 0.76 1.00 
LAMA3: (LAMA3) LAMIN Hs.11669 1.39 - - 1.27 1.38 1.12 
LAMA4: (LAMA4) LAMIN Hs.122645 2.45 0.87 - 1.69 0.95 1.33 
LAMA5: (KIAA533 OR Hs.436983 0.93 - - 0.37 0.98 0.95 
LAMB1: (LAMB1) LAMIN Hs.432855 1.28 0.68 - 0.98 1.37 0.74 
LAMB3: (LAMB3) LAMIN Hs.69954 0.79 0.90 - 0.37 0.85 1.58 
LAMG1: (LAMC1 OR LAM Hs.150101 0.97 1.49 - 0.55 1.26 0.69 
LAMG3: (LAMC3) LAMIN Hs.232432 1.17 1.45 - 0.45 1.19 2.62 
LAMP1: (LAMP1 OR LAM Hs.209983 1.16 0.60 - 0.33 0.74 0.78 
LAMP2: (LAMP2 OR LAM Hs.498997 0.65 - - 0.48 1.29 0.71 
LAP18: (LAP18 OR OP1 Hs.294584 1.83 0.93 0.72 0.92 1.24 0.86 
LAT: (LAT) TYROSINE Hs.154078 - - - 2.53 1.00 1.85 
LB4D: (LTB4DH OR DIG Hs.1765 0.52 - - 0.12 0.89 1.16 
LBP: (LBP) LIPOPOLYS Hs.204238 0.99 0.77 - - 0.89 0.68 
LCK: (LCK)PROTO-ON Hs.2488 0.52 0.41 - 4.72 0.65 0.84 
LCN2: (LCN2 OR NGAL Hs.44865 0.57 - 0.83 - 1.46 1.16 
LCP2: (LCP2) LYMPHOC Hs.25195 Hs.278239 0.78 1.70 - 2.43 1.18 2.69 
LEF1: (LEF1) LYMPHOI Hs.411701 1.83 0.75 0.67 0.98 1.28 1.34 
LEFTA-LEFTB_HUMAN: ( Hs.2250 0.99 1.41 - 1.19 1.47 1.35 
LGALS3: (LGALS3 OR M Hs.446501 0.54 1.25 - 1.90 1.44 0.92 
LIF: (LIF OR HILDA) Hs.100299 1.55 0.51 - 1.37 1.39 1.17 
LIFRA: (LIFR) LEUKEM Hs.166091 0.92 1.23 - - - 1.68 
LIG3: (LIG3) DNA LIG Hs.2799 1.23 - - 0.86 0.93 0.93 
LIG4: (LIG4) DNA LIG Hs.76507 - - - 1.45 - 1.42 
LINK: (CRTL1) PROTEO Hs.81118 1.17 - - 1.14 1.30 1.23 
LITAF: (LITAF OR PIG Hs.3844 1.48 0.77 - 1.66 0.64 0.85 
LKHA: (LTA4H OR LTA4 Hs.148830 0.71 1.20 - 1.32 1.78 1.27 
LMO4: (LMO4) LIM DOM Hs.162757 0.90 0.75 1.20 0.60 0.95 1.22 
LRAT: (LRAT) LECITHI Hs.56729 0.78 0.72 - 0.94 1.47 0.91 
LRP1: (LRP1 OR A2MR) Hs.241257 1.98 0.86 - 1.81 0.98 1.38 
LSP1: (LSP1 OR WP34 Hs.105689 1.11 0.58 - 1.53 - 0.95 
LTBP1: (LTBP1) LATEN Hs.289019 0.87 - - - 0.74 0.97 
LTBP2: (LTBP2) LATEN Hs.85087 1.17 - - 1.34 0.95 1.25 
LTBP3: (LTBP-3) LATE Hs.1116 0.55 1.63 - - 0.87 1.58 
LTBP4: LATENT TRANSF Hs.287921 1.25 - - - 0.88 1.18 
LTBR: (LTBR OR TNFCR Hs.406475 2.74 - - 0.35 1.60 0.68 
LUMAN: (CREB3 OR LZI Hs.153563 1.65 - - 0.57 0.87 0.64 
LUMICAN: (LDC) LUMIC Hs.80887 0.44 0.53 0.59 1.68 0.28 0.76 
LY75: (LY75) RECEPTO Hs.87860 1.13 0.54 - - 1.14 1.65 
LYN: (LYN) TYROSINE- Hs.102267 1.14 - - 1.38 0.98 0.95 
LYP1: (PTPN8) HEMATO Hs.102598 0.74 0.60 0.50 1.56 1.39 0.93 
LYSYLOXIDASE: (LOX) Hs.82548 5.33 0.59 - - 0.78 1.38 
MADCAM-1: (MADCAM-1) Hs.169487 0.91 - - 1.75 0.83 0.90 
MADD: (MADD) MAP KIN - 0.99 - 0.47 - 1.00 1.25 
MAF1: (MAFB) MAFB/KR - 1.26 1.25 - 1.56 1.24 1.66 
MAFF: (MAFF OR BK447 Hs.134859 1.11 0.87 0.89 0.69 0.96 0.84 
MAFG: (MAF OR MAFG) Hs.389137 1.15 0.63 0.33 0.60 1.17 - 
MAF-SHORT: (MAF OR M Hs.300946 1.43 - - 1.17 1.92 0.82 
MAGP1: (MFAP2 OR MAG Hs.132311 1.84 0.83 - 1.67 0.54 - 
MAGP2: (MFAP5 OR MAG Hs.366546 - 1.10 - 5.81 - 0.95 
MAP: MAP KINASE PHOS Hs.180533 0.84 - - 0.64 1.38 0.84 
MAP2K1: (MAP2K1 OR P Hs.436145 0.88 - - 0.52 0.93 1.85 
MAP2K2: (MAP2K2 OR P Hs.256924 2.27 0.57 - 0.45 1.19 0.78 
MAP2K3: (MAP2K3 OR P Hs.110299 0.88 0.96 - 0.41 0.68 0.62 
  Appendices 
 
95 
Gen Name UniGene 2828 3204 3230 2060 2810 3026 
MAP2K5: (MAP2K5 OR P Hs.28827 - - - 1.56 - 0.85 
MAP2K6: (MAP2K6 OR P Hs.390428 - - - 1.14 1.23 0.97 
MAP2K7: (MAP2K7 OR P Hs.290346 1.88 - - 1.27 1.60 0.98 
MAP3K2: (MAP3K2 OR M Hs.432453 1.42 1.26 - 1.40 1.25 1.43 
MAP3K4: (MAP3K4 OR M Hs.324473 1.00 - - 1.16 1.16 0.98 
MAP3K7: (MAP3K7 OR T Hs.25209 1.45 - - 1.40 0.90 1.79 
MAP3K8: (MAP3K8 OR C Hs.57732 1.14 0.43 - 1.27 1.15 1.47 
MAPK1: (MAPK1 OR P Hs.79107 0.56 1.17 - 0.49 0.73 0.88 
MAPK1: (MAPK1 OR PRK Hs.861 1.16 - - 1.92 0.99 1.46 
MAPK11: (MAPK11 OR P Hs.433728 0.96 0.79 0.52 1.66 1.92 1.43 
MAPK14: (MAPK14 OR C Hs.271980 1.15 - - 1.69 - 1.17 
MAPK3: (MAPK3 OR PRK Hs.150136 0.97 0.92 0.85 0.75 1.24 0.98 
MAPK4: (MAPK4 OR PRK Hs.445864 1.34 1.24 0.63 1.15 1.44 0.87 
MAPK6: (MAPK6 OR PRK Hs.234249 1.17 - - - - - 
MAPK7: (MAPK7 OR PRK Hs.356523 0.84 - - - - 1.34 
MAPK8: (MAPK8 OR PRK Hs.348446 1.49 0.48 - 1.30 1.16 1.29 
MAPK8IP1: (MAPK8IP1 Hs.75074 1.41 - - 1.90 1.20 0.95 
MAPK8IP2: (MAPK8IP2 Hs.413901 1.51 1.88 - 1.23 - 1.27 
MAPK9: (MAPK9 OR PRK Hs.437808 0.91 - - 1.19 0.84 0.94 
MAPKAPK2: (MAPKAPK2 Hs.150366 1.23 - - 0.27 0.64 0.66 
MAPKAPK5: (MAPKAPK5) Hs.153647 0.72 1.43 - 0.41 1.15 1.90 
MATK: (MATK OR CTK O Hs.278461 0.63 - - 1.77 0.97 0.98 
MATRILIN1: (MATN1 OR Hs.223745 - - - - - 0.92 
MATRILIN2: (MATN2) M Hs.365706 1.45 1.38 - - 0.17 0.55 
MATRILIN3: (MATN3) M Hs.511397 1.21 0.63 - 0.46 1.25 0.88 
MATRIN3: (MATR3) MAT Hs.86386 0.55 0.89 - 0.27 0.83 1.19 
MATRIXGLA: (MGP) MAT Hs.83532 0.28 - - 0.56 0.14 0.65 
MCAM: (MCAM OR MUC18 Hs.2442 - - - 1.85 0.58 1.44 
MCL1: (MCL1) INDUCED Hs.79748 1.52 - - 0.86 0.74 1.41 
MCP: (MCP) MEMBRANE Hs.55173 0.42 - - 1.45 0.34 1.29 
MDC9: (ADAM9 OR MDC9 Hs.389700 5.66 - - 2.52 0.76 1.71 
MDU1: (SLC3A2 OR MDU Hs.81874 0.35 0.16 0.27 0.11 1.66 0.16 
MEGF2: (MEGF2) MEGF2 Hs.212507 - - - - 0.89 0.88 
MGST1: (MGST1 OR MGS Hs.283477 0.62 0.87 - 0.18 1.30 0.82 
MGST2: (MGST2 OR GST Hs.12256 0.32 - - 0.18 1.72 0.45 
MGST3: (MGST3) MICRO Hs.89690 0.60 0.96 - 0.39 1.45 1.64 
MIC2_HUMAN: ((CD99X - 1.19 0.75 - 1.96 1.26 0.99 
MID2: (MID2 OR FXY2) Hs.54403 0.64 - - - - 1.42 
MIG-2: MIG-2 PROTEIN Hs.100469 Hs.280306 0.76 - - - 0.78 0.96 
MIP2B_HUMAN: (CXCL3 Hs.79889 0.82 - - - - 1.13 
MMD: (MMD) MONOCYTE Hs.83169 1.30 - - 1.62 1.36 - 
MME: (MME OR EPN) NE Hs.2258 1.26 1.54 - 0.23 1.39 1.76 
MMP1: (MMP1 OR STM Hs.143751 - 0.55 - - - 0.44 
MMP11: (MMP11 OR STM Hs.2936 - - - - - 1.00 
MMP12: (MMP12 OR HME Hs.2399 2.19 - - 1.77 - 1.37 
MMP13: (MMP13) COLLA Hs.80343 - 0.68 - - - 1.16 
MMP14: (MMP14 OR MMP Hs.90800 1.12 - - 1.55 0.92 1.23 
MMP15: (MMP15) MATRI Hs.159581 1.56 1.12 0.44 0.82 1.16 1.27 
MMP16: (MMP16 OR MMP Hs.154057 1.35 0.89 - 1.49 1.70 1.52 
MMP17: (MMP17 OR MT4 Hs.367877 1.14 0.94 - 1.45 1.23 0.96 
MMP18: (MMP19 OR MMP Hs.123387 1.35 - - 3.15 - 1.37 
MMP2: (MMP2 OR CLG4A Hs.211819 3.46 - - 0.68 0.72 1.21 
MMP2: (MMP2) MATRI Hs.212581 0.86 - - - 0.96 1.18 
MMP21-22-23: (MMP-23 Hs.528670 1.33 - - 1.16 0.99 0.81 
MMP24: (MMP24 OR MT5 Hs.380710 1.22 - - 1.93 0.99 0.92 
MMP25: (MMP25 OR MT6 Hs.375129 0.96 1.18 - - 1.75 1.15 
MMP28: (MMP28) MATRI Hs.2256 1.20 1.53 - - 0.95 - 
MMP3: (MMP3 OR STMY1 Hs.390002 - 0.68 - - - 0.88 
MMP7: (MMP7 OR MPSL1 Hs.151738 0.15 - - 0.46 3.81 1.80 
MMP8: (MMP8 OR CLG1) Hs.511804 0.99 - - 1.58 1.80 1.86 
MMP9: (MMP9 OR CLG4B Hs.184601 - - - - - 1.27 
MOB-LAK: (MOB-LAK OR Hs.422215 1.74 - - 0.98 1.15 1.35 
MPE16: (SLC7A5 OR LA Hs.75182 1.12 - - 1.41 1.27 0.84 
MPP1: (MPP1 OR EMP55 Hs.438040 0.77 0.99 0.57 0.49 1.57 0.89 
MRC1: (MRC1) MACROPH Hs.432458 1.17 0.39 - 1.81 - 0.58 
MS4A1: (MS4A1 OR CD2 Hs.2942 - - - - - 1.11 
MSF: (PRG4) MEGAKARY Hs.407830 1.26 0.86 - 1.25 1.42 - 
MST1R: (MST1R OR RON Hs.82116 1.29 2.00 - 1.26 1.45 1.17 
MYB: (MYB) MYB PROTO Hs.25812 1.65 0.88 0.67 0.43 0.98 0.98 
MYD88: (MYD88) MYELO Hs.78792 0.83 0.60 0.92 - 0.64 0.74 
NAP4: (SOCS6 OR NAP4 Hs.1565 - - - - - 0.87 
NBS1: (NBS1 OR NBS) Hs.99863 0.89 - - - - 1.15 
NCAM1_3: (NCAM1 OR N Hs.356321 1.22 - - 1.57 1.42 1.18 
NED4: (NEDD4 OR KIAA Hs.77810 1.26 1.00 - 0.71 0.88 1.00 
NELASTASE: (ELA2) LE Hs.512591 1.29 - - 0.54 1.23 0.84 
NFAT1: (NFATC2 OR NF Hs.172674 0.82 1.20 - 1.51 0.87 1.15 
NFAT3: (NFATC4 OR NF Hs.75643 1.31 - - 1.19 1.12 1.58 
NFATCB: (NFATC1 OR N Hs.83469 1.29 - - 1.19 1.34 0.98 
NFATX: (NFATC3 OR NF Hs.160557 0.79 0.78 - 0.75 0.84 0.97 
NF-E2: (NFE2) TRANSC Hs.73090 0.92 0.78 - 1.69 0.93 0.89 
NFE2L1: (NFE2L1 OR N Hs.132594 0.89 0.56 - 0.75 0.87 0.78 
NFKB1: (NFKB1) NUCLE Hs.356764 0.72 - - 0.84 0.98 0.97 
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NFKB2: (NFKB2) NUCLE Hs.413074 1.13 0.83 - 0.62 1.22 0.82 
NFKB3: (RELA OR NFKB Hs.356624 1.23 0.72 - 0.77 0.92 0.80 
NFX1: (NFX1) TRANSCR Hs.135201 0.88 - - - 0.96 0.86 
NIDOGEN: (NID) NIDOG Hs.193788 1.50 - - 1.91 1.19 0.96 
NOD2: (CARD15 OR NOD Hs.311559 0.87 1.18 - - 0.97 1.15 
NOTCH1: (NOTCH1 OR T Hs.8121 1.23 - - 0.67 1.25 1.12 
NOTCH2: (NOTCH2) NEU Hs.436100 1.41 1.29 - 1.36 1.44 - 
NOTCH4: (NOTCH4) NOT Hs.155396 0.79 - - 0.75 1.38 0.96 
NRF2: (NFE2L2 OR NRF Hs.173548 0.32 - - 0.56 1.12 1.34 
NRP1: (NRP1 OR NRP O Hs.151123 1.50 0.49 0.62 1.64 1.49 1.37 
NSHC: (SHC3) P64 ISO Hs.153952 0.96 0.70 0.43 - - 1.26 
NT5: (NT5E OR NT5 OR Hs.511760 1.23 2.87 - 1.13 1.48 1.16 
NTE: NTE NEUROPATHY Hs.332115 1.25 - - 1.57 1.35 1.16 
NUMA: NUMA PROTEIN. Hs.241385 0.83 0.90 - - 0.79 1.30 
OP4: (OPHN4) OLIGOPH Hs.313 1.29 - - 0.51 1.00 1.14 
OPN: (SPP1 OR OPN) O Hs.278388 0.79 - - 1.18 5.65 1.63 
ORM1: (ORM1 OR AGP1) Hs.277704 0.84 - - 0.65 0.86 0.85 
ORP15: (HYOU1 OR OR Hs.47011 1.39 1.82 1.15 0.64 1.21 2.23 
OSF: (OSTF1 OR SH3D3 Hs.135554 1.12 - - 2.58 1.30 0.74 
OSP94: (OSP94) OSMOT Hs.512679 1.17 0.64 - 1.64 1.48 0.96 
OSTEOCALCIN: (BGLAP) Hs.278186 - 1.29 - 0.56 - 1.59 
P115RHOGEF: (ARHGEF1 Hs.408312 - 1.35 - - - 0.95 
P53: (TP53 OR P53) C Hs.512592 - - - - - 0.78 
P53R2: (P53R2) RIBON Hs.192132 1.23 - - 1.48 - 1.32 
P73_1: (TP73 OR P73) Hs.992 1.34 - - 1.45 1.22 1.21 
PA21: (PLA2G1B OR PL Hs.93304 1.18 - - 1.29 0.97 1.19 
PAFA: (PLA2G7) PLATE Hs.77318 1.70 - - 3.60 1.15 1.12 
PAFAH1B1: (PAFAH1B1 Hs.414795 0.66 0.75 - 0.49 1.85 1.28 
PAI1: (SERPINE1 OR P Hs.75716 15.53 0.80 - 5.39 - 1.12 
PAI2: (SERPINB2 OR P Hs.154299 1.28 - - 1.18 1.36 1.25 
PAR2: (PAR2 OR GPR11 Hs.42502 0.55 0.99 - 0.59 0.53 1.37 
PAR3: (F2RL2 OR PAR3 Hs.406074 0.60 - - 1.17 - 0.94 
PAR-4: PROSTATE APOP Hs.430919 1.23 - - 0.68 1.85 0.93 
PC3B: (BTG4 OR PC3B) Hs.128180 0.96 - - 1.27 1.17 0.57 
PCNA: (PCNA) PROLIFE Hs.78996 0.66 - - 0.35 1.16 1.38 
PCTK2: (PCTK2) SERIN Hs.258536 0.76 0.85 - 0.94 0.60 1.85 
PDGA: (PDGFA OR RPA1 Hs.376032 Hs.521331 - - - 1.33 - 0.72 
PDGB: (PDGFB OR C-SI Hs.1976 1.18 0.62 - 1.12 0.76 0.88 
PDGFRA: (PDGFRA) ALP Hs.74615 0.93 - - 1.40 1.62 1.23 
PDGFRB: (PDGFRB OR P Hs.307783 1.18 - - 1.55 1.23 1.42 
PD-L2: (PDL2) BUTYRO Hs.61929 1.77 - - 0.61 0.89 1.14 
PECAM1: (PECAM1 OR P Hs.78146 0.56 1.13 - 2.59 0.42 1.76 
PGH2: (PTGS2 OR COX2 Hs.196384 1.28 1.13 0.78 0.85 1.17 0.96 
PGS2: (DCN) BONE PRO Hs.83974 0.38 1.42 - 0.34 0.32 0.64 
PGT: (SLC21A2) PROST Hs.75251 0.80 0.90 0.68 0.51 1.24 0.88 
PIAS1: (PIAS1 OR DDX Hs.441069 0.76 0.39 2.25 0.96 0.68 0.66 
PIAS3: (PIAS3) PROTE Hs.435761 0.82 0.55 - 0.78 0.75 0.77 
PIASG: (PIASG) PROTE Hs.105779 - - - 1.64 - 0.94 
PIASX: (PIASX OR PIA Hs.249235 0.96 - - 1.10 - 0.92 
PIK3C2A: (CPK-M OR P Hs.22500 - - - 1.50 - 1.26 
PIK3C2G: (PIK3C2G) P Hs.85701 - 0.00 - - - 1.16 
PIK3CA: (PIK3CA) P11 Hs.239818 1.39 0.81 - 1.37 1.33 1.39 
PIK3CB: (PIK3CB) PHO Hs.426967 0.85 - - - 0.69 0.85 
PIK3CD: (PIK3CD) PHO Hs.32942 1.14 0.75 - 1.64 - 1.49 
PIK3CG: (PIK3CG) PHO Hs.6241 - - - - - 0.94 
PIK3R1: (PIK3R1 OR G Hs.372548 0.83 - - 0.98 1.00 1.14 
PIK3R3: (PIK3R3) PHO Hs.81170 0.96 - - - - - 
PIM1: (PIM1) PROTO-O Hs.18586 1.32 - - 0.78 1.16 1.94 
PK428: (MRCK) MYTONI Hs.155342 0.98 - - 0.84 - 0.98 
PKCD: (PRKCD OR PKCD Hs.211587 1.89 0.82 - 0.51 - 0.97 
PLA2G4: (PLA2G4A OR Hs.149623 0.79 - - 1.62 0.85 0.43 
PLA2-III: (PLA2G3 OR Hs.179657 - - - 1.58 - 1.23 
PLAUR: (PLAUR OR UPA Hs.429643 1.56 - - 2.12 1.46 1.15 
PLC: (PLC-L) PHOSPHO Hs.355888 - 0.84 - - 0.77 1.26 
PLCB1: (PLCB1) 1-PHO Hs.437137 1.17 - - 1.17 1.82 1.20 
PLCB2: (PLCB2) 1-PHO Hs.151408 - - - 1.98 - 0.79 
PLCB3: (PLCB3) 1-PHO Hs.380094 - - - 1.31 - 0.90 
PLCB4: (PLCB4) PHOSP Hs.80776 - - - 1.69 - 1.15 
PLC-BC1668: (PLC-B Hs.103417 1.29 - - 1.25 0.97 1.32 
PLCD1: (PLCD1) 1-PHO Hs.268177 0.93 - - - 0.98 0.99 
PLCE: (PLCE OR PLCE1 Hs.512298 1.15 - - 0.62 - 1.23 
PLCG1: (PLCG1 OR PLC Hs.153322 0.33 - - 0.46 0.73 1.13 
PLCG2: (PLCG2) 1-PHO Hs.270411 - - - 0.19 0.50 0.85 
PLGF: (PGF OR PLGF) Hs.252820 1.35 1.12 - 0.93 1.17 0.63 
PNP: (ADAMTS2 OR PCI Hs.444234 1.41 - - 1.42 1.36 0.32 
POU2F1: (POU2F1 OR O Hs.271640 0.91 1.24 - 0.55 1.35 0.92 
PPAR: (PPARA OR NR1C Hs.177766 1.99 0.85 - 0.44 1.90 1.12 
PPOL: (ADPRT OR PPOL Hs.76494 - 0.65 - 0.79 0.83 0.76 
PRELP: (PRELP) PROLA Hs.2200 1.93 - - 1.52 0.83 0.81 
PRF1: (PRF1) PERFORI Hs.69171 - - - - - 0.87 
PRK2: (PRKCL2 OR PRK Hs.349611 0.86 - - - 0.86 1.90 
PRKCA: (PRKCA OR PKC Hs.349845 - - - - - 1.46 
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PRKCB_2: (PRKCB OR P Hs.349845 0.59 0.58 - 3.11 - 0.82 
PRKCB_3: (PRKCB OR P Hs.349845 0.67 - - 1.64 0.81 0.93 
PRKCB_4: (PRKCB OR P Hs.155281 0.62 - - 1.82 0.57 - 
PRKCE: (PRKCE OR PKC Hs.315366 0.92 - - 1.23 0.82 - 
PRKCH: (PRKCH OR PKC Hs.407181 0.79 - - 1.19 0.74 - 
PRKCZ: (PRKCZ OR PKC Hs.1905 - - - - - 1.33 
PRL_1: (PRL) PROLACT Hs.212892 1.28 0.89 - 0.96 1.31 0.92 
PRLR: (PRLR) PROLACT Hs.82353 1.11 - - 0.53 1.14 0.85 
PROCR: (PROCR OR EPC Hs.75111 1.42 - - 1.26 - 1.23 
PRSS11: (PRSS11 OR H Hs.46 0.90 0.81 - 0.30 1.44 0.86 
PTAFR: (PTAFR OR PAF Hs.159526 0.99 - - 3.42 1.20 0.94 
PTCH: (PTCH) PATCHED Hs.249164 1.26 - - 1.50 1.24 0.90 
PTCH2: (PTCH2) PATCH Hs.253309 Hs.493716 0.95 - - - 1.28 0.54 
PTEN1-PTEN2: (PTEN O Hs.306831 0.68 - - 0.54 0.91 1.43 
PTGDR: (PTGDR) PROST Hs.2090 1.28 - - 1.37 1.32 0.82 
PTGER2: (PTGER2) PRO Hs.89418 1.13 - - 1.85 1.29 0.91 
PTGFR: (PTGFR) PROST Hs.458324 0.79 1.13 0.66 - 0.76 0.94 
PTGIR: (PTGIR OR PRI Hs.387553 - 0.86 - 1.12 - 0.96 
PTP: (PTPN13 OR PTP1 Hs.83572 0.38 - - 0.39 0.96 - 
PTP2C: (SHPTP2 OR PT Hs.43666 - - - - - 1.60 
PTP4A3: (PTP4A3 OR P Hs.446126 - 0.56 - 1.53 0.98 1.82 
PTPL1-AR: PTPL1-ASSO Hs.63489 0.98 - - 1.35 0.79 0.83 
PTPN2: (PTPN2 OR PTP Hs.63489 0.61 0.73 0.41 1.29 1.62 1.39 
PTPN6_1: (PTPN6 OR P Hs.402773 0.73 - - 1.72 1.25 1.47 
PTPN6_2: (PTPN6 OR P Hs.75216 - - - 1.78 - 1.83 
PTPN7: (PTPN7) PROTE Hs.171992 1.25 0.62 - 1.95 - 1.34 
PTPRF: (PTPRF OR LAR Hs.76452 1.25 - - - - 1.11 
PTPRJ: (PTPRJ OR DEP Hs.171844 0.85 - - - 0.83 1.12 
PTX1: (PTX1 OR CRP) Hs.405474 1.79 - - 0.93 0.94 0.86 
PVS_1_HUMAN: (PVS OR Hs.73958 1.27 1.16 - 1.23 1.28 1.92 
PYK2: (PTK2B OR FAK2 Hs.159376 1.23 0.82 0.72 1.11 - 0.85 
RAG1: (RAG1) V(D)J R Hs.324051 1.34 - - 1.33 1.35 0.94 
RAG2: (RAG2) V(D)J R Hs.302498 0.93 0.81 - 0.93 0.98 0.95 
RAI: (RAI) RELA ASSO Hs.758 3.78 1.28 - 0.74 1.26 1.32 
RAR: (RAB4B OR SEC4 Hs.307905 0.41 - - - 1.94 0.89 
RASA1_2: (RASA1 OR R Hs.75256 - - - 1.90 - - 
RELB: (RELB) TRANSCR Hs.77273 1.26 - - 1.31 1.85 0.73 
RGS1: (RGS1 OR 1R2 Hs.406064 0.69 - - 11.33 0.98 1.42 
RHOA: (ARHA OR ARH12 Hs.16986 0.94 - - 0.53 0.99 0.94 
RHOB: (ARHB OR ARH6 Hs.282386 1.11 - - 0.52 0.88 1.47 
RHOD-AK198: (RHOD Hs.33254 1.14 0.35 - 0.73 1.38 0.98 
RHOD-AL359617: (TSGA Hs.430725 1.97 1.95 - 0.84 1.56 0.85 
RHOIP2: (RHOIP2) RHO Hs.390758 1.18 0.68 - 0.74 1.13 0.88 
RHOIP3: (RHOIP3) RHO Hs.75447 0.38 - - 0.41 0.67 0.98 
RIPK1: (RIPK1 OR RIP Hs.9238 1.49 1.40 - 1.25 1.52 0.98 
RLIP76: (RIP1) RLIP7 Hs.435065 0.84 1.17 - - 0.76 0.57 
RNF3A: (RNF3A) RING Hs.444012 1.17 1.98 - 0.82 1.16 0.97 
RPS7: (RPS7) 4S RIB Hs.9651 0.78 - - 0.40 0.51 0.99 
RRAS: (RRAS) RAS-REL Hs.206097 2.20 0.31 0.50 0.69 1.16 0.75 
RRAS2: (RRAS2) RAS-R Hs.252189 2.15 - - 0.90 1.77 0.94 
RYUDOCAN: (SDC4) SYN Hs.19413 1.63 - - - - 1.29 
S1A12_HUMAN: (S1 Hs.512813 1.25 1.16 0.71 1.43 1.38 0.76 
SALT Hs.380906 - - - - - 1.28 
SAP3: (SAP3) SIN3- Hs.458346 Hs.174228 0.84 0.78 0.67 1.20 1.90 0.99 
SARP1: (SARP1) SECRE Hs.89546 1.20 1.28 - 0.95 0.88 - 
SARP2: (SARP2)SECR Hs.78979 1.26 - - 0.62 2.23 1.15 
SB135: (MYADM OR MUG Hs.82848 1.30 0.67 - - 0.94 0.96 
SCYC1-SCYC2: (SCYC1 Hs.423077 3.58 1.29 - 2.72 1.67 0.88 
SELE: (SELE OR ELAM1 Hs.511748 - - - - - 1.74 
SELEL: (SELEL OR ESL Hs.24640 1.22 0.57 0.27 0.55 1.46 6.92 
SELL: (SELL OR LYAM1 Hs.278311 0.95 - - 1.98 1.23 0.98 
SELPLG: (SELPLG) P-S Hs.297681 - 1.40 - 3.49 - 0.82 
SEMA4D: (SEMA4D OR C Hs.381167 1.62 1.23 - 1.45 1.25 1.23 
SEMAL: (SEMA7A OR SE Hs.241579 1.13 - - 1.13 1.16 1.81 
SEP: (SEP OR PLEXIN- Hs.41691 1.79 1.15 - - - 1.12 
SERPINA1_1_HUMAN: (S Hs.7306 0.49 0.41 - 0.39 4.50 1.92 
SERPINB1: (SERPINB1 Hs.31386 0.57 - - 0.95 1.34 1.66 
SERPINH1-SERPINH2: ( Hs.433795 3.54 1.49 - 0.76 0.92 0.87 
SFA2: (BATF) ATF-LIK Hs.262886 1.24 - - 1.25 1.28 2.80 
SHC1: (SHC1 OR SHC) Hs.440896 1.49 - - 2.32 0.88 1.25 
SHIP: (INPP5D OR SHI Hs.99724 1.83 0.69 0.54 1.26 0.98 0.93 
SIP1_1: (SLC9A3R2 OR Hs.89864 1.18 - - - 0.68 1.37 
SKAT2: (SKAT2) ZINC Hs.23348 0.98 1.52 - 0.83 1.23 1.00 
SKIV2L: (SKIV2L OR S Hs.32970 1.15 - - 0.71 1.12 0.39 
SKP2: (SKP2) CYCLIN Hs.169611 - 0.97 - - - 1.12 
SLAM: (SLAM) SIGNALI Hs.388294 0.60 0.75 - 2.31 - 0.93 
SMAC: (6141G12RIK Hs.110741 0.89 - - - 0.86 1.28 
SMAD1: (MADH1 OR SMA Hs.167700 0.86 - - 1.00 0.97 1.15 
SMAD2: (MADH2 OR SMA Hs.123119 0.82 - - 0.72 1.53 0.65 
SMAD5: (MADH5 OR SMA Hs.50640 1.85 0.59 - 1.83 1.25 1.16 
SMAD9: (MADH9 OR SMA Hs.405946 1.13 0.85 - 1.22 1.39 1.29 
SOCS1: (SOCS-1 OR SS Hs.436943 0.78 0.78 0.51 0.65 0.97 0.94 
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SOCS2: (HSSOCS-2) SU Hs.169836 1.28 0.76 0.55 1.75 1.25 0.93 
SOCS3: (SOCS3) STAT Hs.44439 - 0.56 - 1.45 1.13 0.74 
SOD1: (SOD1) SUPEROX Hs.270564 0.32 0.90 0.88 0.12 1.30 0.98 
SOD2: (SOD2 OR SOD-2 Hs.443914 1.84 - - 3.80 1.18 1.86 
SODD: (BAG4 OR SODD) Hs.384944 0.97 0.37 0.29 1.55 0.87 0.47 
SOS1: (SOS1) SON OF Hs.194726 0.98 0.89 - 1.67 0.73 1.20 
SOS2: (SOS2) SON OF Hs.326392 0.68 - - 1.35 1.37 1.80 
SP1: (SP1) TRANSCRIP Hs.528126 1.21 - - 1.18 1.29 1.12 
SP3: (SP3) TRANSCRIP Hs.9460 1.75 0.63 0.55 0.83 1.27 1.31 
SPA2L2: (PLA2-XIII O Hs.154295 - 1.15 - - - 0.92 
SPARC: (SPARC OR ON) Hs.333175 3.47 0.98 - 1.12 0.46 0.94 
SPLASH: (PLA2G2D OR Hs.111779 1.35 1.61 - 1.52 1.22 0.42 
SPN: (SPN OR CD43) L Hs.189507 - 0.31 - - - 1.12 
SPOCK: (TESTICAN) TE Hs.461934 1.17 - - 1.92 1.18 1.14 
SPRY1: (SPRY1) SPROU Hs.93029 0.43 1.35 - 0.55 0.96 1.12 
SRC: (SRC OR SRC1) P Hs.436944 1.27 1.58 - 0.95 - 0.93 
SRCAP: (SRCAP) TRANS Hs.436015 0.82 - - - 1.13 0.86 
SRE1_1: (SREBF1 OR S Hs.136227 1.84 - - 1.44 1.78 0.96 
SRF: (SRF) SERUM RES Hs.426528 - - - - - 1.96 
ST2L: (ST2) ST2L (LY Hs.444086 1.20 - - 1.20 1.32 1.94 
STAT1: (STAT1) SIGNA Hs.21486 1.32 - - 3.32 1.18 1.16 
STAT2: (STAT2) SIGNA Hs.72988 1.28 1.50 - 1.52 1.15 1.76 
STAT3: (STAT3 OR APR Hs.421342 1.44 - - 0.43 0.70 0.97 
STAT4: (STAT4) SIGNA Hs.80642 0.98 0.64 0.73 2.76 - 0.65 
STAT5A: (STAT5A OR S Hs.437058 1.12 - - 0.98 0.97 1.37 
STAT5B: (STAT5B) SIG Hs.434992 1.44 - - 1.38 1.43 0.93 
STAT6: (STAT6) SIGNA Hs.437475 0.94 0.94 - 0.97 0.98 1.18 
STCH: (STCH) MICROSO Hs.352341 1.16 - - - 1.40 1.25 
STX3A_2: (STX3A OR S Hs.82240 0.92 1.20 - - 0.85 0.96 
SYK: (SYK) TYROSINE- Hs.192182 - - - 1.27 - 0.87 
SYNDECAN1: (SDC1 OR Hs.82109 1.16 - - 2.82 0.82 0.95 
SYNDECAN2: (SDC2 OR Hs.1501 0.57 - - 0.69 0.92 0.93 
SYNDECAN3: (SDC3 OR Hs.158287 - - - - - 1.23 
TACE: (ADAM17 OR TAC Hs.404914 1.12 - - 0.66 1.00 0.96 
TACI: (TNFRSF13B OR Hs.158341 0.97 0.69 - 1.73 1.14 0.83 
TANK: (TANK OR ITRAF Hs.146847 0.56 - - 1.45 0.67 1.63 
TBLYM_BAD: (TBX21 OR Hs.272409 0.79 - - 0.90 1.31 1.43 
TCF12: (TCF12 OR HTF Hs.438166 1.57 - - 1.40 0.97 1.39 
TCF3: (TCF3 OR E2A O Hs.371282 1.30 1.25 - 1.32 1.16 1.17 
TCF4: (TCF4 OR ITF2 Hs.359289 0.78 0.84 0.62 1.35 0.79 0.88 
TDGF1-TDGF3_2_HUMAN: Hs.496585 Hs.385870 1.25 - - 1.13 1.34 0.74 
TDT: (DNTT OR TDT) D Hs.397294 1.37 1.43 0.74 1.35 1.29 1.50 
TEF: (TEF) THYROTROP Hs.181159 1.35 1.37 - 1.96 1.28 0.94 
TENASCINR: TENASCIN- Hs.54433 1.32 1.29 - 1.82 1.63 0.90 
TFE3: (TFE3) TRANSCR Hs.274184 0.83 - - - 0.86 1.44 
TFRC_MIDDLE: (TFRC) Hs.185726 - - - 2.41 0.88 1.27 
TGFA55: (TGFA) TRANS Hs.170009 - 0.65 0.32 1.36 - 1.23 
TGFB1_1: (TGFB1 OR T Hs.1103 1.33 - - 1.29 0.96 1.10 
TGFB2: (TGFB2) TRANS Hs.169300 0.99 - - 1.15 1.28 0.42 
TGFB3_1: (TGFB3 OR T Hs.2025 1.16 - - 1.24 1.25 1.32 
TGFBI: (TGFBI OR BIG Hs.421496 17.40 1.45 - 6.65 0.52 1.00 
TGFBR1: (TGFBR1) TGF Hs.28005 0.89 - - 0.95 0.91 1.98 
TGFBR2: (TGFBR2) TGF Hs.82028 1.29 - - 2.59 - 0.82 
THBD: (THBD OR THRM) Hs.2030 - - - - - 1.32 
THROMBOSPONDIN1: (TH Hs.164226 1.21 - - 1.12 1.24 - 
THROMBOSPONDIN2: (TH Hs.458354 16.94 0.88 - 5.68 - 0.92 
THROMBOSPONDIN3: (TH Hs.169875 1.53 - - 1.36 1.39 1.86 
THROMBOSPONDIN4: (TH Hs.415041 1.62 - - 1.85 1.30 1.13 
THROMBOSPONDIN5: (CO Hs.134643 0.49 1.15 - 1.78 0.64 0.97 
THY1: (THY1) THY-1 M Hs.115176 1.33 - - 0.83 1.36 0.84 
TIAM: (TIAM) T-LYMPH Hs.446641 1.10 0.52 - - - 0.82 
TIMP1: (TIMP1 OR TIM Hs.6441 1.50 - - 7.14 1.95 1.52 
TIMP2: (TIMP2) METAL Hs.245188 2.29 1.54 - 2.73 1.70 4.17 
TIMP3: (TIMP3) METAL Hs.190787 1.23 1.88 - 0.57 0.68 1.55 
TIMP4: (TIMP4) METAL Hs.17681 1.37 - - 1.25 1.33 0.78 
TIRAP: (TIRAP OR MAL Hs.89643 0.82 1.23 - - 0.97 0.88 
TKT: (DDR2 OR NTRKR3 Hs.111805 0.88 - - 1.54 - 1.51 
TKT1: (TKT1 OR TKT) Hs.120551 1.19 - - 0.73 0.79 0.87 
TLR1: (TLR1 OR KIAA Hs.519033 1.86 - - 0.60 1.26 0.92 
TLR1_HUMAN: (TLR1) Hs.29499 1.28 - - 1.25 1.33 1.36 
TLR2: (TLR2 OR TIL4) Hs.174312 1.13 0.56 - 2.17 1.38 0.98 
TLR3: (TLR3) TOLL-LI Hs.114408 0.68 - - 1.30 0.89 1.17 
TLR4: (TLR4)TOLL-L Hs.366986 1.37 - - 1.45 1.38 1.39 
TLR5: (TLR5 OR TIL3) Hs.179152 1.12 0.74 0.53 0.59 0.98 0.88 
TLR6: (TLR6) TOLL-LI Hs.87968 1.15 0.66 - 0.64 1.75 0.88 
TLR7: (TLR7) TOLL-LI Hs.351316 1.29 - - 1.30 1.55 0.81 
TLR9: (TLR9) TOLL-LI Hs.439586 1.32 0.98 0.62 0.94 1.11 0.95 
TM4SF1: (TM4SF1 OR T Hs.98998 1.00 - - 0.53 0.76 0.92 
TM4SF2: (TM4SF2 OR M Hs.241570 0.45 0.57 0.42 0.39 0.58 0.92 
TNC: (TNC OR HXB) TE Hs.101382 0.63 - - 1.28 - 0.42 
TNF: (TNF OR TNFSF2 Hs.211600 - - - - - 1.42 
TNFAIP2: (TNFAIP2) T Hs.407546 - 0.48 - - 0.89 1.16 
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TNFAIP3: (TNFAIP3 OR Hs.36 0.90 - - - 1.95 0.97 
TNFAIP6: (TNFAIP6 OR Hs.376208 1.12 - - 2.41 1.28 1.28 
TNFB: (LTA OR TNFSF1 Hs.159 0.82 1.42 - 1.47 1.29 1.24 
TNFC: (LTB OR TNFC O Hs.204044 0.33 - - 3.15 0.38 1.26 
TNFR1: (TNFRSF1A OR Hs.81791 2.24 - - 1.46 0.99 1.70 
TNFRSF11A: (TNFRSF11 Hs.434975 0.92 0.85 - 1.90 1.13 0.85 
TNFRSF11B: (TNFRSF11 Hs.256278 0.80 0.63 - 0.65 0.69 1.63 
TNFRSF19L: (TNFRSF19 Hs.299558 1.40 0.79 - 1.54 0.98 2.94 
TNFRSF1B: (TNFRSF1B Hs.504816 - - - - - 0.91 
TNFRSF5: (TNFRSF5 OR Hs.82359 0.77 - - 1.28 0.81 - 
TNFRSF6: (TNFRSF6 OR Hs.355307 0.51 0.75 - 1.69 0.98 1.12 
TNFRSF7: (TNFRSF7 OR Hs.1314 1.98 - - 4.76 0.97 2.28 
TNFRSF8: (TNFRSF8 OR Hs.193418 1.36 0.75 - 1.68 1.37 1.28 
TNFRSF9: (TNFRSF9 OR Hs.333791 1.36 0.99 0.55 1.49 1.47 0.90 
TNFSF11: (TNFSF11 OR - 0.91 1.20 0.72 - - 0.99 
TNFSF12: (TNFSF12 OR Hs.181097 1.38 1.73 - 1.23 0.90 1.18 
TNFSF4: (TNFSF4 OR T Hs.652 - - - 0.67 0.93 1.90 
TNFSF5: (TNFSF5 OR C Hs.2007 1.32 - - - - 0.49 
TNFSF6: (TNFSF6 OR F Hs.99899 0.93 - - - 0.92 1.32 
TNFSF7: (TNFSF7 OR C Hs.177136 1.25 0.44 - 1.45 1.38 1.53 
TNFSF8: (TNFSF8 OR C Hs.1524 - 0.75 - - - 1.00 
TNFSF9: (TNFSF9 OR L Hs.440968 1.19 0.60 - 1.94 1.19 0.88 
TP53BP1: (TP53BP1) T Hs.274404 2.00 - - 0.86 1.19 1.17 
TPA: (PLAT) TISSUE-T Hs.429961 0.49 0.86 - 0.22 0.33 0.89 
TPARL: (TPARL) TRANS Hs.89862 1.25 0.71 - 0.47 0.82 0.58 
TRADD: (TRADD) TUMOR Hs.438253 5.80 - - 3.45 2.12 0.86 
TRAF1: (TRAF1 OR EBI Hs.437575 - 0.71 0.23 - 0.89 5.87 
TRAF2: (TRAF2 OR TRA Hs.297660 1.26 - - 1.12 1.32 0.87 
TRAF3: (TRAF3 OR CRA Hs.8375 0.99 1.00 0.66 1.65 1.19 0.92 
TRAF4: (TRAF4 OR MLN Hs.385685 0.90 - - 0.63 1.66 0.96 
TRAF5: (TRAF5) (TNF Hs.444172 1.55 0.53 - 0.64 1.14 0.98 
TRAF6: (TRAF6) PUTAT Hs.387871 0.88 0.59 - 0.98 1.19 0.83 
TRAIL: (TNFSF1 OR T Hs.401745 0.34 0.89 - 1.75 2.13 0.96 
TRAILR1_HUMAN: (TRAI Hs.51233 0.86 0.80 - - - 2.32 
TRAILR2: (TRAILR2 OR Hs.119684 1.14 - - 1.35 1.64 0.88 
TRAILR3_HUMAN: (TNFR Hs.129844 1.69 1.42 - 1.24 1.33 0.95 
TRAILR4_HUMAN: (TNFR Hs.334174 - 1.59 0.53 - - 2.98 
TRAIN: (TNFRSF19 OR Hs.21254 - - - 1.21 - 1.45 
TTRAP: (TTRAP OR DJ3 Hs.210628 0.46 1.17 - 0.27 0.69 0.95 
TUBA_HUMAN: (TUBA1) Hs.446608 Hs.433394 Hs.406578 4.45 - - 1.55 2.62 0.62 
TUBB1-TUBB5_HUMAN: ( Hs.356729 3.85 1.52 0.81 0.53 1.15 1.43 
UBE2G1: (UBE2G1 OR U Hs.121150 0.72 1.48 - 0.74 1.17 0.81 
UBIQUITIN_BAD: ((UBA Hs.78563 0.55 - - 0.55 1.87 0.97 
UPA: (PLAU) UROKINAS Hs.356190 Hs.183704 2.88 0.52 0.61 0.99 0.93 2.72 
USP2: (USP2 OR UBP41 Hs.77274 0.87 0.95 - 1.32 1.26 1.60 
UVRAG: (UVRAG OR UVR Hs.125902 1.16 - - 1.24 0.89 1.31 
V7: (V7) LEUKOCYTE S Hs.13137 0.93 - - 0.49 0.89 1.43 
VAV: (VAV) VAV PROTO Hs.74115 1.00 - - 1.44 - 1.43 
VAV2: (VAV2) VAV2 PR Hs.116237 - 0.63 0.47 - - 0.99 
VAV3: (VAV3) VAV-3 P Hs.4248 1.76 - - 1.44 0.85 1.43 
VCAM1: (VCAM1 OR L1C Hs.267659 0.79 - - 0.68 1.42 1.16 
VEGC: (VEGFC) VASCUL Hs.109225 - - - - - 1.25 
VEGF_1: (VEGF OR VEG Hs.79141 0.80 - - 1.58 - 1.13 
VEGFB: (VEGFB OR VRF Hs.73793 1.86 - - 0.47 1.11 1.33 
VEGFD: (FIGF OR VEGF Hs.78781 - - - 1.72 - 0.51 
VERSICAN: (CSPG2) VE Hs.11392 2.43 - - 11.15 - 1.16 
VGR2: (KDR OR FLK1) Hs.12337 - - - - - 0.84 
VWF: (F8VWF OR VWF) Hs.440848 0.83 - - - - 1.19 
WISP3: (WISP3 OR CCN Hs.194678 - - - - 1.86 3.32 
WSB-1: (SWIP1 OR WSB Hs.315379 1.20 - - 1.61 0.75 1.29 
WSB-2: (WSB2 OR SWIP Hs.459470 1.59 1.17 - 1.23 1.26 0.97 
XBP1: (XBP1 OR XBP2 Hs.437638 0.68 0.34 - 2.72 0.64 0.88 
XIRAPL2: (IL1RAPL-2 Hs.272354 0.97 0.58 - 0.45 1.34 0.93 
XRCC: (XRCC1) DNA-RE Hs.98493 1.25 0.68 - 0.56 1.67 0.94 
YES: (YES1 OR YES) P Hs.194148 0.95 0.59 - 0.23 1.61 1.13 
YWHAE: (YWHAE) 14-3- Hs.79474 0.45 0.38 0.29 0.26 1.22 1.95 
YWHAZ: (YWHAZ) 14-3- Hs.386834 1.98 0.63 - 1.28 0.73 1.26 
YY1: (YY1) TRANSCRIP Hs.388927 1.98 - - 1.28 1.43 0.88 
ZAKI-4: (ZAKI-4 OR D Hs.156007 0.33 - - - 0.68 1.12 
ZAP7: (ZAP7 OR SRK Hs.234569 - - - - - 1.14 
ZF9: (COPEB OR KLF6 Hs.285313 0.82 0.74 0.65 0.50 0.78 1.20 
ZIC3: (ZIC3) ZINC FI Hs.111227 - - - - - 0.96 
ZMDA1: (IL19 OR ZMDA Hs.71979 0.77 0.99 - 1.15 1.28 1.38 
ZNFN1A1: (ZNFN1A1 OR Hs.435949 0.88 - - 1.38 0.87 1.73 
  Acknowledgment 
 
  
Acknowledgment 
This work was done at the Core Unit Chip Applications, Institute of Human Genetics 
and Anthropology at the Klinikum of the Friedrich-Schiller University, Jena, 
Germany during the years 2002 to 2006.  
Especially I would like to thank: 
PD Dr. Ferdinand von Eggeling for being the supervisor of this thesis. It has been a 
pleasure to work in the Core Unit Chip Applications under excellent scientific 
conditions and in an outstanding and pleasant work environment. I would also like 
to thank him for providing me with all possible scientific and practical help 
throughout the project. 
Professor Dr. Uwe Claussen, the head of the institute, for providing excellent 
research conditions and excellent support of this thesis. 
PD Dr. Kerstin Junker for providing me access to the RCC tumor bank of the 
Department of Urology and for a very productive cooperation. 
Dr. Ivan F. Loncarevic for providing the opportunity to look at things from a 
different point of view. His suggestions were enrichment for my thesis. 
PD Dr. Andreas Henke for a very inspiring conversation about my thesis. 
Susanne Michel for sharing her expertise in cell culture, for extremely helpful 
discussions, and for life-saving coffee-breaks. 
Julia Rosenhahn for sharing her expertise in qPCR and for sharing lots of fun. 
Annett Bleul and Bettina Schimmel for excellent experimental assistance. 
Christian Reeb, Dr. Astrid Bechtold, Dr. Anne Busch and Beatrix Rohrbacher for 
critically proof reading this thesis. 
Dr. Bernhard Gerstmayer and Dr. Stefan Tomiuk from Miltenyi Biotec GmbH for a 
flexible and efficient collaboration. 
Dr. Christian Melle, Niko Escher, Roland Lehmann, Katja Wagenführ, Robert Kob, 
Ulrike Murzik, Heike Thieme, Susann Klebon, Dr. Anita Heller and all other people 
in our institute for their cheerful company, help, and advice. 
Especially I wish to thank my husband Ryan for critically reviewing this thesis, for 
constructive suggestions, for his unfailing support, and for his patience during the 
last months. 
Finally I wish to thank my parents for their love and support of my thesis. 
The IZKF Jena and the BMBF for financial support. 
  Curriculum Vitae 
 
 
Curriculum Vitae 
 
Name:   Julia Diegmann 
Date of Birth: 20th of February 1977 
Place of Birth:  Fulda 
 
e-mail: julia.diegmann@med.uni-muenchen.de 
 
EDUCATION 
 
1987–1996  Marienschule Fulda, Secondary School (Gymnasium), Fulda, Germany. 
1996–1997  Volunteer. Social Year (FSJ), Sigüenza, Spain. 
1997-1999  Spanish. Philipps University, Marburg, Germany. 
1997-1999  Biology. Philipps University, Marburg, Germany. 
1999-2000  Biology. University Alcalá de Henares, Henares, Spain. 
2001-2002  Research Internship. Institute of Anthropology, Giessen, Germany. 
2000-2002  Diplom (Msc). Biology. Justus-Liebig University, Giessen, Germany. 
Advisor: Prof. Dr. Manfred Kunter. 
2004 Research Internship. Institute of Toxicology, Merck KGaA, Darmstadt, 
Germany. 
2002-2006  Ph.D. Student. Friedrich-Schiller University, Jena, Germany. 
Advisor: PD. Dr. Ferdinand von Eggeling. 
10.2006  Post-Doctoral Researcher. Ludwig-Maximilians University, Munich. 
Germany. Institute for Medical Psychology, Department 
Chronobiology 
 
 
 
 
          
(Julia Diegmann) 
   
Erklärung 
 
Ich erkläre, dass mir die geltende Promotionsordnung der Fakultät bekannt ist.  
Ich erkläre, dass ich die vorliegende Arbeit selbstständig und nur unter Verwendung 
der angegebenen Hilfsmitteln und Literatur angefertigt habe. 
Ich erkläre, dass ich mich mit der vorliegenden Arbeit an keiner anderen 
Hochschule um den akademischen Grad Dr. rer. nat. beworben habe und dass ich 
weder früher noch gegenwärtig die Eröffnung eines Verfahrens zum Erwerb des 
oben genannten akademischen Grades an einer anderen Hochschule beantragt 
habe. 
 
I hereby declare that this submission is my own work and that I used only the 
declared materials and literature stated. 
I further declare that this thesis, in substantially its present form, has not been 
submitted or accepted previously for the award of a doctoral degree (Dr. rer. nat) 
in this or any other tertiary institution. 
 
 
 
 
 
              
(Datum/Date)         (Julia Diegmann) 
